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Chapter 01
Vascular network formation
During embryonic development the cardiovascular system is one of the first 
structures to form and function. This is orchestrated by key morphological events, resulting 
in a hierarchical branched vascular network. Embryonic vasculogenesis relies on the 
differentiation of mesodermal precursor cells, also known as angioblasts, into endothelial 
cells (ECs). These differentiated cells then merge into primitive blood vessels and form 
the endocardium, paired aortas, primary vascular plexus in the embryo and the yolk sac 
vasculature in the extra-embryonic membrane (Flamme et al., 1997; Swift and Weinstein, 
2009). The newly formed vessels continue to undergo expansion and remodeling via a process 
referred to as angiogenesis. Angiogenesis includes firstly the sprouting of the pre-existing 
vessels by the generation of new vascular branches. This is achieved via the migration of 
endothelial tip cells followed by the proliferation of endothelial stalk cells.  Secondly, the 
newly formed neighboring vascular sprouts fuse, a process called anastomosis, through 
interactions between filopodia of respective tip cells. This results in the formation of the 
vascular network and the establishment of new cell-cell junctions. Finally, newly established 
networks undergo vascular stabilization and maturation by the coverage of perivascular cells, 
also known as mural cells (Stapor et al., 2014).
 
Deregulation of one of these fundamental vascular features due to defective signaling 
pathways can have major impacts on development, even causing embryonic lethality, or 
severe consequences on adult physiology that lead to a number of vascular pathologies. 
Many signaling pathways are known to orchestrate the development of the vascular network 
and one of the most important is transforming growth factor beta (TGFβ) superfamily. 
TGFβ superfamily
TGFβ superfamily members are evolutionarily conserved and are involved in signal 
transduction pathways with key functions in a plethora of distinct cellular processes during 
normal development and human disease. Most notably, growth inhibition, cell differentiation, 
migration, invasion, apoptosis, epithelial-mesenchymal transition (EMT) and extracellular 
matrix (ECM) remodeling in a wide range of cell types and tissue contexts (Pardali and Dijke, 
2012). Additionally, in recent years, it has also been shown that TGFβ superfamily members 
play a significant role in the progression of cancer, fibrosis and inflammation  (Akhurst and 
Hata, 2012). 
More than thirty secreted ligands, seven distinct type I receptors (activin receptor-like kinase 
or ALKs), five distinct type II receptors, seven type III receptors and eight Smad proteins 
have been identified as members of the TGFβ superfamily in humans and other mammals so 
far (Massague, 2012; Moustakas and Heldin, 2009).
All mature TGFβ ligand family members are characterized by a specific three-dimensional 
structure. They all have cysteine residues in their C-terminus, which form intra molecular 
disulphide-linked dimers.  Dimerization of these proteins is important for receptor binding 
and activation (Dijke and Arthur, 2007). Besides the prototypic TGFβ ligands, the family 
also includes the bone morphogenetic proteins (BMPs), growth and differentiation factors 
(GDFs), activins (ACTs), inhibins (INHs), nodal growth differentiation factor (Nodal), 
left-right determination factor (Lefty) and Mullerian inhibiting substance (MIS). Detailed 
descriptions of the ligands are reviewed elsewhere (Moustakas and Heldin, 2009). 
The TGFβ receptor family to which the ligands bind consists of seven type I receptors 
(ALK1-7) and five type II receptors, including activin receptor typeIIA (ActRIIA), activin 
receptor type IIB (ActRIIB), BMP type II receptor (BMPRII), TGFβ type II receptor (TβRII) 
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and AMH type II receptor (AMHRII). Both type I and II receptors are composed of a single 
transmembrane-spanning region, which is characterized by a short cysteine-rich extracellular 
part and a long intracellular domain. The latter is comprised of strong serine/threonine and 
weaker tyrosine kinase activity (Dijke and Arthur, 2007; Moustakas and Heldin, 2009). It is 
important to note that type I receptors consist of a short juxta-membrane, glycine-serine rich 
domain (GS-box), which are necessary for their activation. In addition to the type I and type 
II receptors, type III co-receptors, such as betaglycan (TβRIII) and endoglin (ENG) have 
been also identified. These accessory receptors are single transmembrane glycoproteins with 
short cytoplasmic tails that lack enzymatic activity. The function of these co-receptors is to 
facilitate ligand-receptor interactions (Dijke et al., 2008; Dijke and Arthur, 2007; Kapur et 
al., 2013). Finally the Smad proteins form essential parts of the downstream TGFβ signaling 
pathway. Smads are conventionally categorized into three groups; the receptor-regulated 
Smad proteins (R-Smads) 1, -2, -3, -5, and -8, common-mediator Smad protein (co-Smad) 4, 
and inhibitory Smad proteins (I-Smads) 6, and -7. These Smad proteins are characterized by 
a N-terminal Mad-homology 1 (MH1) domain, a middle linker domain and C-terminal MH2 
domain. Importantly, the MH2 domain consists of a conserved Ser-Ser-X-Ser (SSXS) motif 
essential for binding to type I receptors (Feng and Derynck, 2005). 
TGFβ signaling 
TGFβ superfamily signaling involves a well-described signaling cascade that is 
initiated at the membrane by ligand binding and extended to the nucleus of the cell. Briefly, 
TGFβ ligands bind to a multi-component receptor complex at the cell surface that consists 
of two pairs of receptor serine/threonine kinases (type I and II). Upon ligand binding, the 
type II receptor, which is constitutively active, trans-phosphorylates the GS box of the type 
I receptor adjacent to its kinase domain. This then propagates the signal into the cell by the 
phosphorylation of Smad proteins. Primarily, R-Smads become phosphorylated by type I 
receptors on two serines within its SSXS motif of the carboxyl-terminus. Activated R-Smads 
are translocated into the nucleus by forming heteromeric complexes with co-Smad4, where 
they interact with a number of transcriptional co-activators and co-repressors to orchestrate 
target gene expression (Chacko et al., 2001; 2004; Inman and Hill, 2002; Kawabata et al., 
1998; massague, 2012; Qin et al., 2001; Qing et al., 2004). By contrast, R-Smad translocation 
can be also inhibited by I-Smad6 and/or I-Smad7, which either compete with R-Smads 
for interaction with type I receptor or recruit Smad ubiquitin regulatory factor (Smurf) E3 
ubiquitin ligases to the receptors leading to proteasomal degradation of the receptors (Ebisawa 
et al., 2001; Hayashi et al., 1997; Imamura et al., 1997; Murakami et al., 2003; Nakao et 
al., 1997). Furthermore, I-Smads can also inhibit receptor activation by dephosphorylating 
the receptor complex in combination with specific recruited phosphatases (Shi et al., 2004; 
Valdimarsdottir et al., 2006).
Interestingly, ligand binding can lead to signaling activation via more than one type II and 
type I receptor combination and signaling can also be triggered by many ligands that interact 
with the same receptor (Groppe et al., 2008). In general, TGFβ ligand superfamily members 
can be separated into two SMAD signaling (so-called “canonical”) categories, the TGFβ/
Nodal/Activin and the BMP/GDF subfamilies (Groppe et al., 2008). Aside from the canonical 
SMAD activation, the TGFβ ligand superfamily can also regulate non-SMAD signaling 
pathways, so called the “non-canonical” pathways (Guo and Wang, 2009).  
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Canonical and non-canonical activation 
To understand the principle pathways relevant the work in this thesis, The TGFβs 
and BMPs will be described as prototypes for signaling activation. TGFβs bind to the type II 
receptor TGFβR-II (TβR-II) and recruit and phosphorylate type I receptors TGFβR-I (ALK5, 
TβR-I), ActR-IB (ALK4) or ALK7 to the complex which induces phosphorylation of Smad2 
and Smad3 proteins (Fig.1) (Bassing et al., 1994; Franzen et al., 1993; Lin et al., 1992). 
By contrast, BMPs typically signal via type II receptor BMPR-II and predominantly recruit 
with type I receptors ACVRL1 (ALK1), ACVR1 (ALK2), BMPR-IA (ALK3) or BMPR-IB 
(ALK6) (Dijke et al., 1994a; 1994b). Additionally, Activin and BMPs share binding for the 
type II receptors ActR-IIA and ActR-IIB (Yu et al., 2005). The activation of the type I receptors 
in this case propagates BMP signaling by phosphorylation of intracellular Smad1, Smad5 and 
Smad8 (Fig.1) (Miyazono et al., 2010). In contrast to TGFβ ligands, only BMPs are able 
to bind type I receptors in the absence of type II receptors but binding affinity increases 
remarkably when both receptor types are present (Rosenzweig et al., 1995). Besides Smad 
canonical pathway activation, TGFβ related ligands have been shown to activate additional 
downstream signaling pathways, including TRAF6 / TAK1 / p38 / JNK pathway (Tumor 
necrosis factor TNF receptor associated factor 6 / TGFβ associated kinase 1 / p38 / c-Jun 
N-terminal kinase), Ras / Erk / MAPK pathway (Ras / extracellular singal-regulated kinase 
/ mitogen activated protein kinases), PI3K / Akt / mTOR (phosphoinosistide 3-kinase / Akt 
/ mammalian target of rapamycin) and small GTPases RhoA, Cdc42 and Rac1 (For further 
reading, see review of (Mu et al., 2011).
TGFβ signaling in homeostasis and pathology 
One of the most important roles of TGFβ signaling in vascular morphogenesis is 
that of promoting vessel maturation via EC-mural cell communication. Mural cells, include 
pericytes and vascular smooth muscle cells (vSMCs), elongate and wrap around small 
capillaries and larger vessels to regulate vessel diameter, stabilization and EC proliferation. 
ECs promote paracrime communication leading to the recruitment of mural cells. Platelet-
derived growth factor-B/ Platelete-derived growth factor receptor-β (PDGF-B/PDGFR-β), 
angiopoietin 1 (Ang 1)/Tie2 and TGFβ signaling pathways have been shown to play a 
remarkable role in this process (Armulik et al., 2011; Gaengel et al., 2009; Stapor et al., 2014). 
In particular, yolk sac vasculature of endoglin deficient mice lacking TGFbRII or ALK5 
exhibits EC-mural cell communication defects leading to fragile blood capillaries similar 
to those seen in human vascular disorders (Carvalho, 2004). Nonetheless, the protagonistic 
role of of TGFβ signaling in the adult vasculature is further indicated by its association with 
the development of human vascular diseases, including hypertension, pre-eclampsia and 
Hereditary haemorrhagic telangiectasia (HHT). 
Hereditary hemorrhagic telangiectasia (HHT)
HHT or Osler-Weber-Rendu syndrome is an autosomal monogenic dominant 
disorder that affects the vascular homeostasis of approximately 1 in 5-8000 individuals 
(Kjeldsen et al., 2005; Marchuk et al., 1998). HTT is caused by mutations on genes involved in 
binding TGFβ and those associated with its signaling pathway. The disorder is characterized 
by the presence of a plethora of small or big arteriovenous malformations (AVMs) at specific 
locations of the body, which evolve with age. AVMs are distinguished by the lack of capillary 
beds between arteries and veins, leading to direct artery-to-vein connection (Fig.2A). 
AVMs are found as congenital and posttraumatic forms and consist of clusters of dilated 
vessels. These clusters vary in size and can develop or grow over time depending on the 
tissue they are found in. In addition, AVMs can hemorrhagic which in most cases becomes 
progressively worse with age (Shovlin, 2010). Small AVMs, also called telangiectasia, are 
pink to red pinhead-size cutaneous lesions mainly on lips, tongue, oral cavity, fingers and
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Figure1. Canonical  TGFβ/BMP signaling
Figure 2. AVMs in HHT 
patients. (A) Schematic 
illustration of a direct con-
nection (black arrow) be-
tween artery (a) and vein 
(v) missing the intervening 
capillary bed (cb). (B-D) 
Telangiectases on nasal 
mucosa (B), tongue/lips 
(C) and fingers (D). (E-F) 
AVMs of the brain (E) and 
lung (F) by MRI and CT, 
respectively. Modified after 
McDonald et al. 2011
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the nasal, buccal, and gastrointestinal (GI) mucosa (Fig.2B-D). By later adulthood, almost 
all HHT patients develop telangiectasia on the hands, lips and face, usually observed only 
by focused examination. Periodic nasal bleedings (epistaxis) during childhood is one of the 
first features that bring individuals to medical attention. HHT patients with spontaneous and 
recurrent sever epistaxic events may develop chronic anemia and become blood transfusion 
dependent. Hemorrhage at the upper GI tract is usually observed in elder HHT patients and 
its severity increases with age. In contrast to small AVMs, large visceral AVMs or shunts, are 
usually present from birth and can be found in the cerebral, hepatic, pancreatic and pulmonary 
circulations (Shovlin, 2010) (Fig.2E-F). These shunts lead to major hemodynamic changes, 
due to altered cardiac output, and life threatening events, particularly in younger individuals 
(McDonald et al., 2011). 
 
The clinical diagnosis of adult HHT patients is based on consensus criteria referred to as 
the Curacao criteria. Family history of the syndrome and at least three major symptoms, 
including recurrent epistaxis, mucocutaneous telangiectasia in characteristic locations and 
visceral AVMs, are sufficient for the diagnosis (McDonald et al., 2015; Shovlin et al., 2000). 
In contrast to their beneficial diagnostic usage in adult patients, Curacao criteria can be 
misleading when applied to young asymptomatic or minimally symptomatic patients (van 
Gent et al., 2013). Thus, early diagnosis by molecular genetic testing is recommended for the 
medical management of possible at-risk family members with serious early complications. 
The majority of HHT patients harbor mutations in ENG (chromosome 9q34) or Activin A 
Receptor Type I-like (ACVRL1/ALK1, chromosome 12q13) genes that cause HHT1 and 
HHT2, respectively (Johnson et al., 1996; McAllister et al., 1994). A minority of HHT patients 
are associated with mutations in Smad4 (chromosome 18q21), GDF2 (BMP9, chromosome 
10q11) or RAS p21 protein activator 1 (RASA1, chromosome 5q13.3) (Gallione et al., 2004; 
McDonald et al., 2015; Wooderchak-Donahue et al., 2013).
A myriad of different mutations including deletions, insertions, missense and splice-site 
mutations have been identified in HHT1 and HHT2 cases without a clear genotype-phenotype 
correlation emphasizing the heterogeneity of the disease (Govani and Shovlin, 2009; Paquet 
et al., 2001; Pece et al., 1997; Pece-Barbara et al., 1999). Reduced protein levels of ENG 
and ACVRL1 are found in HHT patients, supporting the idea that haploinsufficiency is the 
underlying cause of the disease. 
Both HHT1 and HHT2 patients exhibit most of the Curaca criteria symptoms but development 
of specific vascular features is different between the two subtypes. In particular, pulmonary 
and cerebral AVMs are more common in HHT1 patients, whereas hepatic AVMs are more 
prevalent in HHT2 patients. 
 
Most importantly, disease severity can be influenced by the age of onset and the locations of 
these vascular lesions, which differ from one individual to another and also within families. 
The latter suggests that other physiological or environmental factors (second hits) and/or 
modifier genes might be associated with the distinct phenotype of HHT. For this reason, 
various in vivo and in vitro models have been developed which have significantly contributed 
to understanding the pathogenesis of HTT and to finding novel treatment methods.
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Modeling HHT1 and HHT2 in vivo 
The majority of HHT1 or HHT2 mutations correspond to deletion and splice variant 
defects leading to a frameshift and hence truncated proteins that are either not expressed or 
retained intra-cellularly (Cymerman et al., 2000; Paquet et al., 2001; Pece et al., 1997; Pece-
Barbara et al., 1999). Thus, a number of acvrl1 or endoglin loss-of-function mice have been 
generated in order to model HHT. 
Mice deficient in acvrl1 or endoglin die in utero at E10.5-E11.5 revealing their significant role 
during development (Arthur et al., 2000; Bourdeau et al., 1999; Li, 1999; Oh et al., 2000). In 
particular, endoglin null embryos exhibit dilated and hemorrhagic vascular channels in the 
primitive vascular plexus of the yolk sac and the peritoneal cavity of the embryo resulting in 
embryonic lethality (Arthur et al., 2000; Bourdeau et al., 1999; Li, 1999). In the developing 
yolk sac, the vSMC marker SM22a is normally present at E9.5 around the endothelium 
of the capillary plexus. Loss of endoglin causes failure in vSMC development and vessel 
maturation due to reduced active TGFß1 protein secretion by ECs suggesting aberrant EC-
pericyte interaction as contributing to the pathogenesis of HHT (Carvalho, 2004; Li, 1999).
Furthermore, acvrl1 null embryos show hyperfusion of capillary plexes and highly dilated 
dorsal aorta and branchial arch arteries, which is associated with impaired vSMC recruitment 
and differentiation (Oh et al., 2000; Urness et al., 2000). Large AVMs between dorsal aorta 
and cardinal veins develop and fuse by E8.5 and E9.0, respectively (Urness et al., 2000). 
Interestingly, the molecular program for arterial vessel identity was disrupted in the yolk 
sac and caudal dorsal aorta of acvrl1 null embryos, as shown by Efnb2 staining. The latter, 
raises the question whether the arterial-vein vessel identity is also affected in large AVMs 
associated with HHT. 
It is intriguing to note that in both acvrl1 and endoglin null mice, development of the primitive 
vasculature and early vascular plexus of the yolk sac (vasculogenesis) is normal, suggesting 
an important role for acvrl1 and endoglin in angiogenesis rather than vasculogenesis along 
with vascular remodeling.
Mice heterozygous for acvrl1 (acvrl1+/-) or endoglin (endoglin+/-) are viable and fertile and 
based on their genotype, they represent murine models for HHT. Unfortunately, they exhibit 
some but not all vascular phenotypes of the disease, and the do not have the most severe life 
threatening symptoms (Bourdeau et al., 2001; 1999; Oh et al., 2000). In particular, endoglin+/- 
mice develop dilated, weak-walled vessels, multi-organ telangiectases or recurrent nose/
mouth bleeds. Interestingly, these lesions develop with greater severity on a 129/Ola 
mouse genetic background than on an Ola/129-C57BL/6 intercross or C57BL/6 backcross, 
supporting the idea of the presence of alleles or modifier genes prone to influence severity 
of HHT in humans (Arthur et al., 2000; Bourdeau et al., 2001; 1999). More importantly, 
analysis of mouse neonatal retina from endoglin+/- mice revealed excessive angiogenesis at 
the vascular front, which was unexpectedly normalized by thalidomide, a vascular maturation 
factor that has been shown to be beneficial for reducing severity of epistaxis in HHT patients 
(Lebrin et al., 2010). Mural cell coverage of the vasculature due to upregulation of PDGF-B 
expression in endothelial tip cells was found to be the underlying mechanism of action of 
Thalidomide (Lebrin et al., 2010).
Acvrl1+/- mice on the C57BL/6 background develop multi-organ vascular lesions. These 
appear in the nasal mucosa, GI tract, liver, lung, spleen, skin and oral cavity. However 
these vascular defects exhibit age-dependent penetrance and develop at very low frequency 
(Srinivasan et al., 2003).
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It is of note that adult endoglin+/- and acvrl1+/- mice develop spontaneous pulmonary arterial 
hypertension (PAH) in combination with a secondary right ventricular hypertrophy (RVH) 
as well as rarefaction of the peripheral lung vasculature and muscularization of small arteries 
(Ardelean et al., 2014; Jerkic et al., 2011; 2012; Toporsian et al., 2010). PAH was shown 
to be attributable to increased oxidative stress due to NO reduction and eNOS-dependent 
reactive oxygen species (ROS) overproduction in major internal organs including lungs, 
liver and colon (Jerkic et al., 2012). Recent studies have provided evidence that a distinct 
molecular angiogenic/angiostatic imbalance may be involved in the lungs of both HHT 
mouse models. In particular, endoglin+/- lungs exhibited augmentations in the angiostatic 
factor thrombospondin-1 (TSP-1) whereas, acvrl1+/- lungs showed normal levels of TSP-1 
and instead an increase in the vascular destabilizing protein Ang-2 (Ardelean et al., 2014). 
Most importantly, anti-vascular endothelial growth factor (anti-VEGF) treatment using 
the monoclonal antibody G6-31 was able to attenuate the secondary RVH and normalize 
peripheral pulmonary vasculature in both models. Surprisingly, anti-VEGF treatment was 
also able to normalize the TSP-1 and Ang-2 levels even though initial pro-angiogenic VEGF 
levels in the lung tissue were indistinguishable, leading to the speculation that this is a 
secondary effect due to reduced pulmonary VEGF levels. Of interest is the observation of a 
strong tissue rather than HHT-specific anti-VEGF response in the hepatic microvessel density 
(MVD) of control and both endoglin+/- and acvrl1+/- mutant mice (Ardelean et al., 2014). 
As explained above, development of large AVMs in solid organs is the most life threatening 
phenotype in HHT patients. Unfortunately, the development of those lesions in endoglin and 
acvrl1 heterozygous mice occurs in extremely low frequency, which makes the investigation 
of the underlying mechanism very limited (Torsney, 2003). The combination of (i) the 
vSMC defective phenotype observed in null acvrl1 and endoglin embryos and (ii) endoglin 
and acvrl1 expression beyond vascular ECs and including lymphatic ECs and monocytes/
macrophages, raises the question whether ECs or another vascular cell type are the major 
key players for the development of AVMs (Niessen et al., 2010). In order to address this, 
cell type-specific constitutive and conditional acvrl1 or endoglin knock out mice have been 
generated using the Cre-lox technology. 
Constitutive-Conditional deletion of acvrl1 or endoglin
Constitutive acvrl1 deletion from all mouse arterial ECs of the brain, lung and GI 
tract using L1-Cre with Cre activity from late embryogenesis (E13.5) onwards, caused AVMs 
formation with severe hemorrhages in the brain, lungs and GI tract, leading to death by P5 
(Park et al., 2009). It is interesting to note that no vascular defect was found in any other 
tissues of these mutant mice, including kidney, muscle, skin, heart and large intestine (Park 
et al., 2009). 
Furthermore the same group was able to show that tamoxifen induced EC specific deletion 
(Acvrl1-iKOe) of acvrl1 in the first week of postnatal life using Cdh5-CreER gave rise to 
severe vascular defects in the retina undergoing angiogenesis and resulted in rapid lethality 
(48 hours post recombination) (Fig.3C). This was due to severe pulmonary hemorrhage 
(Tual-Chalot et al., 2014). Interestedly, Arthur’s laboratory using a similar Cre deleter, 
reported some overlapping vascular defects in the retina of endoglin mutant mice (Mahmoud 
et al., 2010) (Fig.3B). In particular, both acvrl1 and endoglin mutant retina exhibited venous 
dilation and AVM formation, both marked by venous identity (EphB4 or Aplnr positive) and 
increased EC proliferation. On the other hand, endothelial deletion of acvrl1 alone affected 
the retinal vascular plexus between main arteries and veins, leading to hyperbranching, 
increased number of tip cells and reduced phosphorylation of Smad1/5/8 proteins, where in 
endoglin mutant mice all of the above are normal (Mahmoud et al., 2010; Tual-Chalot et al., 
17
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2014). Furthermore and in agreement with a previous study, arteries of acvrl1 mutant retinas 
exhibit reduced arterial identity as indicated by Jag1 expression (Mahmoud et al., 2010; 
Tual-Chalot et al., 2014; Urness et al., 2000). In contrast to acvrl1 mutant retinas, endothelial 
deletion of endoglin results in two unique vascular defects at the periphery of the retina: (i) 
delayed vascular radial expansion due to endothelial migration defect and; (ii) increased 
capillary density followed by vascular smooth muscle cell coverage due to increased blood 
flow. 
The importance of acvrl1 and endoglin in adult mice is highlighted by the fact that, tamoxifen 
induced endothelial specific (Cdh5-CreER) or global (ROSA26-CreER) deletion of acvrl1 
results in caecal hemorrhage and mortality within 2-3 weeks upon recombination (Park et 
al., 2009; Tual-Chalot et al., 2014). In addition, global deletion of endoglin in adult mice 
using the tamoxifen inducible ROSA26-CreER deleter give rise to signs of illness, including 
dehydration and diarrhea and death 4 to 10 days post recombination (Garrido-Martin et al., 
2014). On the other hand, tamoxifen induced endothelial specific deletion of endoglin in adult 
mice using Cdh5-CreER followed by subcutaneous Matrigel implants consisting of angiogenic 
cytokines (VEGF and bFGF) revealed an endothelial remodeling defect during angiogenesis, 
including topical venous enlargement (Mahmoud et al., 2010). It is therefore important to 
note, firstly, the requirement of acvrl1 and endoglin expression during angiogenesis and 
quiescent vasculature and secondly the requirement of physiological angiogenic stimulants 
for excessive AVMs formation (Fig.3).
Dynamic acvrl1 expression analysis during postnatal pathophysiological conditions or “second 
hits”, such as wound healing, leading to active angiogenesis reveals increased expression 
of acvrl1 in feeding arteries which was further associated with increased blood flow (Seki, 
2003). In accordance with the latter, the relation between injury and the development of HHT 
phenotype was intensively addressed using the HHT mouse models mentioned above. 
In a series of studies, de novo AVM development was revealed in adult mice upon global 
(ROSA26-CreER) genetic ablation of acvrl1 followed by wounding. Specifically, Park et 
al. were able to capture the onset, progression, remodeling and hemodynamic changes of 
subdermal AVM at the area of the wound for 8 days in real-time, using the dorsal skinfold 
window chamber system (Park et al., 2009). In particular, A-V shunts were characterized 
by locally dilated arteries and veins consisting of areas with high-velocity, turbulent arterial 
blood flow and elevated levels of Hb(O2) (Park et al., 2009). Similarly, global deletion of 
endoglin in adult mice using a similar Cre deleter revealed dilated/tortuous vessels and 
formation of A-V shunts in the area close to the wounded mid-dorsum and ear (Choi et al., 
2014; Garrido-Martin et al., 2014).
In a recent study from the same group, the development of AVM in the areas around the 
wounded ear and back skin of HHT1 and HHT2 mouse models was investigated side-by-side 
(Garrido-Martin et al., 2014) (Fig.3D-F). Deletion of endothelial specific acvrl1 or endoglin 
using tamoxifen induced Scl-CreER mice, gave rise to tortuous and enlarged vessels with 
multiple AV shunts at the area of the wounds similarly to those previously reported using 
ROSA26-CreER (Garrido-Martin et al., 2014; Park et al., 2009). Interestedly, endoglin mutant 
mice survived longer than 4 weeks after recombination with no visible signs of AVMs or 
hemorrhages in internal organs, whereas acvrl1 mutant mice further developed AVMs in 
the GI tract followed by severe bleeding in the cecum and lethality after 2 weeks of Cre 
activation (Garrido-Martin et al., 2014).
18
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Figure 3. Development of AVMs in mouse models of HHT1 and HHT2 during angiogenic events. 
(A-C) Top, IsolectinB4 stained ECs in neonatal retina vessels in Control (A), Eng-iKOe (B) and Acvrl1-
iKOe (C); at bottom are higher magnifications from the images in the top row. Red arrows indicate 
direct connection of arteries and veins (AVMs) in Eng-iKOe (B) and Acvrl1-iKOe (C). (D-F) Top, skin 
vasculature of control (D), Eng-iKOe (E) and Acvrl1-iKOe (F) back skin shown by latex dye injection 
after wounding (asterisk); at bottom, higher magnification of the vascular network around the wound. 
Red arrows indicate the development of AVMs. Modified after Tual-Chalot et al.2015 and Garrido-
Martin et al. 2014.
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These data showed firstly, the requirement of environmental stress, such as dermal injury, for 
the development of AVMs in both HHT1 and HHT2 models and secondly, the involvement 
of a non–EC type in the formation of AVMs in HHT1 GI tract. It is important to take in to 
account that hemodynamic changes, previously reported to be associated with acvrl1 ablation 
(Park et al., 2009; Seki, 2003; Tual-Chalot et al., 2014), may play a secondary role in the 
development of vascular malformations, such as AVMs, in distant tissues.
 
As described above, young HHT patients can also develop life threatening large AVMs 
in the brain, thus reproducible in vivo models are necessary to investigate the underlying 
mechanism.Brain AVMs were successfully generated in adult mice upon topical pan-cellular 
deletion of acvrl1 or endoglin and VEGF stimulated angiogenesis using adenoviral vectors 
driven by cytomegalovirus promoter (Chen et al., 2014a; 2014b; Walker et al., 2011). A more 
recent report from the same group also describes AVM formation in the brain, intestine, 
lung and around ear-tag wounds of adult acvrl1 mutant mice characterized by increased 
EC proliferation as indicated by BrdU+ and ki67+ positive staining (Chen et al., 2014a; 
2014b). In contrast to their study before, vascular malformations in the angiogenic area were 
generated upon tamoxifen induced endothelial specific deletion of acvrl1 using Pdgfb-iCreER 
and VEGF stimulated angiogenesis using adenoviral vector leading to lethality 6 to 13 days 
after recombination (Chen et al., 2014a). This demonstrates the requirement of additional 
angiogenic stimulus for the development of tissue specific AVMs.
Aims and chapter outline of this thesis 
The aims of the research described in this thesis are three-fold: (1) to investigate 
a new gene targeting knock-in fusion strategy that can be used to study early steps in 
cardiovascular specification using human embryonic stem cells (hESCs), (2) to develop in 
vitro models of HHT from patient specific cells induced pluripotent stem cells (iPSCs) and 
(3) to identify new potential modifier genes for HHT2.
Chapter 2-3 are related to the development of a new gene targeting knock-in fusion strategy. 
Chapter 2 serves as a proof-of-concept study of this new knock-in fusion approach, 
including its biallelic applicability, whereas Chapter 3 focuses on the direct differentiation 
of hESC towards ECs, in which this knock-in fusion approach can be applied to study early 
cardiovascular commitment.  Focusing on one cell type, endothelial cells, -that is a disease 
target and can be derived from patient hiPSC, Chapter 4 describes the derivation of iPSC lines 
from healthy individuals and patients diagnosed with HHT. In Chapter 5, this investigation 
is extended specifically to the derivation of HHT1 iPSC-ECs with view to exploring the 
consequences for ligand induced signaling and endothelial cell function. Chapter 6 focuses 
on the role of a new potential modifier gene in the formation of arteriovenous malformations 
(AVMs) in an HHT2 mouse model. Chapter 7 is a general discussion, which combines and 
discusses Chapter 2-6.
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Chapter 02
Transcription factors (TFs) and their networks are central effectors controlling pluripotency 
(Young, 2011). Numerous involved TFs have been identified, but a subset of core pluripotency 
TFs regulates the majority of others. One such factor, Nanog, is expressed in pluripotent cells, 
is required for self-renewal of mouse embryonic stem cells (ESCs) in vitro, is able to force 
ESC self-renewal upon overexpression in the absence of LIF, and is necessary for the normal 
development of early mouse embryos (Young, 2011). Several studies have shown that Nanog 
expression is heterogeneous in populations of pluripotent ESCs, which can express high or 
low Nanog levels (Young, 2011), making Nanog regulation an interesting model for analyzing 
the dynamic regulation of fluctuating but stable TF expression states. Recently, allele-specific 
expression of Nanog-as assessed by a combination of fluorescent in situ hybridization (FISH) 
to detect Nanog mRNA and protein-based assays involving fusion of destabilized fluorescent 
proteins connected to Nanog via a self-cleavable peptide-has been described as a potential 
mechanism for regulation of Nanog expression and, consequently, pluripotency (Miyanari 
and Torres-Padilla, 2012). These studies suggested that Nanog is predominantly expressed 
in a monoallelic manner in serum/LIF-cultured ESCs but biallelically in 2i ‘‘ground state’’ 
conditions, and they led to the conclusion that switching to higher biallelic Nanog expression 
is associated with a more stable pluripotent state. However, the underlying mechanisms 
and functional relevance remained unclear. To examine the allelic distribution of Nanog 
expression at the protein level, we created knockin ESC lines in which the two endogenous 
Nanog alleles are targeted with a yellow (VENUS) and red (KATUSHKA) fluorescent protein 
(FP), respectively (Fig.1A and Fig.1B). The FPs are fused to the C terminus of the Nanog 
protein, so they reflect all of the regulatory mechanisms influencing the amount of Nanog 
protein in ESCs and measure functionally relevant levels of Nanog protein, not separate 
markers that could have different stability or regulation. To confirm the functionality of the 
Nanog-FP fusions, the pluripotency of the NanogVENUS/KATUSHKA ESC reporter lines was tested 
in vitro and in vivo. Loss of Nanog leads to differentiation and loss of ESC maintenance, 
and Nanog-deficient embryos do not develop past the implantation stage (Mitsui et al., 
2003). In contrast, NanogVENUS/KATUSHKA ESCs survived and proliferated normally over at least 
250 population doublings in vitro, exhibited normal morphology of undifferentiated ESCs 
(Fig.1C), and expressed other ESC-pluripotency-specific TFs like Oct3/4, Sox2 (Fig.1D), 
and Rex1 (data not shown).
Both Nanog-FP reporters also showed normal downregulation during induced ESC 
differentiation upon LIF withdrawal (Fig.1H). We also verified the functionality of the 
NanogVENUS and NanogKATUSHKA fusion proteins through a tetraploid aggregation assay, the 
most stringent test for ESC pluripotency: normal day 9.5 embryos can be generated from 
NanogVENUS/KATUSHKA ESCs without contribution of tetraploid cells (Fig.1E). In addition, the 
stability of NanogVENUS and NanogKATUSHKA fusion proteins is identical to that of wildtype 
Nanog protein (Fig.1F). Thus, the normal function and stability of NanogVENUS and 
NanogKATUSHKA fusion proteins indicates that they can be used as faithful reporters of Nanog 
protein expression.
We used the labeled cells to examine Nanog expression. As previously described (Chambers 
et al., 2007), we saw a range of Nanog expression levels when the ESCs were cultured in 
serum/LIF conditions, although the dynamic range was not as broad as in some previous 
reports. We found that the extent of this variability of Nanog expression depended on 
culture conditions and strain background and could also vary between genetically identical 
ESC clones. However, we unexpectedly did not see evidence for widespread monoallelic 
expression of Nanog protein (Fig.1G).Instead, Nanog expression was highly correlated 
between the two alleles in terms of the expression level within individual cells. This situation 
remained unchanged in ESCs cultured over many weeks (data not shown). Consistent with
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Figure 1: Nanog protein is expressed from both alleles in embryonic stem cells. A) Targeting 
strategy for generation of allele specific fluorescent Nanog protein reporter alleles. White boxes denote 
Nanog Exons; asterisk denotes Nanog stop codon in Exon 4. B) Southern Blot analysis showing correct 
targeting of NanogVENUS/KATUSHKA clones 1 and 2. Expected band sizes are 7.7kb for wt Nanog, 6.5kb 
for VENUS fusion, and 10.1kb for KATUSHKA fusion. Southern Blot bands shown were run on the 
same gel, lanes without correctly targeted clones were removed from panel to save space. R1: parental 
wild type R1 ESCs. NV: R1 ESCs with only one Nanog allele targeted with VENUS construct. C) 
and D) Normal functionality of NanogVENUS and NanogKATUSHKA protein fusions. C) NanogVENUS/KATUSHKA 
ESC clones maintain normal undifferentiated morphology (size bar: 200μm), and retain expression of 
other pluripotency transcription factors (size bar: 50μm) (D). E) Contribution of NanogVENUS/KATUSHKA 
ESCs to normal embryo development at 9.5dpc (left panel) as examined by tetraploid aggregation 
demonstrates normal function of Nanog-FP fusions. Tetraploid cells for the generation of extra 
embryonic tissues were derived from a mouse with ubiquitous eYFP expression (right panel). F) Normal 
stability of NanogVENUS and NanogKATUSHKA protein fusions. Unchanged protein degradation rates (upon 
Cycloheximide treatment) demonstrate normal stability of Nanog-FP fusions. G) Nanog protein is not 
expressed in an allele specific way in ESCs. ESC populations cultured in serum/LIF conditions exhibit 
the expected heterogeneous Nanog expression. As with other reporters, Nanog distributions which can 
vary between clones and cultures. Culture in serum free medium containing chemical inhibitors of 
differentiation (ISTEM) leads to homogeneous Nanog expression. H) Induction of ESC differentiation 
by LIF withdrawal leads to Nanog down regulation but does not induce its monoallelic expression.
prior reports, Nanog expression changed to a more uniform high distribution in ESC 
populations cultured in 3i ground state conditions (Ying et al., 2008) (Fig.1G). We cannot 
exclude potential monoallelic Nanog protein expression in a very small subset (less than 2%) 
of ESCs due to potential noise levels of FACS analysis (individual dots in FACS plots of 
Fig.1G). We can, however, conclude that we do not see evidence for significant monoallelic 
Nanog expression in ESCs at the protein level. Although we did not analyze the potential 
for monoallelic Nanog protein expression in other ESC lines, the normal self-renewal and 
pluripotency properties of our cells suggest that monoallelic regulation of expression is not 
required for wild-type Nanog function.
It is unclear at this point what the basis is for the difference between our results and those of 
Miyanari and Torres-Padilla (Miyanari and Torres-Padilla, 2012). One possible explanation 
could lie with transcriptional bursts, which seem to occur at a low frequency even for actively 
expressed genes (Suter et al., 2011). Thus, FISH data from one point in time might detect 
transcription of only one allele because of burst behavior rather than overall monoallelic 
Nanog expression. Differences in terms of stability between the separate reporter proteins 
and Nanog itself could also influence the results seen at the protein level.
It is important to note that we did not analyze the potential for allele-specific bias of Nanog 
transcription. However, even if it occurs, our data suggest that it would not lead to prevalence 
of Nanog protein from one allele in ESCs, and thus it is not likely to be functionally relevant as a 
central mechanism of regulating pluripotency or heterogeneity in pluripotency TF expression. 
Instead, we would suggest that other regulatory mechanisms, including Nanog autorepression 
(Fidalgo et al., 2012; Navarro et al., 2012) and the topology of the pluripotency TF and 
signaling networks (MacArthur et al., 2012), underlie the heterogeneous molecular states 
seen in individual pluripotent cells. A related paper in this issue from Faddah et al. (Faddah et 
al., 2013) draws similar conclusions to ours regarding biallelic expression of Nanog, and in 
addition looks more broadly at variability in Nanog expression at the transcriptional level and 
the activity of a range of reporter constructs. Together, these studies will help inform future 
analysis of the regulation of Nanog expression and pluripotency networks.
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Methods
ESC culture. Mouse ESCs were cultured in DMEM basal medium (catalog number: 31053-
044, Gibco, CA, USA) supplemented with 2mM L-Glutamine (catalog number: 25030-024, 
Gibco, CA, USA), 100U Penicillin/Streptomycin (catalog number: 15140- 0122, Gibco, CA, 
USA), 1% Non-essential amino acids (catalog number: 11140-035, Gibco, CA, USA), 1mM 
Sodium Pyruvate (catalog number: S8636, Sigma, MO, USA), 10-4 M β-mercaptoethanol 
(catalog number: 31350-010, Gibco, CA, USA), 10% FCS (catalog number: 2602P250915, 
PAN, Aidenbach, Germany) and Leukemia Inhibitory Factor (LIF) on 0.1% porcine gelatin 
(Sigma, catalog number: G1890-100G) coated tissue culture grade plastic ware (Falcon, NJ, 
USA)ESCs were also cultured in serum free ISTEM medium (Ying et. al., 2008) (Catalog 
number: SCS-SF-ES-01, Stem Cells Inc. Cambridge, United Kingdom), or serum containing 
medium without LIF. 
Generation of targeting constructs. All steps for the generation of the plasmids containing 
fluorescent reporters and the targeting constructs were done using recombineering technology. 
Details are available upon request. 
ES Cell targeting. Mouse ESCs from the R1 parental line (129 sub-strain) were 
electroporated with linearized targeting vector and correct integration in Blasticidin (5 μg/
ml, catalog number: A11139-02, Invitrogen, CA, USA) resistant ES clones was confirmed 
by Southern blotting. NanogKATUSHKA heterozygous fusion mESCs underwent a second round 
of electroporation and were selected by G418 (200 μg/ml, catalog number: G8168-10ML, 
Invitrogen, CA, USA) addition. Resistant mESCs were then FACS (Fluorescence Activated 
Cell Sorting) sorted for VENUS positivity, reselected in G418 and confirmed for correct 
integration by Southern blotting.
Imaging and Immunofluorescence Staining. ESCs were cultured on gelatin coated μ-slides 
(Catalog number: 80606, Ibidi, Martinsried, Germany) in serum/LIF medium as described 
above. Images were acquired with a Zeiss Axio Observer Z1 microscope, an Axiocam Hrm 
camera (Zeiss, Munich, Germany) and a Lumencor Spectra-X multichannel light engine 
(Lumencor, Beaverton, USA). After cell fixation with 4% formaldehyde solution, it was 
confirmed that 100ms exposure (used for antibody detection below) does not yield detectable 
signals from fluorescent proteins. Cells were stained with a goat anti Oct3/4 antibody (1μg/
ml, Catalog number: sc8628, Santa Cruz, USA) and a rabbit anti Sox2 (2.5μg/ml, Catalog 
number: Ab5603, Millipore, USA) primary antibody. Secondary antibodies donkey anti-goat 
IgG Alexa 488 (4μg/ml Catalog number: A-11055, Invitrogen, California, USA) and donkey 
anti-rabbit IgG Alexa 555 (4μg/ml Catalog number: A-31572 Invitrogen, California, USA), 
were then applied Cells were counterstained with Roti-mount fluorcare DAPI solution and 
images of stained cells were re-acquired.
Fluorescence Activated Cell Sorting (FACS). Analysis of NanogVENUS/KATUSHKA double 
knockin ESCs was performed using a FACSAriaIII flow cytometer using a BD FACSDiva 
software package (Becton Dickinson, Heidelberg, Germany). The Blue 488nm laser 
combined with a 530/30 filter was used to detect NanogVENUS and the Yellow/Green 561nm 
laser combined with a 610/20 filter was used to detect NanogKATUSHKA. The R1 wt mESCs 
were used to set negative gates. 
Generation of Chimeras. Tetraploid chimeras were generated according to standard 
protocols and aggregations with NanogVENUS/KATUSHKA double knockin ESCs were performed 
in YV1 (Yellow fluorescent protein Viral 1) (a kind gift from Andras Nagy and Marina 
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Gerstenstein) and examined for contribution at embryonic day E10.5dpc.
Protein half-life assay. ES cultures were treated with 50μM Cycloheximide for 2, 4, 6 and 8 
hour intervals after which cells were lysed in 0.1% NP40 lysis buffer. Lysates were resolved 
by western blotting on 10% polyacrylamide gels and Nanog protein was detected with rabbit 
anti-Nanog antibody ab80892 (Abcam, Cambridge, United Kingdom). Quantification of 
protein levels was performed by Image J software using the Gel analyzer feature to gate on 
protein lanes and to uniformly quantify band intensities over background (NIH, USA).
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Introduction
Human pluripotent stem cells (hPSCs), both embryonic (ESCs) and induced (iPSCs) 
represent a renewable source of any cells of the body. These include the most important 
cells of the cardiovascular system: ECs (Orlova et al., 2013), cardiomyocytes (CMs) (Elliott 
et al., 2011), haematopoietic cells (HPCs) (Choi et al., 2011) and mural cells (Cheung et 
al., 2012). hPSCs are widely used as in vitro models to investigate molecular mechanisms 
underlying human development and disease. Of the distinct lineages that can be generated 
with this technology, those of the vasculature are of special interest as ECs are a major 
target of the deleterious effect of drugs and inherited diseases (Ardelean and Letarte, 2015). 
Although significant advances have been made in inducing endothelial differentiation from 
hPSCs (Masumoto et al., 2014; Orlova et al., 2013; Park et al., 2014; Skelton et al., 2014), 
new methods would be useful to identify the critical regulators guiding commitment and 
diversification of endothelial progenitors and allow the derivation of tissue type specific ECs 
(Wilson et al., 2014).
  
In vascular development, there is a close link between the formation of ECs and HPCs 
(Donaldson et al., 2005; Palis et al., 1999; Xu M et al., 2001). At embryonic day 7.5 (E7.5) 
of mouse development, a common competent cell state, known as the hemangioblast, 
has been described which is able to give rise to the primitive hematopoietic system and 
endothelial progenitors (Myers and Krieg, 2013). In fact the first definitive hematopoietic 
stem cells (HSCs) actually arise from hemogenic endothelium (HE), with blood-forming 
potential within the aorta-gonad-mesonephros (AGM) region at E10.5 embryo (de Bruijn et 
al., 2002; Medvinsky and Dzierzak, 1996; Muller et al., 1994; Zovein et al., 2008). The ETS 
domain transcription factor Etv2/Etsrp has been reported to be transiently expressed during 
mesoderm specification, giving rise to both hematopoietic cells and ECs cells in developing 
zebrafish, Xenopus laevis and mice (Liu et al., 2012a; Wong et al., 2009a). Ectopic expression 
of Etv2/Etsrp can significantly increase EC differentiation of mESCs and hESCs(Elcheva et 
al., 2014; Koyano-Nakagawa et al., 2012a; Lee et al., 2008a; Lindgren, 2015). However, the 
ETV2 interacting regulators and DNA binding sites driving this process during physiological 
endogenous expression are not known. Here, taking advantage of the forced aggregation 
(spin) embryoid body (EB)(Ng et al., 2008) based differentiation protocol of hESCs to 
mesoderm and then to ECs (Orlova et al., 2013), we examined the expression pattern of 
ETV2 over time. We found that ETV2 expression is enriched at day 4 of differentiation in 
both PDGFRα+APJ+KDR+ and PDGFRα-APJ+KDR+ mesodermal populations. Finally, 
we describe a new endogenous ETV2 tagging/reporter system based on gene targeting by 
homologous recombination and provide a recombineering pipeline for the generation of an 
ETV2-targeting construct. 
Results
Generation of endothelial cells from human embryonic stem cells
To generate endothelial cells from hESCs, we used previously described optimized 
differentiation protocols (Elliott et al., 2011; Orlova et al., 2013). Undifferentiated NKX2-
5eGFP/w hESCs were allowed to form spin embryoid bodies (EBs) by adding 2000 cells in 
suspension to each well of 96-well V-shape-bottomed low-attachment plate in defined medium 
(bovine serum albumin (BSA) Polyvinylalcohol Essential Lipids, BPEL) supplemented 
with a cocktail of cytokines inducing mesodermal differentiation: activin-A (ACT-A; 25ng/
ml), bone morphogenic protein 4 (BMP4; 30ng/ml), GSK3-kinase inhibitor (CHR-99021; 
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1.5umol/L), stem cell factor (SCF; 40ng/ml) and vascular endothelial growth factor (VEGF; 
50ng/ml) (Fig.1a). After three days, EBs were supplemented with VEGF (50ng/ml) and 
BMP4 (30ng/ml) until day 7. By day 7 under these conditions >13% of cells were expressing 
endothelial cell surface markers CD34 and KDR, contrasting with the differentiating cultures 
not supplemented with additional growth factors (‘No Factors’) (Fig.1b). 
To investigate whether the generation of ECs was absolutely dependent on VEGF, we omitted 
BMP4 from the medium after day 3 and supplemented EBs with VEGF alone. This analysis 
revealed similar timing of peak expression of the EC marker CD31 on day 5 independent 
of whether differentiation was with VEGF and BMP4 or VEGF alone (Fig.1c). Apart from 
the similar expression pattern of the CD31 transcript, the proportion of cell population co-
expressing the surface proteins CD31 and CD34 on day 8 of differentiation was similar under 
both differentiation conditions (Fig.1d). This suggested that the day4 population contains 
endothelial progenitors capable of generating ECs through activation of the VEGF signaling 
pathway.
ETV2 is transiently expressed in differentiating hESC
In both zebrafish and mice, specification of the vascular ECs is dependent on the 
transient expression of Ets variant 2 (Etv2) (Liu et al., 2012a; Wong et al., 2009a). To determine 
the timing of endogenous ETV2 expression in mixed population of hESCs differentiating into 
ECs, we supplemented the spin EBs with VEGF from day 3 of differentiation and analyzed 
over the subsequent 7-day period using quantitative real time PCR (qRT-PCR) (Fig.2). Our 
analysis revealed that the decline in expression of PSC markers, such as POU5F1 and NANOG, 
between days 2 to 3, overlapped with the expression of primitive streak and mesendoderm 
genes (EOMES, BRACHYURY (BRY), NODAL, SOX17) (Fig.2). BRY and EOMES have been 
reported to bind and regulate the promoter of MESP1 (Costello et al., 2011; David et al., 
2011) (a marker of common multipotent cardiovascular progenitor), and in accordance with 
this, we also found that MESP1 transcript levels were enriched in parallel (Fig.2). Analysis of 
VEGF-treated hESC-derived mesoderm mixed population revealed a transient wave of ETV2 
expression at day 4 to 6, identifying this timepoint as the stage of hemangioblast or HE in our 
differentiation system (Fig.2).
This data is consistent with previous findings from our group, demonstrating the kinetics 
of differentiation using the “monolayer” system in BPEL medium supplemented at day 3 
with VEGF or VEGF and SB43152 (SB, a TGFβ-I receptor kinase inhibitor) (Orlova et al., 
2013). Furthermore, the onset of genes that are important for hematopoietic and endothelial 
lineage development, such as GATA2, FLT4, PECAM1 and TAL1, overlapped with the peak 
of ETV2 (Fig.2), further confirming the bi-potentiality of this population. Interestingly, we 
also observed that cardiac differentiation transcription regulators, NKX2.5 and ISL1, were 
also upregulated at day 6 (Fig.2), but we were unable to detect any NKX2.5-eGFP expression 
using flow cytometry (data not shown), which is probably due to a slower and less robust 
cardiac differentiation under these culture conditions. These findings demonstrate that our 
differentiation protocol is a controlled sequential process starting from the early embryonic 
mesoderm, via a hematovascular mesodermal precursor stage, to ECs, recapitulating 
endothelial development in vivo. Therefore, it serves as a good system to further specify the 
cell population enriched in ETV2 expression. 
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Figure1. Characterization of hESC-derived endothelial cells. a. Schematic of the protocol used to 
differentiate hESCs to the endothelial lineage. ACT-A (activin), BMP4 (bone morphogenic protein 4), 
CHIR99021 (GSK3 inhibitor), SCF (stem cell factor), VEGF (vascular endothelial growth factor). b. 
Flow cytometry analysis showing the proportion of kinase insert domain receptor (KDR+)/CD34+ cells 
on day 7 of differentiation (n=3). Purple, positive cells. c. qRT-PCR analyses of CD31 expression at 
different stages (day-3 to 6) of differentiation. (n = 2) d. Flow cytometric analysis showing the average 
percentages of CD31+/CD34+ cells in the populations at day 8 of culture (n = 3).
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Enrichment of ETV2 expression in the APJ+KDR+ population
To determine whether the emerging ETV2 expressing cells can be distinguished by 
cell-surface markers, we next differentiated hESCs for 4 days and examined the expression 
of the mesodermal markers platelet-derived growth factor receptor-α  (PDGFRα) (Kataoka 
et al., 1997), angiotensin type I-like receptor (APLNR, here referred to as APJ) (Choi et al., 
2012; D’Aniello et al., 2009; Vodyanik et al., 2010) and vascular endothelial growth factor 
receptor 2 (VEGFR2 or KDR) (Shalaby et al., 1997) by flow cytometry. 
Kinetic analyses showed that PDGFRα cells emerged as early as day 2 (13%) of 
differentiation and by day 4, the proportion of positive cells increased to 60% (Fig.3a), 
approximately 9% of this fraction also co-expressed APJ and KDR (PDGFRα+APJ+KDR+) 
Figure2. Gene expression profiling of hESC-
derived EBs during endothelial differentiation. 
Heatmap demonstrating gene expression profiles 
(qRT-PCR analysis) of POU5F1, NANOG, 
NODAL, BRY, EOMES, SOX17, MESP1, ETV2, 
GATA2, TAL1, CD31, ALK1, ENG, ISL1, NKX2.5 
in hESC-derived EBs at different stages during 
differentiation (n =2).
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(Fig.3b, left panel), a pattern of interest given that hemangioblasts emerging on the day 
3 after hESC co-culture with OP9 stromal cells are PDGFRα+, APJ+ and KDR+ (Vodyanik 
et al., 2010). The development of this population was dependent on VEGF signaling as it 
did not emerge when supplemented with BPEL-only  (no factors) (Fig.3b, right panel). 
Rather, under this condition, we observed that the proportion of APJ+ cells increased from 
50% to 73% (PDGFRα+APJ+KDR-) and from 0.3% to 3% (PDGFRα-APJ+KDR-) on day-4 
of differentiation (Fig.3b, right panel). Interestingly, a small proportion of KDR+ cells co-
expressing APJ+ could be detected in the PDGFRa- fraction (PDGFRα-APJ+KDR+), similar 
to a previous observation in hESCs differentiated on OP9 at day 4 with a hematovascular 
precursor (HVMP) phenotype (Choi et al., 2012). 
qRT-PCR analyses of the different fractions in the day 4 population confirmed the flow 
cytometric findings (Fig.3c) and demonstrated reduced pluripotent gene expression (POU5F1, 
NANOG) (Fig.4d) and an upregulation of primitive streak-like and early mesodermal 
markers (BRY, EOMES, MESP1) in APJ+ fractions (PDGFRα+APJ+KDR- and PDGFRα-
APJ+KDR-) (Fig.3e), indicating the heterogeneity of the differentiating population and that 
day-4 APJ expression represents early mesoderm. Interestingly, emerging day-4 KDR+ 
cells (PDGFRα+APJ+KDR+ and PDGFRα-APJ+KDR+) highly expressed the hemangioblast 
markers (ETV2 and GATA2) (Fig.3f), suggesting that these populations could represent the 
hemangioblast stage from our hESC cultures. The expression profile of these populations also 
mirrored the upregulation of the first endothelial specific genes, including TIE2, TAL1, ENG, 
ALK1 and CD31 (Fig.3f). Collectively, these findings indicate that day-4 APJ+ cell population 
(PDGFRα+APJ+KDR- and PDGFRα-APJ+KDR-) consists of early mesoderm populations and 
that VEGF was sufficient to advance mesoderm specification toward a hematovascular fate, 
as signified by the increase of the KDR+ cell population.
Generation of ETV2 targeting construct for gene targeting by homologous 
recombination
To enable future purification and characterization of hESC-derived ETV2 expressing 
populations, we chose a knock-in tag/reporter gene targeting strategy, which relies on 
homologous recombination (HR). The C-terminus of the ETV2 protein is fused to a tag and a 
self-cleavable peptide, followed by a red (mcherry) FP. Using this approach, the gene on the 
target allele is not deleted and the tag/reporter is introduced without creating heterozygous 
lines.  
As a first step for generating the ETV2 targeting construct, we subcloned the BAC containing 
the ETV2 gene into a p15A/ampicillin targeting vector with short homology arms (HA) (7 
kb 5’HA and 3kb 3’HA) using Red/ET recombineering technology (Ciotta et al., 2010). 
Furthermore, a negative selection cassette (herpes simplex virus thymidine kinase gene 
(HSV-TK)) driven by HSV promoter was present in the backbone of the targeting vector 
allowing counter-selection by FIAU or gancyclovir for selecting against random integration 
events.
As a second step we aimed to insert the tagging/reporter cassette by recombineering in the 
ETV2 targeting vector (Fig4a). The tagging/reporter cassette was built from the R6Kγ-
origin plasmid and consists of the regions encoding the protein tag (tag), a Thosea asigna 
virus 2A peptide (T2A), a red (mcherry) FP and an antibiotic resistance protein (NeoR, 
Neomycin phosphotransferase). The tag region is composed of a composite affinity tag 
sequence encoding a biotinylable tag (Bio), a protease cleavage site (PreScission), a Flag 
tag, a second protease cleavage site (Tev) and a V5 affinity tag, allowing multi-step protein 
purification to be performed. The T2A sequence, encoding a self-cleaving 2A peptide, was 
placed upstream of the FP sequence leading to the translation of two separate proteins when 
ETV2 is expressed: a fusion tagged ETV2 protein and a red fluorescent protein. Because the 
ETV2 gene is not expressed in hESCs during the gene targeting selection process, we used 
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a promoter-driven antibiotic resistance gene (PGK-NeoR) selection cassette flanked by FRT 
site-specific recombination target sites. This system allows the identification of correctly 
targeted events after the modified ETV2 targeting construct has been transfected into hESCs 
(Fig.4b) by screening G418 resistant colonies either by Southern blotting or long-range 
PCR (Fig.4b). Finally, since the PGK (phosphoglycerate kinase) promoter can interfere with 
expression of the tagged gene either at the transcriptional or post-transcriptional level, the 
selection cassette can be removed by transient expression of Cre-recombinase (Fig.4c).
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Figure3. Characterization of major subsets of day-4 hESC-derived mesodermal cells. a. Kinetics 
of expression of PDGFRa in differentiating hESCs. b. Flow cytometry analysis of day-4 hESC-derived 
mesoderm cells supplemented with VEGF (left panel) or without any growth factor (no factor, right 
panel) at day 3 of differentiation (n =2). c-f. Heatmap demonstrating expression profiling (qRT-PCR) of 
selected genes associated with primitive streak, lateral plate mesoderm, endothelial and hematopoietic 
cells in day-4 population subsets (n =1). 
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Figure 4. Targeting ETV2 allele by homologous recombination. a. At top, the targeting construct for 
ETV2 after subcloning from the BAC containing 7 kb upstream (5’HA) and 3 kb downstream (3’HA) 
of the stop codon (stop). At bottom, insertion of the tagging/reporter cassette (tag-T2A-mcherry-FRT-
PGK-NeoR-FRT) fragment using recombineering technology. b. Structure of the final ETV2 targeting 
construct used to insert the tagging/reporter cassette before the stop codon of the ETV2 locus using 
homologous recombination. c. Southern blot and long-range PCR (LR-PCR) screening strategy on 
G418 resistant hESC colonies. d. Removal strategy of the selection cassette (PGK-NeoR) from correctly 
targeted hESC colonies by Cre-mediated recombination. Black rectangles denote ETV2 exons. E, exon; 
HA, homology arms; HR, homologous recombination; stop (red circle); ETV2 stop codon sequence; 
tag (purple rectangle), Bio-PreS-Flag-Tev-V5; T2A (blue rectangle), self-cleaving 2A peptide; mcherry 
(red rectangle), red fluorescent protein; PGK-NeoR (white rectangle), mammalian promoter driven 
gene encoding G418 resistance; LoxP (black triangle), LoxP site; AseI, AseI restriction site; 5’ probe, 
probe hybridization domain for Southern blot analysis; small arrows, forward and reverse primers for 
long range-PCR (LR-PCR) screening. 
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Discussion
Our study showed that hESC can recapitulate key aspects of human endothelial 
development through a directed spin EB differentiation protocol that generates ECs. With this 
approach, we were able to generate CD31+CD34+ ECs in vitro and confirm that generation 
of human endothelial lineage is dependent on VEGF signaling, as described by others (Bao 
et al., 2015). These observations are consistent with those from a recent study from our group 
(Orlova et al., 2013), demonstrating the generation of functional ECs from hPSCs using a 
“monolayer” differentiation system. It remains to be determined whether the ECs generated 
from the spinEB protocol also display functional properties in vivo (Orlova et al., 2013). 
Through analysis of ETV2 expression in VEGF-treated hESC-derived mesoderm population, 
we were able to identify the time window in our differentiation for hemangioblast specification 
that could represent fate commitment for hematopoietic and vessel development as seen in the 
mouse embryo (Ferdous et al., 2009; Kataoka et al., 2011; Liu et al., 2012b; Wong et al., 2009b). 
Our demonstration that ETV2 expression is enriched in PDGFRα+APJ+KDR+ and PDGFRα-
APJ+KDR+ fractions provides strong evidence that these cell populations are equivalent to 
the hemangioblast stage, as studies following hPSC differentiation in co-culture with OP9 
stromal cells have shown the potential of these populations to generate hematovascular cells 
in vitro (Choi et al., 2012; Vodyanik et al., 2010). Additionally, it remains to be determined 
whether spinEB-derived PDGFRα+APJ+KDR+ and PDGFRα-APJ+KDR+ fractions are also 
able to form hematoendothelial clusters under appropriate culture conditions. 
 
A plethora of in vivo studies have described the critical role of Etv2 in the development of 
both blood and endothelial lineages (Liu et al., 2012b; Wong et al., 2009b). ETV2 belongs to 
the transcriptional regulatory ETS protein family and is transiently expressed in the primitive 
streak, yolk sac blood islands, and large vessels such as dorsal aorta during early embryonic 
development (Lee et al., 2008b). Ectopic transient expression of etv2 in differentiating 
mESCs(Koyano-Nakagawa et al., 2012a; Lee et al., 2008b) and hESCs(Elcheva et al., 2014; 
Lindgren et al., 2015) has been demonstrated to be effective in increasing the number of ECs. 
Mechanistically, Etv2 regulates this process through interaction with other factors, such as 
OVOL2 (Kim et al., 2014), Jmjd1a (Knebel et al., 2006) and Gata2 (Shi et al., 2014), and 
direct activation of critical genes for blood and endothelial lineages, including VE-cadherin 
(Cdh5), Fli1, Erg, Tie2 and Lmo2 (Koyano-Nakagawa et al., 2012b; Liu et al., 2012b). On 
the other hand, Scl and Nkx2.5-mediated transcriptional repression of etv2 is functionally 
responsible for the development of endocardial and myocardial precursor cells during zebrafish 
embryogenesis (Schupp et al., 2014). This diverse role of Etv2 in different mesodermal fate 
choices indicates that Etv2 plays a protagonist role in transcriptional complexes mediating 
mesodermal plasticity of early progenitor cells. Thus, new strategies are necessary to allow 
non-invasive identification of novel Etv2-specific cellular markers and characterization of 
the transcription factor network and its binding sites throughout differentiation of hESCs.
 
Here, we describe a new endogenous ETV2 tagging/reporter system based on gene targeting 
by homologous recombination. A hESC ETV2 knock-in tag/reporter line, in which the 
C-terminus of the endogenous Etv2 protein is directly fused to a composite affinity tag 
protein followed by a self-cleavable peptide and a red fluorescent protein, will provide 
a powerful tool to decipher the molecular mechanisms governing the function of Etv2 
during endothelial and/or hematopoietic specification in vitro.  Through this approach, 
the expression of functional etv2-tag protein will allow multi-step protein purification to 
be performed using TAP (tandem affinity purification) technology(Rigaut et al., 1999) in 
order to identify: i) new protein components of the Etv2 TF network by mass spectrometry, 
ii) new genome-wide critical tissue-specific binding sites or target genes of Etv2 using 
chromatin immunoprecipitation coupled to ultra high throughput sequencing (ChIP-Seq) 
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analysis. Furthermore, characterization of the first cells to express red fluorescent protein 
(mcherry) during our differentiation protocol using both antibody arrays and transcriptomic 
technologies could enable the identification of new cell surface marker signatures, which 
can be associated with new regulatory growth factors and signaling pathways during 
hematopoietic or endothelial specification. 
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Materials and Methods
Human embryonic stem cell culture and differentiation. The NKX2-5eGFP/w hESC 
line(Elliott et al., 2011), in which the generation of NKX2-5+ cells can be followed by eGFP 
expression, was maintained as reported elsewhere(Devalla et al., 2015)  and differentiated as 
spin EBs according to previously established protocols(Ng et al., 2008; Orlova et al., 2013). 
Defined medium containing bovine serum albumin and polyvinylalcohol essential lipids 
(BPEL), was supplemented with the following growth factors at the concentrations indicated: 
30ng/ml BMP4 (Miltenyi Biotec, 130-095-549), 25ng/ml Activin A (Miltenyi Biotec, 130-
095-547), VEGF165 (R&D Systems, 2930VE), 1.5umol/L GSK3-kinase inhibitor (CHR-
99021, Tocris Bioscience, 4423), 50ng/ml human bFGF (Miltenyi Biotec, 130-093842) and 
40ng/ml SCF (Miltenyi Biotech). 
Flow cytometric analysis. EBs were dissociated with 1xTrypLE Select (Gibco, 12563029) 
and prepared for cell sorting at day 4 of culture on BD FACSAria III (BD Bioscience) as 
described previously(Birket et al., 2015). The antibodies used in this study were phycoerythrin 
(PE)-conjugated anti-human kinase insert domain receptor (KDR) (1:20, R&D Systems, 
FAB357P), anti-human PDGFRa; peridinin-chlorophyll (PerCP-Cy5.5)-conjucated anti-
human CD34 (1:100, BD Pharmingen, 347203), anti-human kinase insert domain receptor 
(KDR); allophycocyanin (APC)-conjucated anti-human CD31 (1:100, eBioscience, 17-
0319), anti-human APLNR. Flow cytometry gates were set using control cells labeled with 
appropriate isotype control antibody. 
 
Gene expression analysis. EBs were collected at the days indicated, put on ice and processed 
for RNA extraction. Total RNA was isolated using NucleoSpinII RNA Kit (Macherey-
Nagel), DNase treated using Ambion TURBO (Life Technologies) and complementary 
DNA (cDNA) was made from equal amount for all samples using iScriptII (BioRad). 
Quantitative real time PCR (qRT-PCR) was performed under standard conditions with an 
initial denaturation step of 3 min at 95oC followed by 40 cycles of 15 s denaturation at 
95oC, 30 s annealing at 60oC, and 45 s extension at 72oC using the primer sets listed in 
Supplementary Table 1. qRT-PCR was performed using SYBR Green Supermix (Bio-Rad) 
mixture and expression levels were normalized to hARP gene and calculated as described 
previously (Orlova et al., 2013). Heatmaps were generated using the ggplot2 package, 
included in R/Bioconductor.Illu-mina microarray data were processed using the lumi package 
and differentially expressed genes were identified using the limmapackage, included in R/
Bioconductor [25, 26]. ConsensusPathDB-human (http://cpdb.molgen.mpg.de/) web server 
was used forgene ontology analysis. Additional analysis was performed usingGenespring 
(Agilent Technologies, California, USA)
Generation of targeting constructs. The subcloning step from the BAC carrying the ETV2 
genomic sequence (RZPDB737H072181D) and the insertion of the tagging/reporter cassette 
into the p15A targeting construct were performed using recombineering technology(Ciotta 
et al., 2010). Oligonucleotides used for recombineering are described in Supplementary 
Table 2.  The tag protein was conventionally cloned into R6K-vector giving rise to pR6K-
Bio-PreS-Flag-Tev-V5-T2A-mcherry-FRT-PGK-NeoR-FRT. The ETV2 targeting construct 
was generated by first subcloning from the BAC using oligonucleotides ETV2-sub1 and 
ETV2-sub2 into p15A-vector. The tagging/reporter cassette was inserted upstream the stop 
codon using the oligonucleotides  ETV2-fusionstop-1  and ETV2-fusionstop-2 giving rise to 
the final ETV2 targeting construct.  Materials for recombineering were kindly provided by 
Richard Davis (Anatomy and Embryology, LUMC, The Netherlands). 
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Statistical Analysis. Data were analysed by one-way analysis of variance, and un-paired 
Student’s t-test using Prism software (GraphPad) and expressed as mean ±SEM. 
Acknowledgements: We thank Richard Davis for recombineering reagents. This work was 
supported by the Netherlands Heart Foundation (CLM. NHS2008B106) and the Stichting 
Weber-Ondu-Resler SWORO (KG). 
Supplementary Table 1. Quantitative real time PCR (qRT-PCR) primers
Supplementary Table 2. Recombineering primers
Genes Forward primer 5’-3’ Reverse primer 5’-3’
POU5F1 ACGACCATCTGCCGCTTTG GCTTCCTCCACCCACTTCTG
NANOG GCCGAAGAATAGCAATGGTG TGGTGGTAGGAAGAGTAGAGG
NODAL GGCTCAGGAAGGAGAAGTCA TACATGCTGAGCCTCTACCG
BRY ATCACCAGCCACTGCTTC GGGTTCCTCCATCATCTCTT
EOMES TCTGTCCCATTGAGCTTCTC TCTGTCCCATTGAGCTTCTC
SOX17 TGTCACCCCTGTCCTCTGCCTCAC TTGTAGTTGGGGTGGTCCTG
MESP1 CTCTGTTGGAGACCTGGATG CCTGCTTGCCTCAAAGTG
ETV2 CAGCTCTCACCGTTTGCTC AGGAACTGCCACAGCTGAAT
GATA2 CACAAGATGAATGGGCAGAA GCCATAAGGTGGTGGTTGTC
TAL1 GGATGCCTTCCCTATGTTCA CTGTTGGTGAAGATACGCCG
CD31 CAGGTGTTGGTGGAAGGAG GGATCGTGAGGGTCAACTG
ALK1 CTGGTTCCGGGAGACTGAGAT TGCGGGAGGTCATGTCTGA
ENG CCCGCACCGATCCAGACCACTCCT TGTCACCCCTGTCCTCTGCCTCAC
ISL1 TGATGAAGCAACTCCAGCAG GGACTGGCTACCATGCTGTT
NKX2-5 TTCCCGCCGCCCCCGCCTTCTAT CGCTCCGCGTTGTCCGCCTCTGT
PDGFRα ATTGCGGAATAACATCGGAG GCTCAGCCCTGTGAGAAGAC
APJ TTCTGCAAGCTCAGCAGCTA GGTGCGTAACACCATGACAG
KDR CCATCTCAATGTGGTCAACCTTCT TCCTCAGGTAAGTGGACAGGTTTC
TIE2 TCTCTGTGGAGTCAGCTTGC AGGCAATGCAGGTGAGAGAT
HARP CACCATTGAAATCCTGAGTGATGT TGACCAGCCCAAAGGAGAAG
Name Sequence 5’-3’
ETV2-sub1 CATCTCCTTCCTCAGCCATTGCACGGCTGCCCCATGGCGTCTGTGATAT-
GGCGTCGACGCTCTCCTGAGTAGGACAAATC
ETV2-sub2 GTAGCGGTGCGCATCTGTAATCCCAGCTACTCGGGAGGATGAGGCGG-
GAGAATCGTCGACTCCGCCTCAGAAGCCATAGA
ETV2-fusionstop-1  GCCTAGCCTATCCGGACTGTGCGGGAGGCGGACGGGGAGCAGAGACA-
CAAGAGAACCTGTACTTCCAGGGCGGCGGCCCGGCGGCGGCA
ETV2-fusionstop-2 AAGAATGCTGCAGAGGAGCACGCGCGAAGAGGTTTGACCGG-
GAATTTTTAGATGGATGCAGAGTGTGCGTAGACTATGAACGTACTTAAC
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One of the most exciting breakthroughs in stem cell research of the last couple of 
years has been the discovery that it is possible to reprogram somatic cells, for example from 
skin, to a developmental ‘ground state’ (induced pluripotent stem cells, iPS cells). This means 
that cells from an adult individual can be turned into pluripotent stem cells that are broadly 
indistinguishable from embryonic stem cells (ESCs) derived from early human embryos. In 
2006, Takahashi and Yamanaka discovered that simply introducing four ‘pluripotency genes’ 
(genes identified previously as being prominently expressed in ESCs) into mouse skin cells 
made them immortal and able to form all cells in the body of an adult mouse (Takahashi and 
Yamanaka, 2006).Previously, the only way to make somatic cells become pluripotent was by 
somatic cell nuclear transfer (SCNT). This involves transferring a somatic cell nucleus into 
an unfertilised egg and then reisolating cells from the resulting embryo after a few days of 
culture. Human SCNT, also referred to as ‘therapeutic cloning’, is banned in many countries, 
including the Netherlands, since an embryo is created as an intermediate step. Since the first 
generation of iPS cells from human skin in 2007 (Takahashi et al., 2007; Yu et al., 2007), this 
technology has become a robust way of obtaining pluripotent stem cells, not only from skin 
of healthy individuals but also from patients with specific (genetic) diseases (Park et al., 
2008). Much of the technology developed for characterising and inducing differentiation 
of human ESCs in culture has proven transferable to human iPS cells (Yamanaka, 2009). In 
the context of the study of cardiovascular disease, this means it should be possible to derive 
pluripotent stem cells from tissue samples of specifically chosen patients, differentiate them 
into cardiovascular derivatives (cardiomyocytes, vascular endothelial cells, vascular smooth 
muscle cells and possibly cells of the conduction system), and study the effects of the disease 
on the phenotype and physiology of those cells (Freund and Mummery, 2009; Passier et 
al., 2005).A potential caveat is that differentiated stem cells in culture tend to be immature 
compared with their normal adult counterparts so the question will be whether the disease 
phenotype does in fact manifest, and this is an area currently subject to intense research.
Cardiovascular disease is still one of the leading causes of death in the Western world. 
Although deterioration in heart function can be initiated by multiple extrinsic factors (diet, 
high blood pressure, atherosclerosis and infarction), intrinsic factors (gene mutations, genetic 
variants leading to predisposition) are also known to underlie many of the cardiovascular 
diseases. For example, some patients suffering from long-QT syndrome have a mutation 
in a gene encoding the cardiac sodium ion channel, and can develop severe arrhythmias 
unexpectedly with a high risk of sudden cardiac death (Ruan et al., 2009). In many cases, 
a combination of the genetic abnormality and extrinsic stimuli can precipitate onset of 
arrhythmia. To date mechanisms of genetic cardiovascular disease have mainly been studied 
in animal models, especially transgenic mice expressing ectopic genes or with specific gene 
mutations. Differences in the physiology of mouse and human hearts (with beat rates of 500 
beats/min vs. 60 to 80 beats/min respectively being the most striking) are limiting aspects 
of the mouse as a good model of human cardiac diseases. The advent of iPS cell technology 
may now offer new models for disease physiology in the human heart and vascular system.
The four transcription factors used by Yamanaka for deriving human iPS cells from fibroblasts 
were OCT4, SOX2, KLF4 and C-MYC (Takahashi et al., 2007). Recent publications have 
now shown that cells from several different adult tissues can also be reprogrammed (Aasen 
et al., 2008; loh et al., 2009), and that depending on the endogenous expression profile of the 
starting cell population or the addition of chemicals or small molecules, c-myc (an oncogene) 
and also other factors may be dispensible for this process (Kim et al., 2009; Shi et al., 2008). 
In addition, intensive research is being conducted on reprogramming methods independent 
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of DNA-integrating retrovirus or lentivirus (e.g. adenovirus or direct plasmid transfection) 
(Okita et al., 2008; Stadtfeld et al., 2008). However, with all of these approaches, the 
reprogramming efficiencies remain low and the process is labour intensive. With whatever 
method used, the pluripotent state of the reprogrammed human cells must be demonstrated. 
This is typically achieved by confirming that the iPS cells express a gamut of markers 
normally associated with human ESCs, and the ability to form benign tumours (teratomas) 
in immunodeficient mice. The teratomas should consist of tissues arising from all three 
embryonic germ layers, such as cartilage, muscle, primitive neural cells and gastrointestinal 
tract tissue. In addition to the generation of human iPS cell lines that do not have any obvious 
genetic abnormalities, there are now multiple examples of iPS cell lines derived from patients 
with genetic diseases (Park et al., 2008). By deriving the afflicted cell type from these iPS 
cells, it may be possible to study how the disease develops, and in the near future these 
differentiated cells could be used to screen new drugs and chemical compounds to inhibit 
disease progression. For example, an iPS cell line was recently derived from a patient with 
spinal muscular atrophy (SMA) (Ebert et al., 2009). SMA-patients suffer from selective 
loss of a certain type of motor neurons, resulting in life-threatening progressive muscular 
atrophy and weakness. The underlying cause of the disease is a mutation in the survival 
motor neuron 1 gene (SMN1). Although SMA-iPS cells initially produced similar numbers 
of motor neurons as wildtype iPS cells, at later time points they were fewer in number and 
were smaller in size. These initial experiments demonstrate that SMA-iPS can at least partly 
recapitulate features of the disease observed in vivo, and the iPS cell model may provide a 
platform for identifying compounds that prevent cell deterioration. In the long-term, patient-
specific iPS could also be used in cell replacement therapies, for example, transplantation of 
iPSderived cardiomyocytes after cardiac infarction. However, there are still many issues to 
be solved before even the transplantation of embryonic stem cell-derived cardiomyocytes can 
occur (Freund and Mummery, 2009; van Laake et al., 2007). With patient-specific iPS cells, 
no rejection reaction would occur, because the transplanted cells would be immunologically 
identical to the individual.
We have now established human and mouse iPS cell technology in our laboratory, and have 
derived several human iPS cell lines from skin fibroblasts obtained from healthy individuals, 
and more recently from a biopsy of a patient with a vascular disease known as hereditary 
haemorrhagic telangiectasia (HHT). HHT is a familial disease characterised by small vascular 
malformations on the skin and mucosal linings and epistaxis. These are the first healthy and 
disease human iPS cell lines to be generated in the Netherlands and are described here for 
the first time. Human skin fibroblasts were reprogrammed by retroviral overexpression of 
the four transcription factors OCT3/4, SOX-2, KLF4 and C-MYC, the most reproducible 
method described to date. Four weeks after retroviral infection, small, tightly packed colonies 
emerged, which displayed the typical morphology of human embryonic stem cells, e.g. large 
nuclei, a small amount of cytoplasm and tight intercellular contacts (Fig.1A and B). Similar 
to hESCs, the iPS cells derived expressed a typical set of human stem cell markers, including 
OCT3/4, SOX-2, Nanog, SSEA-3, and TRA-1-81, but were negative for mouse ESC marker 
SSEA-1 as determined by immunostaining (Fig. 1C to H). The expression of additional 
stem cell markers at the mRNA level was confirmed by semiquantitative RT-PCR (data not 
shown). In culture, the iPS cells continuously self-renew and have so far been maintained 
for more than 30 passages (more than six months) without any obvious phenotypic changes. 
Additionally, all of these human iPS cell lines display a wide spectrum of differentiated cell 
phenotypes when appropriately stimulated in culture, including cardiomyocytes and vascular 
endothelial cells.
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Figure1. Undifferentiated human iPS cells (A) resemble undifferentiated hESC (B) in morphology. 
Immunofluorescence analysis of undifferentiated iPS cells for a range of proteins expressed in 
undifferentiated embryonic stem cell (C-H). Undifferentiated human iPS cells express pluripotency 
transcription factors OCT3/4, SOX-2 and Nanog (C-E, nuclear localisation) and cell surface markers 
TRA-1-81 and SSEA-3 (F, G) but are negative for the mouse ESC marker SSEA-1 (H). All cells were 
co-stained with a nuclear dye (Dapi, blue).
Figure2. Human iPS cells can differentiate into cardiomyocytes in co-culture with END-2 cells. 
Immunofluorescent staining of contracting areas with antibodies against cardiac structural proteins 
β-myosin heavy chain (A, red) or α;-actinin (B, C, red) and cardiac transcription factor NKX 2.5 (A, 
B, green). At higher magnifications, cells stained for α;-actinin show the characteristic striated pattern 
of cardiomyocytes (C). All cells were co-stained with a nuclear dye (Dapi, blue).
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We have developed an efficient co-culture system to differentiate hESC into cardiomyocytes 
(Freund et al., 2008; Mummery et al., 2003; Passier et al., 2005). This method recapitulates 
signals present in early embryonic development, where the endoderm cell layer provides 
signals to drive cells in the adjacent mesoderm into the cardiac lineage (Nascone and Mercola, 
1995). When seeded on visceral endoderm-like (END-2) cells, hESC form rhythmically 
contracting areas within seven days following initiation of co-culture. Similarly, contracting 
areas appeared within a similar time frame when human iPS cells were co-cultured with 
END-2 cells. The cardiac identity of beating cells derived from the human iPS cells was 
confirmed by immunostaining with cardiac specific markers α;-actinin, β-myosin heavy 
chain (MHC) and NKX-2.5 (Fig. 2A and B). In addition, the cells showed an intracellular 
striated pattern that is typical for cardiomyocytes (Fig. 2C). As expected, the HHT human 
iPS cell lines were also pluripotent and able to form cardiomyocytes (data not shown). 
Currently, further characterisation of these iPS cell-derived cardiomyocytes using patch-
clamp electrophysiology and multielectrode arrays (MEA) is ongoing, and responses to drugs 
that, for example, alter QT interval, are being investigated. Whilst preliminary, the stability 
of the cells lines including their maintenance of a normal karyotype is encouraging, and 
demonstrates that the methodology used can be extended to studies of other cardiovascular 
genotypes of interest, particularly those with an expected electrophysiological phenotype 
such as long QT or Brugada syndrome.
The generation of iPS cell lines from patients with mutations in genes encoding contractile 
proteins will also be of interest. Hypertrophic cardiomyopathy (HCM) is frequently caused 
by mutations in genes encoding sarcomeric proteins (e.g. β-myosin heavy chain) which 
often leads to impaired contractile performance (Soor et al., 2009). Recent publications have 
shown that contractile properties of cells can be demonstrated in vitro by plating for example 
cardiomyocytes on flexible substrates where the degree of distortion is proportional to the 
contractile force (Feinberg et al., 2007).
The iPS cell lines generated in our laboratory to date were all derived from fibroblasts grown 
from skin samples. Small biopsies are at the borderline of feasibility because quiescence 
of skin fibroblasts, precluding retroviral reprogramming, can occur before sufficient 
numbers have been obtained in culture. Currently we are investigating whether alternative 
sources of somatic human cells, perhaps more readily available in the clinic, can be used 
for reprogramming. For example, keratinocytes from hair follicles have been reported to 
reprogram more efficiently than skin fibroblasts (Aasen et al., 2008). A small volume of blood 
(  3 ml) may also contain sufficient reprogramming-permissive cells. In addition, experiments 
to reprogram cells without the use of retroviral vectors are ongoing, including the re-excision 
of integrated DNA encoding the reprogramming factors after complete reprogramming.
With the development iPS cell technology three years ago, a new era of disease pathology 
and possibly future therapy is evolving: easily accessible cells from the adult body and cord 
blood can be converted within a few weeks into an embryonic stem cell-like state, which in 
turn can differentiate into many cell types of the human body. We have shown here that we 
are able to convert a cell from a skin sample of an individual to a beating cardiomyocyte from 
the same individual in a best case, within eight weeks. In instances where a cell from a patient 
with a genetic mutation is reprogrammed, the resulting iPS cell line and its differentiated 
derivatives will serve as excellent models for a better understanding of mechanisms 
underlying the disease. This, together with the ability to test new drugs, will lead to novel 
therapeutic concepts in the near future. In the long-term, iPS cell derivatives may also serve 
as a customised source of cells for cell replacement therapies. To achieve these goals in the 
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cardiovascular field, close collaboration between clinicians from the principal hospitals in the 
Netherlands and basic researchers could support major contributions to the field worldwide.
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The discovery that somatic cells in humans can be reprogrammed to a pluripotent 
state as induced pluripotent stem cells (hiPSC) (Takahashi et al., 2007; Yu et al., 2007) has 
presented unprecedented opportunities to study cell types normally inaccessible for research 
as biopsies. These include cells of the cardiovascular system like cardiomyocytes, endothelial 
cells (ECs), smooth muscle cells and epicardial cells (Cheung et al., 2012; Choi et al., 2009; 
Witty et al., 2014; Zhang et al., 2009).
Endothelial cells from hiPSC from healthy individuals (hiPSC-ECs) offer opportunities to 
model early human vascular development (Choi et al., 2009; Rafii et al., 2013), whereas 
hiPSC-ECs derived from patients with genetic vascular disorders in principle enable 
research on the molecular alterations responsible for vascular disease pathology (Kinnear et 
al., 2013). Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber syndrome, 
is an autosomal dominant vascular disorder, which affects 1:5000 individuals. The major 
clinical symptoms are arteriovenous malformations (AVMs), ranging from small AVMs or 
telangiectases in the nasal septum, oral mucosa and gastrointestinal tract to large AVMs in 
lung, brain and liver. Most cases of HHT are caused by mutations in one of two receptors of 
the transforming growrh factor (TGF)β family, endoglin (ENG) or activin receptor-like kinase 
1 (ALK1 or ACVRL1), which are mainly expressed by ECs and lead to HHT1 and HHT2, 
respectively (Shovlin, 2010). Haploinsufficiency for ENG or ALK1 has been shown to be the 
underlying cause of HHT (Pece-Barbara et al., 1999). TGFβ receptors regulate transcription 
via receptor-dependent phosphorylation of SMAD proteins (Pardali et al., 2010), where their 
nuclear accumulation mediates downstream transcriptional responses. Previous studies have 
shown that studying the signaling responses to TGFβ ligands is confounded by effects of 
culture density in many cell types: signaling appears coupled to cell density (Petridou et 
al., 2000; Varelas et al., 2010; Zieba et al., 2012) making interpretation of the relevance to 
endothelial cells in vivo and in vitro difficult. How endoglin and cell density are coupled and 
affect TGFβ signaling in healthy hiPSC-ECs and HHT1 hiPSC-ECs is unknown. Since we 
wished to use hiPSC-EC as a model for studying HHT1 to investigate the consequences of 
reduced ENG in ECs, a necessary prelude was to determine ligand responses as a function 
of EC culture density. We found that cell density is an important determinant for SMAD 
activation in hiPSC-ECs and that ENG haploinsufficiency in response to TGFβ family 
members. Under controlled cell density culture conditions we were then able to compare 
hiPSC-ECs from healthy controls and from an HHT1 individual by microarray; this showed 
that ENG was reduced as expected but another gene (MTUS1), which has been previously 
linked to TGFβ signaling in chicken (Kosla et al., 2013), was strikingly upregulated. Delivery 
of two different ENG siRNAs in control hiPSC-ECs resulted in the upregulation of MTUS1 
mRNA and protein levels, further suggesting the direct link between ENG and MTUS1. 
This was shown at the protein and mRNA level to be independent of cell density by siRNA 
knockdown in control hiPSC-EC.  Further, MTUS1 was upregulated in vivo in human skin 
ECs from HHT1 patients. Thus MTUS1 is a new TGFβ signaling candidate gene that is 
highly upregulated when ENG levels are reduced. 
Results
ENG and cell proliferation of hiPSC-derived EC cells
Several studies in mouse and human tissues have indicated that endoglin is broadly 
expressed in endothelium during development as vessels form through angiogenesis but that 
it is expressed at low levels in quiescent adult endothelium (Lebrin et al., 2004). However, it 
is upregulated when endothelium is activated, for example as an injury response following 
tissue damage or during inflammation (van Laake et al., 2006). Whether this is cause or effect 
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is unknown. Here, we exploited some recently generated hiPSC lines from HHT1 patients 
(Orlova et al in prep;(Freund et al., 2010)) to determine whether ECs from these HHT1 
hiPSC lines showed reduced proliferation in vitro.
We first measured the levels of ENG mRNA and protein in hiPSC-ECs to determine whether 
these had been maintained at the (reduced) levels in mononuclear cells in peripheral blood 
from HHT1 patients (Orlova et al, in prep) during the reprogramming process. hiPSC-ECs 
were derived as described previously (Orlova et al., 2013; 2014) from control and ENG 
mutant hiPSC lines. Constitutively reduced ENG mRNA and protein levels were detected 
in HHT1 patient hiPSC-ECs when compared to controls (Fig.1A, Fig.1B). Proliferation was 
then assessed as the number of human ECs after 24, 36, 48, 60 and 84 hours of plating in 
culture in the presence of low concentrations of VEGF. Growth rates were similar over the 
whole time course (Fig.1C) suggesting that reduced ENG within this range does not affect 
proliferation of these patient derived hiPSC-derived ECs in culture. 
Figure 1. Reduced levels of ENG in HHT1 iPSC-ECs (HHT1) are not affected in cell proliferation. 
hiPSC-ECs were grown for 24, 36, 48, 60 and 84 hours in culture, when ENG mRNA, protein levels 
and cell number were measured. A. ENG mRNA levels in Control and HHT1 hiPSC-ECs measured by 
RT-qPCR (n=3). B. ENG protein levels in Control and HHT1 hiPSC-ECs measured by FACs (n=3). C. 
Proliferation growth rates assessed as the cell number of Control and HHT1 hiPSC-ECs (n=3). All error 
bars represent s.e.m. *P < 0.05, **P< 0.01, ***P <0.001, and ****P <0.0001, results from unpaired t 
test.
Cell density affects TGFβ signalling in hiPSC-ECs.  
In most cell types TGFβ binding to its cell surface receptors induces phosphorylation 
of SMAD2 via ALK5 but exceptionally in ECs, TGFβ phosphorylates ALK1. ALK1 in turn 
recruits and phosphorylates SMAD1/5, normally activated by BMP signaling (Pardali et al., 
2010). Furthermore, previous studies have demonstrated that SMAD protein variations in 
response to TGFβ can be cell density-depended (Petridou et al., 2000; Zieba et al., 2012). For 
biologically meaningful comparisons of the properties of different types of ECs it is therefore 
essential that cells are harvested or analyzed at the same cell density. Since ENG is a co-
receptor in the signaling complex, we examined how cell density affected phosphorylation of 
SMADs  prior to comparing control hiPSC-ECs and HHT1 hiPSC-ECs. 
We first investigated which ligands were able to phosphorylate SMAD1/5 or SMAD2 proteins 
selectively in control hiPSC-ECs under subconfluent culture conditions using Western blot 
analysis. BMP-9 and TGFβ-3 activated (phosphorylated) SMAD1/5 and SMAD2 proteins, 
respectively, with a peak response 30-60 min after first exposure (Supplementary Fig.1A). 
Since BMP and TGFβ can cross-react with each other’s receptors at high concentrations 
(Brown et al., 2005; Suzuki et al., 2010; Thomas et al., 2007), we determined the effects of 
low (0.1ng/ml) and high (2ng/ml) concentrations of each ligand as a function of cell density 
(Supplementary Fig.1B). Density categories were based on cell number per unit of surface 
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area of the culture dish (35-50x103 (low) and 1.25-1.50 x105 (high) cells, respectively). 
SMAD1/5/8 and SMAD2 were stimulated in control hiPSC-ECs by BMP-9 and TGFβ-3, 
respectively, at both low and high cell densities. Of note, cell density alone affected ENG 
protein levels: these were significantly lower at high cell densities compared with low 
(Supplementary Fig.2A).
Figure 2. Cell density and reduced levels of ENG affect activation of downstrem TGFβ SMAD 
proteins. hiPSC-ECs were stimulated with low or high concentrations of BMP9 and TGFβ3 ligands 
under low or high cell density culture conditions and downstream phosphorylation of SMAD proteins 
was assessed. A. Western blot analysis of stimulated hiPSC-ECs. High exposure times were used for 
the quantification in B and C. B. Histogram showing quantification of SMAD1/5 phosphorylation 
relative to PECAM1 in control and HHT1 hiPSC-ECs cultured in low and high cell density (n=3). C. 
Quantification of SMAD2 phosphorylation in stimulated control and HHT1 hiPSC-ECs cultured under 
low or high cell density conditions (n=3). D. Heatmap showing pSMAD intensity of Figure2A. The 
data are presented as ratio of pSMADs / PECAM1(n=3). All error bars represent s.e.m. *P < 0.05, **P 
<0.01, results from unpaired t test.
TGFβ-3 stimulation at both low and high concentrations phosphorylated SMAD2 proteins in 
control hiPSC-ECs equally at both high and low cell densities, thus was independent of cell 
density (Fig.2A Lane 4-5 versus14-15, Fig.2A). High concentrations of TGFβ-3 however 
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also phosphorylated Smad1/5 proteins although only at high cell densities (Fig.2A Lane 5 
versus15). This indicated that cross-phosphorylation of SMAD1/5 by TGFβ-3 in hiPSC-ECs 
was dependent on cell culture density. 
Investigation of the effects of BMP-9 ligand on control hiPSC-ECs by contrast showed 
different density dependencies of SMAD activation. More specifically, at both high and 
low cell densities, BMP9 induced SMAD1/5 phosphorylation in a concentration dependent 
manner but at low cell density the absolute levels of pSMAD1/5 were higher than at high cell 
density (Fig.2A Lane 2 versus12, Fig.2B). Furthermore, both low and high concentrations of 
BMP-9 significantly phosphorylated SMAD2 protein but only under high cell density culture 
conditions (Fig.2A Lane 2-3 versus12-13). These results indicated that phosphorylation of 
SMAD1/5 and SMAD2 upon BMP-9 stimulation is ligand concentration and cell density 
dependent
Cell density affects gene expression levels of TGFβ related genes
To investigate whether the pattern of phosphorylated SMADs at different cell 
densities was caused by differences in expression levels of components of the signaling 
pathway, we examined the expression of genes encoding the TGFβ family of receptors.
Control hiPSC-ECs were cultured and collected from low and high cell density cultures; 
mRNA expression was determined using RT-qPCR. ENG mRNA was significantly lower 
at high cell densities compared to low, confirming the Western blot data at the protein level 
(Fig.3A, Supplementary Fig.2A). Some, but not all, of other TGFβ receptor family genes 
were also affected by cell density. For example, ALK5, ALK2 and TGFβRII mRNA levels 
decreased at high cell densities compared to low (Fig.3B, 3C and 3F), whereas ALK1 and 
BMPRII levels were not altered (Fig.3D and 3E). These findings indicated that cell density 
can affect expression of genes associated with TGFβ signaling so that care should indeed be 
taken to analyse hiPSC-ECs from different (ENG mutant) lines at the same density. 
Figure 3. Endothelial cell density and reduced levels of ENG affect the gene expression of certain 
TGFβ related receptors. We measured mRNA levels of TGFβ related receptors in control and HHT1 
hiPSC-ECs after grouping them into low (35-50 x 103 cells) and high (125-150 x 103 cells) cell 
densities. Values were additionally normalized to endothelial specific marker, PECAM1. A. ENG B. 
TGFBRII C. ALK5 D. BMPRII E. ALK1 and F. ALK2 mRNA levels in Control and HHT1 hiPSC-ECs 
cultured under low and high cell densities (n=3). All error bars represent s.e.m. *P < 0.05, **P < 0.01 
and ***P <0.001, results from unpaired t test. NS, not significant.
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Reduced ENG in HHT1 hiPSC-ECs affects TGFβ signaling only at low cell 
density.
As indicated above, ECs are sensitive to density in culture: their response to BMP-
9 and TGFβ -3 ligands and gene expression associated with TGFβ signaling all change in 
the transition from low- to high density. Since ENG is a co-receptor in the TGFβ signaling 
complex and its protein levels are cell density dependent, we examined its effect on SMAD 
phosphorylation at low and high cell density. We stimulated HHT1 hiPSC-ECs with low (0.1 
ng/ml) and high (2 ng/ml) concentrations of BMP-9 and TGFβ-3 ligands at both low and 
high cell densities and compared phosphorylation of SMAD1/5 and SMAD2 proteins with 
control hiPSC-ECs.
We first focused on low cell density and the phosphorylation of SMAD1/5 and SMAD2 
proteins upon stimulation with BMP-9 and TGFβ-3, respectively. 
Stimulation with either low or high concentrations of BMP-9 revealed significantly reduced 
levels of pSMAD1/5 in HHT1 hiPSC-ECs compared with controls (Fig.2A Lane 2-3 versus 
7-8, Fig.2C). This indicated the importance of ENG for pSMAD1/5 stimulation by BMP-9. 
Notably, HHT1 hiPSC-ECs also exhibited significantly lower levels of pSMAD2 compared to 
controls but when stimulated only with low concentrations of TGFβ-3 (Fig.2A Lane 4 versus 
9, Fig.2B, Fig.2D). These results indicated the importance of ENG for phosphorylation of 
SMAD2 protein upon stimulation with low concentrations of TGFβ-3 under low cell density 
culture conditions.
 
We next examined pSMAD1/5 and pSMAD2/3 protein under high cell density conditions. 
BMP-9 stimulation showed activation of SMAD1/5 proteins (Fig.2A Lane 12-13 versus 17-
18, Fig.2C) and SMAD2 proteins (Fig.2A Lane 12-13 versus17-18, Fig.2D) but without 
significant consistent differences between control and HHT1 hiPSC-ECs. This confirmed 
that high concentrations of BMP-9 phosphorylate SMAD2 protein and that ENG probably 
does not have significant role in this process.
 
TGFβ-3 stimulation at either low or high concentrations resulted in similar levels of pSMAD2 
between control and HHT1 hiPSC- ECs (Fig.2A Lane 14-15 versus 19-20, Fig.2B). 
Interestingly, stimulation with high concentrations of TGFβ-3 resulted in lower levels of 
pSMAD1/5 in HHT1 hiPSC-ECs (Fig.2A Lane 15 versus 20, Fig.2D). The results overall 
showed that high concentrations of TGFβ-3 can phosphorylate SMAD1/5 proteins and that 
ENG plays a key role in this process. 
Reduced ENG in HHT1 hiPSC-ECs alters TGFβ superfamily receptor 
expression in a cell density dependent manner 
Reduced levels of endoglin in MEECs derived from mutant mouse embryos or 
after knock-down experiments have been reported to either upregulate or downregulate 
alk5 expression (Lebrin et al., 2004; pece-Barbara et al., 2005). In order to understand the 
differences in SMAD phosphorylation between control and HHT1 hiPSC-ECs and find 
out whether reduced ENG in HHT1 hiPSC-ECs affects ALK5 expression or other TGFβ 
family receptors, we determined their expression by RT-qPCR at high and low densities. As 
expected from Western blotting, HHT1 hiPSC-ECs had significantly lower levels of ENG 
mRNA at both cell densities compared with controls hiPSC-ECs (Fig.3A). We next analyzed 
the expression of ALK1, ALK2, ALK5, TGFβRII and BMPRII. In accordance with the result 
in endoglin mutant mouse ECs, ALK5 expression was also significantly reduced at low cell 
densities (Fig.3C). ALK1, ALK2 and BMPRII expression was unaffected by reduced levels 
of ENG (Fig.3D, 3E, 3F) independent of cell density. 
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Thus endogenous reduction of ENG can reduce the expression of important signaling 
receptors of TGFβ in hiPSC-ECs, which may in turn affect their response to ligands but this 
effect is cell density dependent in culture.  
Reduced levels of ENG lead to the upregulation of MTUS1, a microtubule 
associated tumor suppressor 
Previous gene expression analysis of human umbilical vein endothelial cells 
(HUVEC) from newborns with ENG mutations revealed multiple differentially expressed 
genes when compared to healthy control cells (Thomas et al., 2007). The major caveat of this 
study however was that clinical signs of HHT1 are not evident in HUVECs because of their 
high levels of ENG when cultured (Chan et al., 2004; Ota et al., 2002). In order to overcome 
this issue of extraordinarily high levels of ENG, we analysed global gene expression in 
control and HHT1 hiPSC-ECs derived from genetically confirmed HHT1 patient with severe 
disease symptoms. In light of the observed effects of hiPSC-EC density of TGFβ pathway 
signaling components, we harvested the cells from cultures at high cell density.
Microarray analysis showed 41 differentially expressed genes between control and HHT1 
hiPSC-ECs (Fig.4A). As expected from the qPCR data above, ENG mRNA levels were 
significantly reduced in HHT1 ECs.  One of the genes that was highly upregulated in HHT1 
hiPSC-ECs and that has not been previously characterized in human ECs but its expression 
has been correlated with the early angiogenic pattern of ENG, was microtubule associated 
tumor suppressor 1 (MTUS1) (Bundschu and Schuh, 2014). Upregulation of MTUS1 in 
HHT1 hiPSC-ECs was further demonstrated by qPCR (Fig.4B). To confirm that MTUS1 
upregulation was due to reduced levels of ENG and not to any differences in the cell density, 
we showed by siRNA-mediated downregulation of ENG expression in control hiPSC-ECs that 
indeed MTUS1 increased as function of ENG downregulation (Fig.4C and Supplementary 
Fig.4A). We also observed increased levels of MTUS1 in independently derived HHT1 
hiPSC-ECs compared with controls (Supplementary Fig.4B). Notably, MTUS1 mRNA levels 
were also upregulated in HHT1 hiPSC-ECs at low and high cell densities (Supplementary 
Fig.4C). In addition, MTUS1 protein levels were also upregulated by Western blot analysis 
when ENG was knocked-down in control hiPSC-ECs (Fig.4D). 
Figure 4. Increased MTUS1 mRNA and protein levels in iPSC-ECs with reduced levels of ENG. A. 
Differentially expressed genes identified by microarray analysis. Data are presented as fold change > 2. 
B. MTUS1 mRNA levels in Control and HHT1 hiPSC-ECs measured by qPCR (n=3). C and D. MTUS1 
mRNA and protein levels in Control hiPSC-ECs treated with scrambled (control) or two independent 
ENG-targeting small interfering RNAs (siENG #1, siENG #2)(n=3). E. ATIP1 mRNA levels in Control 
and HHT1 hiPSC-ECs (n=3). All error bars represent s.e.m. *P < 0.05, results from unpaired t test.
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MTUS1 encodes a number of isoforms, termed AT2 receptor-interacting proteins (ATIPs), in 
humans and nothing is yet known specifically about its role in ECs. We therefore determined 
which MTUS1 isoforms are expressed in hiPSC-ECs. We first designed and tested the qPCR 
primers in human embryonic brain and placenta, organs that have been previously reported 
to express the different MTUS1 isoforms (Supplementary Fig.4D and 4E) (Di Benedetto 
et al., 2006). Finally, we found that ATIP1 is the principle isoform expressed by hiPSC-ECs 
and that MTUS1 upregulation in HHT1 hiPSC-ECs is mainly due to upregulation of ATIP1 
(Fig.4E).
Increased MTUS1 protein levels in HHT1 skin biopsies   
The in vitro findings that MTUS1 expression is increased in HHT1 hPSC-ECs led 
us to the test whether MTUS1 is also upregulated in vivo. We first examined the expression 
of ENG in sections of human nasal mucosal biopsies from HHT1 patients compared to a 
healthy individual and found that ENG protein levels were significantly reduced (Fig.5A). 
We then examined the expression of MTUS1 in the same specimens to see whether there 
was an inverse correlation between ENG and MTUS1 protein levels in vivo. We confirmed 
this relationship by showing substantially higher MTUS1 staining in the endothelial layer of 
HHT1 skin compared to healthy individual (Fig.5B). 
Figure 5. HHT1 human skin exhibits increased MTUS1 protein levels. Confocal images of human 
skin biopsies from Control and HHT1 individuals. A. Left, α-smooth muscle actin (α-SMA) in 
green and ENG immunostaining in red. Right, quantification of ENG staining intensity (n= 8) B. Left, 
PECAM1 (red) and MTUS1(green) immunostaining. Right, quantification of MTUS1 staining intensity 
normalized to PECAM1 intensity (n= 8). All error bars represents.e.m. *P < 0.05 and ****P <0.0001, 
results from unpaired t test.
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Discussion
It has been more than 20 years since the cloning of endoglin (Gougos and Letarte, 
1990) and since then its functional role in TGFβ signaling has been extensively characterized. 
In vitro studies using various EC lines have clearly demonstrated that endoglin is crucial 
for downstream “canonical” and “cross-over” TGFβ signaling pathway activation. Here, we 
demonstrated that ECs derived from control- or HHT1 hiPSC lines can be used to reveal 
downstream TGFβ signaling differences and that cell culture density is an important factor in 
determining signaling responses and thus their interpretation. 
We chose to use control and HHT1 iPSC-ECs because they serve as healthy- and diseased 
human EC models respectively and can be used to study human physiological and pathological 
cell responses.  Since hiPSC-ECs have only been used recently to study downstream TGFβ 
signaling (Orlova et al, in prep), we first identified BMP-9 and TGFβ-3 as the most reliable 
cytokines for “canonical” (BMP-9/SMAD1/5 and TGFβ-3/SMAD2) SMAD activation. As 
observed in mouse embryonic ECs (MEEC) and bovine aortic endothelial cells (BAEC) 
(Goumans et al., 2003), high concentrations of TGFβ-3  induced phosphorylation not only 
of SMAD2 but also of SMAD1/5 in control hiPSC-EC but only at high cell density. In line 
with this, by comparing the control hiPSC-ECs and those from HHT1-ECs, we could confirm 
that, as described by others, (Blanco et al., 2005; David et al., 2007; Lebrin et al., 2004), 
ENG is required for TGFβ-3/ALK1-mediated activation of SMAD1/5 in hiPSC-ECs. This 
was further supported by our finding that ENG mRNA and protein were reduced in hPSC-
ECs at high cell densities. Additionally, only at high cell densities, were we able to detect 
phosphorylation of SMAD1/5 and SMAD2 upon stimulation with BMP-9. This finding is 
consistent with a study using human pulmonary artery endothelial cells (PAECs), in which 
phosphorylation of SMAD1/5 and SMAD2 via BMPRII/ActRII/ALK1 was induced by 
BMP-9 stimulation (Upton et al., 2009).
At low cell densities, we did not detect any “cross-over” in TGFβ induced SMAD 
phosphorylation, which highlights the importance of studying EC responses in precisely 
defined ranges of cell density, rather than unknown conditions under which signaling “cross-
over” may or may not occur. Although there was no “cross-over” at low cell density, it 
appears that ENG is able to potentiate BMP9/ALK1/pSMAD1/5 signaling. Indeed, in NIH-
3T3 fibroblasts, endoglin overexpression only increased BMP9-induced BRE promoter 
activity and not that by BMP-2 (David et al., 2007; Nolan-Stevaux et al., 2012). As observed 
in endoglin-depleted MEECs (Lebrin et al., 2004), reduced ALK5 mRNA expression was 
also detected in HHT1 hiPSC-ECs under low cell densities. This finding, in combination with 
the reduced phosphorylation of SMAD2, suggested that ENG and ALK5 are required for 
“canonical” TGFβ-3/ALK5/pSMAD2 signaling. The latter is also confirmed by more recent 
evidence using HUVECs (Nolan-Stevaux et al., 2012).
 
We then sought to elucidate whether under defined conditions we could identify genes affected 
by reduced levels of ENG. Microarray analysis of HHT1 hiPSC-ECS revealed alterations in 
the expression levels of 41 genes, among which MTUS1 had not been described before in 
ECs. We confirmed the direct dependence of MTUS1 on ENG levels by siRNA knockdown 
of ENG and showed that both mRNA and protein were upregulated by reduced ENG in 
hiPSC-ECs. Our data also provide the first evidence of ATIP-1 as the predominant isoform of 
MTUS1 in both control and HHT1 hiPSC-ECs although further investigation will be required 
to reveal its function in these cells. MTUS1 protein is expressed in the developing mouse 
cardiovascular system, including vascular plexus of the yolk sac and is strongly correlated 
with the early angiogenic pattern of endoglin(Bundschu and Schuh, 2014). Additionally, 
MTUS1 has been identified as upregulated upon inhibition of TGFβ signaling in chicken 
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embryo dermal myofibroblasts (Kosla et al., 2013), thereby further suggesting its association 
with TGFβ signaling. Nevertheless, our demonstration of a marked MTUS1 increase in 
HHT1 patient skin corroborates its association with endoglin and further suggests a possible 
role in the pathogenesis of HHT, which remains to be fully elucidated.
Methods
Generation of human induced Pluripotent Stem Cells (hiPSCs)
Control iPSC and HHT1 patient-specific  (HHT1, exon 5 IVS 5+2 (T>C)) iPSC were 
generated and characterized previously ((Freund et al., 2009); Orlova et al. in prep). 
Briefly, fibroblast from skin biopsies and blood outgrowth endothelial cells (BOECs) from 
peripheral blood were used along with a self-inactivating polycistronic lentivirus system for 
reprogramming(Dambrot et al., 2013). 
hiPSC culture and endothelial cell differentiation
hiPSC were maintained and differentiated to endothelial cells as previously described 
(Orlova et al., 2013). Briefly, hiPSC lines were grown in serum-free, mTeSR1 (Stem Cell 
Technologies) medium and penicillin-streptomycin (5,000 U ml-1, Gibco). They were 
enzymatically passaged once a week on Matrigel (BD Biosciences) -coated 6-well plates. 
hiPSC were differentiated in monolayer culture using sequential treatment of growth 
factor addition, as follows: VEGF (50ng/ml, R&D Systems), BMP4 (30ng/ml, Miltenyi 
Biotec), Activin A (25ng/ml, Miltenyi Biotec), GSK inhibitor CHIR-99021 (1.5uM, Tocris 
Bioscience) is added for three days to induce mesoderm which is then specified to endothelial 
cells by SB431542 (10mM, Tocris Bioscience) and VEGF (50ng/ml) for 7 days. Endothelial 
cells were isolated using CD31-Dynabeads (Invitrogen) and DynaMag-15 magnet (Life 
Technologies) and plated on gelatin-(Sigma-Aldrich) -coated T75 tissue culture flask with 
EC culture medium (human endothelial-SFM, Gibco) containing 1% platelet poor plasma 
derived serum (Biomedical Technologies) and 50ng/ml VEGF until they reach confluence. 
EC proliferation assay and cell density categorization 
hiPSC-ECs were plated in 24-well plates at a density of 30,000 cells per well. EC culture 
medium containing 1% platelet poor plasma derived serum and 25ng/ml VEGF was refreshed 
every 12 hours. Cell proliferation was analyzed by counting the cell number after 24, 36, 48, 
60 and 84 hours.  Each experiment was performed in triplicate and repeated minimally three 
times. For low- and high-density cell cultures, 25000 cells were plated in 24-well dishes and 
grown for 36-48 (35-50x103 cells) or 84 hr (125-150 x103 cells), respectively. 
EC stimulation
hiPSC-EC were seeded in 24-well plates and grown to low or high cell densities as described 
above. Cells were washed with phosphate-buffered saline (PBS, Gibco) and serum-starved 
for 5 hours. Cells were stimulated for 30 minutes with 0, 0.1, or 2 ng/ml of BMP9 (R&D 
Systems) or TGFβ-3 (Peprotech), put on ice, washed with cold PBS and processed for protein 
extraction. 
Flow cytometry 
Fluorescence-activated cell sorting (FACs) analysis was performed as described before(Orlova 
et al., 2013). 
Immunohistochemistry of human skin biopsies and quantification
HHT1 and control donor skin samples were obtained from St Antonius Hospital (Department 
of Pulmonary Disease, Nieuwegein, The Netherlands) and Leiden University Medical Center 
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(Department of Molecular Cell Biology, Leiden, The Netherlands) respectively. Sections were 
handled as described previously (Lebrin et al., 2010). Briefly, cryosections (5μm) of HHT1 
and control donor skin biopsies were fixed in 2% paraformaldehyde, permeabilized in PBS 
with 0.1% Triton X100 (Sigma-Aldrich) and blocked in PBS with 4% normal swine serum. 
Cryosections were incubated with primary or secondary antibodies in blocking solution 
(4% normal swine serum) overnight at 4C or 2 hours at room temperature, respectively. 
Primary antibodies: mouse anti-PECAM (1:30, Dako), anti-SMA conjugated to Cy2 (1:200, 
Sigma-Aldrich), mouse anti-Endoglin (1:100, BD Bioscience), rabbit anti-MTUS1 (1:100, 
Novusbio). Secondary antibodies: anti-mouse Alexa555 (1:200, Life Technologies) and 
anti-rabbit Alexa488 (1:200, Life Technologies). Stained cryosections were examined using 
Confocal Leica-SP5 MP. Eight images for each group and set of immunostainings were 
taken at the same laser intensity. Anti-SMA, anti-Endoglin, anti-PECAM1 and anti-MTUS1 
staining intensity was quantified using Fiji software.  For each image the vessels were 
delineated, in which staining intensity was calculated using the mean grey value function. 
Protein extraction, Western blot analysis and Densitometry
Cell lysates were prepared with RIPA buffer (50mM Tris-HCl, 250mM NaCl, 2% NonidentP40, 
2.5mM EDTA-Na, 0.1% SDS, 0.5% DOC, pH 7.2) containing complete protease inhibitor 
cocktail II (Roche Applied Science). Protein concentrations were determined using the 
DC Protein Assay Kit II (BioRad). Samples were analyzed by Western blot using 10% 
polyacrylamide gels, followed by overnight wet-transfer of the proteins to activated 
nitrocellulose membranes Hybond-C Extra (Amersham, Biosciences). Membranes were 
blocked in TBS-T (0.01 M Tris-HCl, pH 7.4, 0.15M NaCl, 0.1% Tween-20) with 5% dried 
milk and incubated overnight with the indicated antibodies. Signal detection was performed 
using the ECL system and SuperSignal West Pico Chemiluminecent Substrate (Thermo 
Scientific). Signals were quantitatively analysed using ImageJ software. The antibodies 
used in the study are the following: Goat Endoglin/CD105 (1:1000, R&D Systems), rabbit 
anti-PECAM1 (1:500, Santa Cruz), mouse anti-β-actin (1:5000, Sigma-Aldrich), rabbit 
anti-MTUS1 (1:2000, Novusbio), rabbit anti-pSmad1/5 (1:500, Cell Signaling), rabbit anti-
pSmad2/3 (1:500, Cell Signaling), HRP-conjugated secondary antibodies anti-rabbit IgG 
(1:5000, Cell Signaling), HRP anti-goat IgG (1:5000, Santa Cruz), HRP anti-mouse IgG 
(1:5000, Cell Signaling). 
ENG knock down
All transfections were carried out at a final concentration of 5nM in 24-well plates using 
Oligofectamine (Invitrogen) according to the manufacturer’s instructions. Control hiPSC-
EC were transfected with two siRNAs directed against human ENG and a non-targeting 
control siRNA (FlexiTube siRNA, QIAGEN, SI02663024 and SI02663031), si-CONTROL 
non-targeting siRNA(AllStars Negative Control, QIAGEN, 111754271). The medium was 
changed after overnight incubation and 48hr after transfection the cells were analysed as 
indicated. 
RNA isolation and Quantitative PCR
Total RNA was isolated using NucleoSpinII RNA Kit (Macherey-Nagel), DNase treated using 
Ambion TURBO (Life Technologies) and complementary DNA (cDNA) was made from 
equal amount for all samples using iScriptII (BioRad). Quantitative PCR (CFX96 Real-Time 
System, Bio-Rad) was performed using oligonucleotide primers for human ALK1, ALK2, 
ALK5, ENG, BMPRII, TGFβRII, MTUS1, ATIP1, ATIP2, ATIP4 and the human reference 
gene ARP for normalization. Quantitative PCR was performed using SYBR Green Supermix 
(Bio-Rad) mixture with an initial denaturation step of 3 min at 95oC followed by 40 cycles of 
15 s denaturation at 95oC, 30 s annealing at 60oC, and 45 s extension at 72oC. Technical and 
MTUS1
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biological replicates were carried out for all quantitative PCR reactions. 
Statistical analysis
Experimental data were statistically analyzed with Prism6 software and unpaired/paired 
Student’s t test. P values <0.05 were considered statistically significant. 
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Supplementary Figures
Supplementary Figure 1. Activation of BMP/TGFβ downstream SMAD proteins. hiPSCECs were 
serum-starved and stimulated under subconfluent cell culture conditions. Downstream phosphorylation 
of SMAD1/5 and SMAD2 proteins was assessed by Western blot. A. Stimulation of Contol hiPSC-ECs 
with BMP4, BMP6, BMP9 and TGFβ3 ligands for 1 h. B. Dose-response of BMP9 and TGFβ3-induced 
phosphorylation in Control and HHT1 hiPSC-ECs for 1 h. Control hiPSC-Ecs were stimulated either 
with BMP9 (2ng/ml) or TGFβ3 (2ng/ml) and used as positive controls for pSMA1/5 and pSMAD2 
activation, respectively.
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Suplementary Figure 3. Increased MTUS1 mRNA levels in iPSC-derived ECs with reduced levels 
of ENG. A. ENG mRNA levels in Control hiPSC-ECs transfected with Scroble or two different ENG 
siRNA constructs (n=3). B. MTUS1 mRNA levels in Control and additional HHT1 hiPSC-ECs derived 
from HHT1 patient with different mutation (n=3). C. MTUS1 mRNA levels in Control and HHT1 
hiPSC-ECs under low and high cell density conditions (n=3). D. Schematic representation of MTUS1 
locus with the primers designed to amplify its different isoform (ATIP1, ATIP3 and ATIP4). E. ATIP1, 
ATIP3 and ATIP4 mRNA levels in human embryonic tissue. All error bars represent s.e.m. *P < 0.05, 
results from unpaired t test.
Supplementary Figure 2. ENG protein levels 
in control hiPSC-ECs. A. Histogram showing
quantification of ENG protein levels relative to 
PECAM1 as assessed by Western blot (n= 3). All 
error bars represent s.e.m. *P < 0.05, results from 
unpaired t test.
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Supplementary Figure 4. HHT1 human skin exhibits increased MTUS1 protein levels. Additional 
confocal images of skin biopsies from Control and HHT1 subjects. A. α-SMA(green) and ENG (red) 
immunostaining. B. PECAM1 (red) and MTUS1 (green) immunostaining.
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Introduction
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic 
vascular disease that affects 1 in 5000 individuals worldwide 1. The abnormal vascular 
structures in HHT result predominantly from mutations in ENG (HHT1) 2 or ACVRL1 
(HHT2) 3. The protein products of these genes are receptors for Transforming Growth 
Factor-β (TGF-β) and/or Bone Morphogenetic Protein (BMP) expressed in endothelial cells 
that share functions in signaling 4, 5. Mutations identified to date represent null alleles that 
lead to reduced levels of receptor at the cell surface indicating that haploinsufficiency is 
the predominant underlying mechanism of HHT 6. Both receptors signal to the downstream 
effectors Smad1/5/8, second messengers that translocate to the nucleus after activation 6. 
Therefore, the primary cause of HHT is considered defective TGF-β/BMP signaling in 
endothelial cells that may lead to the abnormal vasculature 1. 
Clinical manifestations of HHT are evident as multiple vessel abnormalities known as 
telangiectases in the nose, mouth and gastrointestinal tract. These lesions exhibit focal 
dilation of post-capillary veins that are susceptible to rupture and hemorrhage because 
of weak vessel walls and high perfusion pressure. As consequence, recurrent and severe 
epistaxis and gastrointestinal bleeding are common presentation of the disease; this leads to 
severe anemia requiring iron supplementation and blood transfusions 7. Large arteriovenous 
malformations (AVMs) are also found in major organs. They can cause life-threatening 
complications, although the majority of AVMs remain asymptomatic 7. AVMs are arteries and 
veins that appear to fuse without intervening capillaries, to form a network of direct high flow 
arteriovenous (AV) shunts 8. They form at the interface between arteries and veins where the 
capillary bed normally lies and are thought to arise from smaller lesions such as telangiectasia 
by progressive vascular remodeling 9. Typically present at birth in the brain, they may develop 
and grow over time in the lung and liver, although there is still little direct evidence to support 
this idea 7. Nevertheless, the recent development of mouse models for HHT and intravital 
imaging technologies have provided important insights into the mechanisms of AVM 
formation 10. Heterozygous Eng+/- and Acvrl1+/- mice, which are the closest animal models 
of HHT in terms of genotype, surprisingly develop a relatively normal vasculature with no 
major defects during developmental angiogenesis. However, some vascular lesions appear in 
these mice age but only at very low frequency and in an unpredictable manner. This suggests 
that additional triggers are needed for AVM development 11-13. Local homozygous loss of 
Eng or Acvrl1 gene expression, neoangiogenesis, inflammation and wounding have been 
implicated triggering AV shunt formation, in accordance with secondary triggers acting as 
underlying mechanisms. Ectopic expression of Vascular Endothelial Growth Factor (VEGF), 
the prime angiogenic growth factor, using adeno-associated viruses has been shown to 
induce cerebrovascular dysplasia in both HHT1 and HHT2 mouse models 14, 15. Inflammation 
induces “endoglin protein null” locally 16 that may increase the risk of vascular abnormalities 
in Eng+/- mice 13. Post-natal homologous loss of the Eng or Acvrl1 gene in endothelial cells 
leads to the formation of AV shunts resembling those seen in HHT individuals only in sites 
where angiogenesis is active, supporting an hypothesis that at least three hits - the loss of both 
Eng or Acvrl1 alleles combined with environmental pro-angiogenic triggers - are necessary 
for AVM development 10. 
How mutations in the Eng or Acvrl1 genes lead to AVM formation is still poorly understood, 
although recent findings indicate that aberrant angiogenesis may account for the development 
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of such vessel abnormalities 10. Although the initial stages of AVM formation occur 
irrespective of blood flow, this process is further exacerbated by flow 17-19. High-velocity 
turbulent arterial blood flow results in dilatation and tortuosity of the downstream veins in the 
skin of mice harboring homologous deletion of Acvrl1 17 and promotes mural cell coverage 
of AVMs in Eng-iKO mice 18. In Zebrafish, ALK1 acts downstream of blood flow to limit the 
number of endothelial cells maintaining the vessel caliber. In agreement, arteries of Zebrafish 
harboring alk1 mutations deliver a greater blood volume to the downstream vessels that in 
turn adapt by enlarging and retaining AV connections that are normally transient during 
angiogenesis in order to normalize hemodynamic forces. This vessel remodeling seems 
to represent a normal adaptive response to increased blood flow 19. It is not known how 
ALK1 regulates arterial vessel caliber. Two flow responsive genes, cxcr4a and edn1, have 
been proposed to act downstream of ALK1 to control vessel diameter. These genes encode 
a pro-angiogenic chemokine receptor and a vasoconstrictive peptide respectively, although 
additional experiments are required to establish their functions during AVM development 
in HHT 19, 20. Here, we describe cooperation between ALK1 and connexin40 (Cx40) in the 
regulation of blood vessel caliber. The study revealed that reduced expression of Cx40 
results in enlargement of the arterial vessels in HHT2 mice and that consequent altered blood 
flow precipitates flow-dependent adaptive responses involving rarefaction of the capillary 
network and the formation of direct AV connections. This cooperation is sufficient to trigger 
AV shunt formation during active angiogenesis and upon additional environmental insult, 
which resembles vascular lesions seen in HHT patients. Our data suggest that GJA5 might be 
a genetic modifier in HHT2.
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Results
BMP9/ALK1 regulates endothelial Cx40 expression 
Both circumferential strain and wall shear stress affect endothelial gene expression, so 
that these mechanical forces can be transduced to biochemical signals that facilitate adaptation 
to changes in blood flow. As ALK1 expression requires blood flow, it is reasonable to assume 
that this receptor might lie in a mechano-transduction pathway either upstream or downstream 
of known mechano-responsive genes. However, these genes need to be identified. Here, we 
revealed that BMP9 stimulation of Human Arterial Endothelial Cells (HAECs) not only 
induced expression of ID1 and HEY2 (Fig.1A, B) common downstream targets of ALK1 and 
Notch signaling pathways 21 but also strongly stimulated the expression of GJA5 to levels 
approximately 20-fold higher than the untreated cells after 24 hours of growth factor addition 
(Fig.1C). BMP9 has been shown to activate ALK1-inducing Smad1/5 phosphorylation in 
endothelial cells 5. To examine whether ALK1 controls GJA5 expression, we analyzed the 
effect of siRNA-mediated knockdown of ALK1 on BMP9-induced GJA5 in HAECs. siRNA-
mediated downregulation of ALK1 expression was confirmed by quantitative PCR (Fig.1D). 
We validated that Smad1/5 phosphorylation was reduced (Figure 1E) and importantly found 
that GJA5 mRNA expression was blocked (Fig.1F) when ALK1 was decreased in endothelial 
cells stimulated by BMP9. Among the endothelial Connexins (Cx), Cx40, which is highly 
expressed in arterial vessels, is essential for the effective transduction of vasodilatation 22-25. 
In sections of human skin biopsies stained for Cx40 and Platelet-Endothelial Cell Adhesion 
Molecule-1 (PECAM-1) as a marker of endothelial cells (Fig.1G), we compared 5 control 
samples with samples isolated from 4 individuals with HHT2. All of these patients had 
severe HHT-related nosebleeds: the recurrent epistaxis (often 4 incidents per day) did not 
improve with the regular Argon plasma treatment or medication like tranexamine acid and 
N-acetylcysteine. Hemoglobin levels were generally low:  for one patient for example they 
varied from 4.4- 8.0 mmol.l-1 over a 5 year period and 56 blood transfusions with monthly iron 
transfusions were necessary to maintain normal blood levels. This patient was also treated 
with Thalidomide with benefit but stopped because of neuropathy side effects 26. Another had 
recurrent epistaxis particularly at night and was also diagnosed with atrial fibrillation. All 
four patients underwent a Saunders procedure in which their nasal epithelium was partially 
replaced by skin of their upper arm because of the severity of their symptoms. The surplus 
skin from the Saunders surgery was frozen and sectioned for analysis of Cx40 expression by 
immunofluorescence. Cx40 intensity levels were defined as the ratio of the Cx40 integrated 
intensity to the vessel surface measured as PECAM-1 positive pixels. Cx40 protein levels 
were particularly low in HHT2 individuals compared to control biopsies (Fig.1H) suggesting 
that the down regulation of Cx40 expression levels in HHT2 individuals is most probably 
caused by the fact that the remaining wild-type ACVRL1 allele is unable to contribute protein 
for normal vascular functions. Our data support an association between ALK1 signaling and 
Cx40 expression in vivo. 
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Figure 1: Cx40 is a target gene of BMP9/ALK1 signaling pathway. (A-C) Effect of BMP9 stimulation 
on ID1 (A), HEY2 (B) and GJA5 (C) mRNA expression in human arterial endothelial cells as determined 
by quantitative PCR. Results are representative of four independent experiments. (D) The expression 
of ALK1 in human arterial endothelial cells transfected with siRNA-scramble or siRNA-ACVRL1 
was analyzed by quantitative PCR. (E) ALK1 down-regulation inhibits Smad1/5 phosphorylation 
induced by BMP9. Human arterial endothelial cells transfected with siRNA-scramble or siRNA-
ACVRL1 were stimulated with 1 ng/ml of BMP9 for 45 min at 37°C before lysis. Whole-cell extracts 
were fractionated by SDS-PAGE and blotted. The filter was incubated with pSMAD1/5, SMAD1/5 
or GAPDH antibody. (F) SiRNA-ACVRL1 leads to a reduced BMP9-induced GJA5 transcriptional 
activity. (G) Confocal imaging showing Cx40 protein expression in arterial endothelial cells in skin 
sections of one representative healthy donor and one representative HHT2 individual. Endothelial cells 
are stained for PECAM-1 (red) and Cx40 (white) therefore representing arterial vessels. Scale bars: 
50µm. (H) Quantification of Cx40-positive surface intensity normalized to PECAM-1 expression in the 
skin of five healthy donors and four HHT2 individuals. ****P< 0.0001, results from one-way ANOVA 
that compare means of multiple groups
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Reduced levels of Cx40 affect angiogenesis in Acvrl1+/- mice
To investigate whether Acvrl1 and Gja5 function in the same pathway, we took 
advantage of the Acvrl1+/- mutant mice that develop vascular lesions similar to those in HHT2 
patients only at very low frequency and in an unpredictable, age-dependent manner 12. We 
generated Acvrl1+/-; Gja5EGFP/+ mice that have reduced expression of both genes as validated 
by quantitative PCR (Fig.IA, B in Data Supplement), and first examined the neonatal retina. 
Gja5EGFP/+ mice are normally viable and fertile without cardiovascular abnormalities 27. The 
retinal vasculature of the single or double heterozygotes at postnatal day (P)7 showed a regular 
alternating pattern of arteries and veins with an intervening capillary network as in control 
mice (Fig.2A). Endothelial tip cells formed filopodial protrusions at the sprouting front of 
the plexus (Fig.2A). However, Acvrl1+/- retinas showed excessive angiogenesis with a denser 
and more highly branched vascular plexus at the front, as previously reported in Acvrl1-iKO 
mutants 28 (Fig.2A-C). By contrast, Acvrl1+/-; Gja5EGFP/+ mutant mice reproducibly showed 
reduced angiogenesis with much less dense post-arteriolar capillary plexus (Fig.2B) that had 
fewer branch points (Fig.2C). By comparison, capillaries in other regions appeared unaffected 
(Fig.2A-C and Fig.IIA-C in Data Supplement). Changes in blood flow are known to drive 
vessel pruning, leading to maturation of the vasculature. Blood flow is generally low during 
vascular development in the neonatal retina excepted for the arterial segments close to the 
optic disc and for some of the first arterial branches 29 (Figure IIA in Data Supplement). 
Interestingly, the reduced number of capillaries was in areas where the blood flow is estimated 
to be relatively high (Fig.2A-C and Fig.IIA in Data Supplement) 29. Moreover, mural cell 
coverage of the arteries was enhanced in Acvrl1+/-; Gja5EGFP/+ mutant mice at P7 compared 
to single heterozygote and wild-type littermates as revealed by staining for asmooth muscle 
actin (aSMA). Arterioles where only few aSMA positive cells would be normally found at 
P7 were covered by regular layers of smooth muscle cells, especially near their branch points 
with the arteries (Fig.2D-F). In agreement, Gja5 expression that correlates with the arterial 
flow pattern was strongly increased in the arterial vessels of Acvrl1+/-; Gja5EGFP/+ P7 mutant 
mice compared to Gja5EGFP/+ heterozygous mice as revealed by green fluorescent protein 
EGFP, suggesting that the blood flow is perturbed in the Acvrl1+/-; Gja5EGFP/+ mutant mice 
(Fig.2D). 
To eliminate adaptive processes that may occur during embryonic development, in particular 
those related to blood flow regulation, confounding the analysis, we generated Acvrl1Flox/+; 
cdh5 (PAC)-CreERT2 (Acvrl1-iHET); Gja5EGFP/+ mice in which tamoxifen injection of neonatal 
mice led to efficient reduction of Acvrl1 mRNA expression to generate Acvrl1+/-; Gja5EGFP/+ 
mice (Fig.IIIA, B in Data Supplement) 30 31. Impaired angiogenesis was much more severe 
in Acvrl1-iHET; Gja5EGFP/+ mice than in Acvrl1+/-; Gja5EGFP/+ mice, with particularly strong 
inhibition of post-arterial capillary plexus density (Fig IIID, E in Data Supplement). This 
confirmed that ALK1 signaling regulates angiogenesis by directly cooperating with Cx40. 
Thus, reduced Cx40 in HHT2 mice disrupts proper formation of the capillary bed connecting 
the artery and vein. 
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Figure 2: Effect of Acvrl1 and Gja5 haploinsufficiency in vivo. (A) Isolectin B4-stained endothelial 
cells in retinal vessels in control  (n=11), Gja5EGFP/+ (n=10), Acvrl1+/- (n=9) and Acvrl1+/-; Gja5EGFP/+ (n=8) 
mice at P7. The outlined red boxes indicate the areas in which vascular parameters were quantified. 
(B-C) Quantification of post-arterial capillary density (B) and number of vessel branch points (C) 
per field. (D) Confocal imaging of retinas from control (n=6) Gja5EGFP/+ (n =4), Acvrl1+/- (n=5) and 
Acvrl1+/-; Gja5EGFP/+ (n =7) at P7 stained for Isolectin-B4 that marks endothelial cells (blue) and for 
aSMA that marks vascular Smooth Muscle Cells (vSMCs) (red). EGFP expression reveals arteries. 
(E-F) Quantification of the aSMA (+) vessel length from the first arterial branch and the number of 
arterial branch points. All error bars represent s.e.m. *P< 0.05, **P< 0.01 and ****P< 0.0001, results from 
unpaired t test. NS, not significant a, arteries; v, veins. Scale bars, 200μm. 
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Low levels of Cx40 leads to AV shunts in Acvrl1+/- retinas
Because AV shunts are thought to arise from an abnormal capillary bed, we 
next explored the possibility that reduced levels of Cx40 promote AVM development in 
Acvrl1+/- retinas. We defined vessels ã 12.5 m as AV shunts because AV connections of this 
diameter were not observed in control or single heterozygous mice at P7 (Fig.3A-D). AV 
shunts occurred in 71% (n=14) of the Acvrl1+/-; Gja5EGFP/+ P7 mice, but were completely 
absent in controls, Acvrl1+/- or Gja5EGFP/+ mice. The AV shunts were found to arise from 
the capillary bed starting at the post-arterial capillary vessels to form enlarged vessels that 
connected directly to the veins (Fig.3E). Similar phenotypes were observed in Acvrl1-iHET; 
Gja5EGFP/+ mice with a prevalence of 61% (n=13) (Fig.IVA in Data Supplement). Acvrl1-
iHET mice did not develop any AV shunts (Fig.IVA in Data Supplement). To determine 
whether the increase in AVM diameter was attributable to increased endothelial cell number, 
we performed BrdU analysis of isolectin b4-stained vessels. In Acvrl1-iHET; Gja5EGFP/+ 
mice, the number of BrdU-labeled endothelial cells was significantly higher than in the 
other genotypes, particularly in the capillary plexus where AV connections were found (Fig.
IVB in Data Supplement). Moreover, these AV shunts lacked smooth muscle cell coverage 
(not shown). Because increased mural cell coverage of the AVM has been proposed to be a 
secondary response to increased blood flow, our data indicated that the AV shunts found in 
the Acvrl1+/-; Gja5EGFP/+ mutant mice at P7 might represent an early stage of AVM formation. 
Thus, our data are consistent with a primary abnormality at the capillary level and point to 
vessel enlargement promoting the development of AVM. 
Figure 3: Development of multiple 
transient arteriovenous connections in 
Acvrl1+/-; Gja5EGFP/+ neonatal retina. (A-
D) Confocal images of flat-mounted reti-
nas labeled with isolectin-B4 that reveals 
the vascular plexus from control, Gja5EG-
FP/+, Acvrl1+/- and Acvrl1+/-; Gja5EGFP/+ at P7. 
The red arrow indicates a direct connection 
between an artery and a vein (E) Higher 
magnification of a typical micro-shunt 
found in Acvrl1+/-; Gja5EGFP/+ P7 retinas. 
Yellow dotted lines delimit the shunt. a, 
arteries; v, veins. Scale bars, 200μm. 
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Low levels of Cx40 promote the production of Reactive Oxygen Species and 
lead to arterial dilation in Acvrl1+/- mice 
To explore the possibility that the enlargement of capillary-like vessels plays a 
causal role in the development of AVM, we examined the vasculature in the dorsal ear skin 
of Acvrl1+/-; Gja5EGFP/+ adult mice. This area of skin has recently proven extremely useful 
for intravital vascular imaging and is widely used to follow AVM development in real time, 
particularly in wound healing 17. We stained whole-mounts of 3-month-old mouse ears for 
PECAM-1 and aSMA (Fig.4A). This staining showed that the overall vessel patterning in 
Acvrl1+/-, Gja5EGFP/+ mice was very similar to controls, Gja5EGFP/+ or Acvrl1+/- mice (Fig.4A), 
The vascular network forming a finger-like architecture of larger veins that localize together 
with arteries that were stained for aSMA (Fig.4A). However, the main arteries in the ear 
skin were reproducibly enlarged in Acvrl1+/-; Gja5EGFP/+ adult mice compared to controls, 
Acvrl1+/- or Gja5EGFP/+ mice (Fig.4A, B). Interestingly, the latter seems to occur from early 
development as seen in the mesencephalic artery of embryonic (E) day 12.5 embryos (Fig.
VA-C in Data Supplement) and in the lung and intestine tissue of E17.5 embryos (Fig.
VD in Data Supplement).  We next investigated the Gja5 expression pattern by following 
EGFP expression as an indicator of hemodynamic changes and capillary arterialization. In 
the Gja5EGFP/+ mice, EGFP expression was restricted to the main arteries and first arteriole 
branches (data not shown) copying the aSMA staining (Fig.4A). By contrast, Acvrl1+/-; 
Gja5EGFP/+ mice showed numerous enlarged pre-arteriolar capillaries that expressed EGFP 
(not shown) or aSMA (Fig.4A) compared to Gja5EGFP/+ mice. Quantification of the number of 
branch points and the length of the EGFP (+) vascular networks revealed an arterialization of 
the blood capillary bed in Acvrl1+/-, Gja5EGFP/+ mice (Fig.4C, D). We explored how reduced 
Gja5 expression affects the arterial vessel functionalities in Acvrl1+/- mice. We examined 
the spontaneous oscillation in tone of the skin arterial vessels (Fig.4E) and the ability of the 
retinal arteries to constrict following an electrical stimulation (Fig.4F). The arterial responses 
of Acvrl1+/-, Gja5EGFP/+ mice did not differ from the controls, Gja5EGFP/+ or Acvrl1+/- mice 
(Fig.4E, F) suggesting that the functionalities of the arteries are not defective per se. Both 
in vitro and in vivo biochemical data have suggested that reduced expression of Acvrl1 or 
Gja5 altered ROS production 32, 33. To access the potential role of oxidative stress, ROS 
production was measured by identifying Dihydroethidium (DHE)-positive nuclei in arteries 
of lung sections of one month-old controls, Gja5EGFP/+, Acvrl1+/- or Acvrl1+/-; Gja5EGFP/+ mice. 
Interestingly, greater DHE-staining was observed in Acvrl1+/-; Gja5EGFP/+ mice suggesting 
higher O2
- production (Fig.4G). 
Basal Red Blood Cell (RBC) flow in individual capillaries of Acvrl1+/-; Gja5EGFP/+ 
ROS production and reduced Nitric Oxide (NO) bioavailability have been reported 
to reduce endothelial cell survival leading to pruning of the microvasculature and contributing 
to the muscularization of the small arteries 34. We observed a strong reduction in the density 
of the capillary bed (Fig.5A, B) associated with a slight increase in capillary diameter 
(Fig.5C) in Acvrl1+/-; Gja5EGFP/+ mice compared to controls, Acvrl1+/- and Gja5EGFP/+ mice. 
Capillary rarefaction is associated with local blood flow deregulation. To examine whether 
this contributed to the vascular phenotype here, we used two-photon microscopy to measure 
RBC flow with micrometer spatial- and millisecond temporal 
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Figure 4: Increased ROS production and arterial dilation in Acvrl1+/-; Gja5EGFP/+ mice. (A) Images 
of whole-mounted ears of control  (n=4), Acvrl1+/- (n=5), Gja5EGFP/+ (n=8) and Acvrl1+/-; Gja5EGFP/+ 
(n=12) mice stained with antibodies against PECAM-1 (endothelial cells in red) and aSMA (vSMCs in 
green) at P60-P90. aSMA reveals arteries. The main arteries and veins are shown in left panels. Scale 
bars, 500μm. Right panels, higher magnifications of the whole-mount ears reveal an extension of the 
arterial network in Acvrl1+/-; Gja5EGFP/+ mice evident as increase numbers of aSMA (+) vessels. White 
asterisks indicate arterial branch points. Scale bars, 200μm. (B) Quantification of the arterial diameters. 
(C-D) Quantification of the number of branch points and vessel length of the EGFP (+) vascular 
network. (E) The relation between vessel diameter and a vasomotion index defined as the area under 
the curve for percent spontaneous changes in vessel diameter with a ±5% cutoff threshold, at least n=21 
vessel segments from 3 mice per genotype were analyzed. (F) Mean intensities that are able to induce 
the first retinal arterial constriction in controls (narteries= 32), Gja5EGFP/+ (narteries= 28), Acvrl1+/- (narteries= 32) 
or Acvrl1+/-; Gja5EGFP/+ (narteries=30) mice. At least 4 mice of 8-weeks old were analyzed per group (G) 
Increased DHE (red fluorescence) staining in lung sections of 8-week-old Acvrl1+/-; Gja5EGFP/+ (n=3) 
mice versus age-matched control (n=3), Gja5EGFP/+ (n=3) and Acvrl1+/- (n=3) mice. Arterial vessels 
show more positive nuclei with more intense red fluorescence in Acvrl1+/-; Gja5EGFP/+ mice. Scale bars: 
50µm. Quantification of the DHE red fluorescence intensity as determined by subtracting the image 
background from the average gray value within the a-SMA (+) vessels in control (nartery=40), Gja5
EGFP/+ 
(nartery=62), Acvrl1
+/- (nartery=35) and Acvrl1
+/-; Gja5EGFP/+ (nartery=53) lung sections. All error bars represent 
s.e.m. *P< 0.05, **P< 0.01, ***P< 0.001, results from unpaired t test or from one-way ANOVA test for 
multiple group comparison. NS, not significant, a, arteries; v, veins; l, lymphatic vessels. 
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resolution in individual capillaries 35. Retro-orbital injection of Red-dextran revealed the 
vascular architecture of the ear skin as well as individual RBCs, which appeared as shadows 
flowing in the fluorescent plasma (Fig.5D). We used rapid line scans along the capillary axis 
to determine the instantaneous RBC flow (Fig.5E).  We analyzed basal RBC flow in at least 
29 capillaries that were located in a post-arteriolar position in each genotype and detected all 
passing RBCs for 20 seconds (Fig.5F, G). Acvrl1+/-; Gja5EGFP/+ mice showed an increase in 
basal RBC flow compared to controls, Acvrl1+/- and Gja5EGFP/+ mice most likely reflecting an 
increase in blood flow (Fig.5F, G)
Reduced Cx40 promotes wound-induced AVM formation in Acvrl1+/- 
To explore the possibility that reduced expression of Cx40 might predispose to 
AVM formation in adult Acvrl1+/- mice, we generated punch wounds in the ears of 3-months-
old control, Acvrl1+/-, Gja5EGFP/+ and Acvrl1+/-; Gja5EGFP/+ mice. This type of wound induces 
environmental stress that triggers AVM formation in homozygous Acvrl1-iKO mice 17, 36. Left 
ventricular injection of latex blue into the heart was performed 30 days after wounding to 
visualize AV connections in the skin. As expected, the blue latex did not cross the capillary 
bed and was retained within the arterial branches in controls or Gja5EGFP/+ mice (Fig.6A). 
Moreover, Acvrl1+/- also showed normal morphology and latex only in arterial branches 
confirming that three events are required for AVM formation (Fig.6A) 10. By contrast, 
Acvrl1+/-; Gja5EGFP/+ mice showed dilated and tortuous vessels and the latex dye was found 
in both arteries and veins, indicating the presence of AV shunts (57%, n=7) (Fig.6A). Blood 
vessels away from the wound in Acvrl1+/-; Gja5EGFP/+ mice had normal morphology and no AV 
shunts. We also stained whole mounts of mouse ears for PECAM-1 and aSMA 14 days after 
wounding. This staining showed that even at this stage Acvrl1+/-; Gja5EGFP/+ mice developed 
abnormal connections between arterioles and enlarged capillary-like vessels that were EGFP 
(+) forming a nidus (Fig.6B). Thus, our data identify Gja5 as a possible genetic modifier of 
HHT2 and provide proof-of-concept that genes implicated in blood flow regulation might 
have important functions during AVM formation.
. 
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Figure 5: Measurements of RBC flow in skin capillaries of Acvrl1+/-; Gja5EGFP/+ mice. (A) Images 
of whole-mounted ears of control  (n=4), Acvrl1+/- (n=5), Gja5EGFP/+ (n=8) and Acvrl1+/-; Gja5EGFP/+ 
(n=12) mice stained with antibodies against PECAM-1 (endothelial cells in red) and aSMA (vSMCs 
in green) at P60-P90. aSMA reveals arteries. The capillary network in whole-mount images of ears 
reveal rarefaction of the capillary network and increased capillary diameter in Acvrl1+/-; Gja5EGFP/+ 
mice compared to control, Acvrl1+/- or Gja5EGFP/+ mice. White arrows indicate increased capillary 
diameter. Scale bars, 200μm. (B-C) Quantification of the number of capillary branch points and vessel 
diameters. (D) Injection of Rhodamine B isothiocyanate-Dextran reveals capillaries in skin. The white 
arrow indicates an enlarged capillary directly connected to a small arteriole labeled with EGFP in 
Acvrl1+/-; Gja5EGFP/+ mice. Scale bars, 200μm. (E) The fluorescence of Rhodamine B isothiocyanate-
Dextran in the plasma is shadowed by passing RBCs during the excitation gate. Red arrows correspond 
to individual RBC on the bottom. (F) Automatic detection of RBC transients allows local extraction 
of blood flow rates. (G) Quantification of RBC per second in capillaries of adult ears in control 
(ncapillary=29), Gja5
EGFP/+ (ncapillary=29), Acvrl1
+/- (ncapillary=45) and Acvrl1
+/-; Gja5EGFP/+ (ncapillary=34) mice. 
All error bars represent s.e.m. *P< 0.05, **P< 0.01, ***P< 0.001 and ****P< 0.0001, results from unpaired 
t test. NS, not significant, a, arteries; v, veins; l, lymphatic vessels. 
91
01
02
03
04
05
06
07
A
ALK1 & Connexin40
Figure 6: Wounding can induce de novo AVM formation in Acvrl1+/-; Gja5EGFP/+ mice. (A) Skin 
vasculature of control (n=8), Gja5EGFP/+ (n=5), Acvrl1+/- (n=9) and Acvrl1+/-; Gja5EGFP/+ (n=7) ear shown 
by latex dye injection after one month of wounding. Scale bars, 1mm. Right, higher magnifications 
of the vascular network around the wound. Scale bars, 200μm. The development of AVM is indicated 
by white arrow. Note that only in Acvrl1+/-; Gja5EGFP/+ mutant mice developed AV shunts, revealed by 
the presence of blue latex in both arteries and veins as indicated in (white arrowhead). The presence 
of AVMs was only found in the wound area. Asterisks indicate the center of the wound. a, arteries and 
v, veins. (B) Confocal images of whole-mounted ears of 3 months old control (n=8), Gja5aEGFP (n=5), 
Acvrl1+/- (n=9) and Acvrl1+/-; Gja5aEGFP (n=7) mice stained two weeks after wounding for PECAM-1 
marking endothelial cells in red and for aSMA (VSMCs in green) or labeled in EGFP to identity the 
arteries.  The white arrow indicates the formation of a system of multiple feeding arteries, the tangle 
or nidus and enlarged draining veins in Acvrl1+/-; Gja5aEGFP. (C) Working model for AVM formation 
in HHT2. Heterozygosity of Acvrl1 represents the baseline situation in HHT2. The vascular network 
shows distinguishable arteries and veins separated by a highly branched vascular plexus. Pathological 
enlargement of the arterial vessels results in the delivery of more blood volume to the downstream 
capillaries that adapt by enlarging and by forming transient AV shunts. Sustained angiogenesis promotes 
further the enlargement of these AV shunts that may form large AVMs.
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Discussion
In this study, we identified Gja5 as a potential genetic modifier of AVMs in 
HHT2. Our work revealed that the BMP9-ALK1 signaling pathway targets Gja5 and that 
reduced expression of Gja5 in Acvrl1 heterozygous mutants leads to arterial vasodilation 
and rarefaction of the post-arterial capillary network. In order to normalize the changes in 
hemodynamic forces and drain the engorged arterial system, capillaries become enlarged 
and form transient arteriovenous connections that can develop into AVMs when exposed to 
environmental insults (Figure 6C). Our data suggest that Acvrl1 haploinsufficiency combined 
with the effects of modifier genes that regulate vessel caliber and blood flow are responsible 
for the heterogeneity and severity of the clinical manifestations in individuals with HHT2 
and provide a novel “three hits hypothesis model” for AVM development.
  
Our data provide the first demonstration that changes in arterial vessel precede AVM 
formation in HHT mouse models and importantly, we identify Gja5 as a potential modifier 
gene for HHT2. We report that the ALK1 signaling pathway stimulates the expression of 
Gja5, most importantly though BMP9. Reduced expression of Gja5 in Acvrl1 heterozygous 
mice results in enlarged arterial vessels, altered blood flow and the formation of transient 
AV shunts in the capillary bed; these can remodel into large AVMs where there is a pro-
angiogenic and pro-inflammatory environment. Our findings are consistent with recent work 
showing that loss of Acvrl1 in zebrafish embryos leads to pathological arterial enlargement 
and consequently altered blood flow to induce lethal AVM formation 19. Acvrl1+/-; Gja5EGFP/+ 
double heterozygous mice provide a novel genetic model in which AVMs develop 
consistently and robustly. Most importantly, the AVMs resemble those seen in HHT patients, 
making this model an invaluable tool for uncovering the molecular and cellular defects that 
lead to vascular malformations in HHT, in particular those related to blood flow alterations. 
The Gja5 gene encodes for Cx40, a gap junction protein expressed in the developing 
arterial network, starting at the onset of perfusion 37. In the vascular system, endothelial 
cells predominantly express Cx37 (Gja4) and Cx40 whereas vascular smooth muscle cells 
mostly express Cx43 (Gja1) and Cx45 (Gjc1). Gap junction proteins form channels between 
neighboring cells to allow direct intercellular exchanges of ions and small metabolites, which 
are needed to coordinate vasoconstriction and vasodilation along the vessels 38, 39. Genetic 
studies show that mice lacking Cx40 develop hypertension because of increased secretion 
of renin and reduced relaxation of peripheral vessels 40. These defects have recently been 
shown to be at least partially dependent on endothelial Cx40 function indicating that Cx40 
expression levels regulate blood pressure. How endothelial Cx40 controls blood pressure 
remains poorly understood but might be attributable to endothelial nitric oxide synthase 
(eNOS) activity, an important modulator of vascular tone 40. Interestingly, both ALK1 and 
Cx40 interact and regulate the activity of eNOS 33, 41 suggesting that the phenotype of the 
Acvrl1+/-; Gja5EGFP/+ mice may be at least partially attributable to uncoupled eNOS activity. 
To support this hypothesis, we have found an increase production of ROS in the lung arteries 
of Acvrl1+/-; Gja5EGFP/+ mice. Mice carrying deletions in Gja5 also have fewer collateral 
arterioles 37, whereas Gja4-/-; Gja5-/- double-knockout mice die in utero, showing angiogenic 
remodeling defects with dilated blood vessels and hemorrhages 42, suggesting that Cx40 
might regulate angiogenesis. Loss of Acvrl1 expression results in excessive endothelial cell 
proliferation that precedes the development of AV shunts in zebrafish 19 and in Acvrl1-iKO 
mice 17. Here, we show that reduced expression of Gja5 in Acvrl1 heterozygous embryos and 
in neonatal retinas of postnatal day 7 mice leads to significant vasodilation of the arteries 
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and markedly reduced numbers of post-arterial branches. In contrast to Acvrl1+/- mutant 
mice, we did not observe excessive endothelial proliferation in Acvrl1+/-; Gja5EGFP/+ mice. 
Defective angiogenesis may therefore be the primary event responsible for this arterial 
enlargement, although the mechanisms that account for this observation -decreased arterial 
growth, retarded migration and/or defective endothelial sprouting- remain to be elucidated. 
The presence of dilated arteries that deliver more blood induces the enlargement of the 
downstream Cx40-independent capillary-like vessels to drain this system and the formation 
of AV connections. This enlargement is accompanied by increased endothelial proliferation 
suggesting that the presence of flow stimulates further the remodeling of the capillary bed, a 
mechanism that might be independent of Cx40. Furthermore, loss of Acvrl1 in zebrafish has 
previously been shown to result in increased expression of cxcr4a and decreased expression 
of edn1, suggesting that ALK1 might promote the quiescence of nascent arteries by alternative 
mechanisms 19. Given the fact that these genes encode a pro-angiogenic chemokine receptor 
and a vasoconstrictive peptide respectively, it is logical to consider that they may regulate 
arterial caliber downstream of ALK1. Nevertheless, concomitant increase in cxcr4a and 
loss of edn1 in zebrafish embryos did not copy the lack of Acvrl1 and was not sufficient to 
generate AVMs 19. 
Genetic polymorphisms have been detected in both promoter regions of GJA5 and 
suspected to be associated with risk of cardiovascular diseases including hypertension 39. 
These polymorphisms have been shown to affect GJA5 promoter activity by reducing gene 
expression by approximately half with inter-assay variations ranging from 20% to 65% 
reduction. By comparing the expression levels of Cx40 in sections of human skin biopsies 
isolated from 5 healthy donors and 4 HHT2 patients, we have confirmed that important 
differences exist between individuals and more importantly, we reveal that Cx40 protein 
levels are particularly low in the majority of a small selection of HHT2 patients compared to 
the healthy donors supporting an association between ALK1 signaling and Cx40 expression. 
In conclusion, our findings provide novel insights into the mechanisms underlying AVM 
pathogenesis in HHT2 elicited by increased arterial caliber that might ultimately be used for 
drug development for HHT. Moreover, we identity GJA5 as a potential modifier gene for 
HHT2 in which, genetic variations such as polymorphisms affecting “normal” expression 
levels are associated with disease progression.
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Materials and Methods
Mice and tissues. Experiments were carried out according to the guidelines of the European 
Community Council Directives of January 1st 2013 (2010/63/EU) and all efforts were 
made to minimize the number of animals used and their suffering. The Animal Experiment 
Committee of Ile de France approved all protocols. The following mouse strains were used: 
Cdh5-CreERT2 mice were provided by R. Adams, Max Planck Institute for Molecular 
Biomedicine, Münster, Germany 43. Acvrl1+/- and Acvrl1flox/flox mice were kindly provided 
by Paul Oh, University of Florida, Gainesville, USA 12,17. Cx40EGFP/+ mice were provided 
by L. Miquerol, Aix Marseille University, CNRS, IBDM, UMR 7288, France 44. Mice were 
maintained as heterozygotes on a mixed C56BL/6 and CD1 genetic background. Acvrl1fl/
fl; Cdh5-CreERT2 mice have been previously described 17. These mice were bred with 
Gja5EGFP/+ mice to generate Acvrl1fl/+; Cdh5-CreERT2 and Acvrl1fl/+; Cdh5-CreERT2; 
Gja5EGFP/+mice. To activate CreERT2, neonatal mice were IP injected twice with 50μl 
oftamoxifensolution (1mg ml-1, Sigma-Aldrich, T5648) at P2 and P4, respectively. To 
analyze post-natal angiogenesis in the mouse retina, P7 pups were sacrificed and eyes were 
removed and prefixed in 4% Paraformaldehyde (PFA) in PBS for 10min at room temperature. 
We dissected the retinas post-fixed them in 4% PFA in PBS overnight and then processed 
them for immunohistochemistry as described 26. Ear wound healing was performed as 
described 17. Briefly, ears from mice at P60 were wounded using a 2mm-needle. One month 
later, mice were anesthetized with 2% isoflurane (Baxter S.A.S, DDG9623) and latex blue 
(BR80B, Connecticut, Valley Biological Supply, USA) was steadily injected into the left 
ventricle as previously described after dilatation with PBS-vasodilator solution containing 
heparin 10U/ml (Sigma-Aldrich, H3149), papaverin 0.04mg/ml (Sigma-Aldrich, P3510) and 
sodium nitroprusside 100mM (Sigma-Aldrich, 71778) and after fixation with PFA 4%. For 
whole-mount staining of cutaneous blood vessels, mice were killed 2 weeks post-wound 
and ears were dissected with forceps, separating the dorsal and the ventral leaflets. We fixed 
dorsal halves in 4% PFA overnight at 4°C and processed them as described 26.
Human material. Four HHT2 and five healthy donor skin samples were obtained from St 
Antonius Hospital (Department of Pulmonary Disease, Nieuwegein, The Netherlands) and 
Leiden University Medical Center (Department of Molecular Cell Biology, Leiden, The 
Netherlands) respectively following informed consent. Sections were processed as described 
previously 26. Briefly, we collected skin biopsies in physiological salt, fixed them overnight 
in 0.2% paraformaldehyde in 0.1M phosphate buffer with 0.12 CaCl2 and 4% sucrose. We 
used 8μm sections for staining. We fixed frozen sections in cold acetone, washed them with 
PBS, blocked them with blocking reagent (Roche) and incubated them overnight at 4 °C with 
primary antibodies in PBS plus 0.2% BSA (A4503, Sigma). After washing, we incubated 
sections for 1 h at 20 °C with secondary antibodies diluted in PBS with 0.2% BSA and 
mounted them in DAKO mounting medium (S3023, DAKO). We captured images with a 
confocal laser-scanning microscope SP5 (Leica).
Antibodies and recombinant proteins. Antibody rat anti-mouse PECAM-1 (clone MEC 
13.3) was purchased from BD Biosciences (553370), FITC (F3777) or Cya3- (ab7817) 
conjugated anti-Smooth Muscle Actin (SMA) (clone 1A4) was obtained from Sigma-
Aldrich, antibody mouse anti-human PECAM-1 (IR61061) and goat anti-human Cx40 (sc-
20466) were purchased from Dako and Santa Cruz Biotechnology, respectively. AlexaFluor-
conjugated secondary antibodies were anti-goat alexa488 (A11055), anti-mouse alexa555 
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(A21422) and anti-rat555 (A21434) from Invitrogen. Nuclei were counterstained with 
DAPI (Invitrogen, D1306). To analyse microvasculature, mouse retinas were stained with 
biotinylated Griffonia simplicifolia lectin (isolectin B4) (B-1205) obtained from Vector 
Laboratories and streptavidin Cya-3 (PA43001) or Cya-5 (PA45001) from Sigma-Aldrich. 
Recombinant BMP9 was obtained from R&D Systems (3209-BP-010).
Immunofluorescence and DHE staining. ROS levels were assessed by dihydroethidium 
(DHE) staining of mouse lung sections as previously described (D-1168, Molecular Probes, 
Thermo Fisher). We used 7μm sections for staining. Arteries were stained with FITC 
(F3777) conjugated anti-Smooth Muscle Actin (SMA) (clone 1A4) obtained from Sigma-
Aldrich. Whole-mount immunofluorescent staining of retinas or ears was as previously 
described 21, 45. Images were captured with a confocal laser-scanning microscope SP5 
(Leica), Leica DMRB, Zeiss stereo Discovery V20 microscopes or Zeiss Axio Zoom V.16.
Morphometry and quantitative analysis. We quantified branch points per field and vessel 
length as previously described 26. At least three images were analyzed per mouse. For density, 
we measured the total cellular area (pixels) by converting compressed Z-stacks to black and 
white followed by manual threshold adjustment to highlight cell contours. Cell surface area 
was quantified with ImageJ software (US National Institute of Health). Vessel diameter was 
measured using PECAM-1 (+) compressed Z-stack images from similar regions in the ear 
using ImageJ. Digital images of human skin sections were acquired with a Leica SP5 confocal 
microscope. ImageJ software was used for computerized analysis of immunostained vascular 
structures. The images were fixed at threshold intensity, values below being excluded from 
analysis. For each image, vessel surface was defined as PECAM (+) pixels and determined by 
the total grey value. In the corresponding Cx40 image, fluorescence intensity was calculated 
with the integrated intensity defined as the sum of all pixels in the image. Cx40 fluorescence 
intensity was defined as the ratio of Cx40 integrated intensity to PECAM total grey value of 
at least 5 independent images for each individual.
Cell culture and transfection. Human Arterial Endothelial Cells (HuAECs) were obtained 
as described 45 and cultured in EGM-M2 SupplementPack (PromoCell, C-39211) at 37°C 
in 5% CO2. Cells were washed with phosphate-buffered saline (PBS) (Gibco, 14200-067) 
and then serum-starved for 5 hours prior to stimulation with either 1ng/ml for 3h or 10ng/ml 
BMP9 for 24h to assess the effect of BMP9 on gene expression.
HuAECs were transfected either with siRNA control (AllStars negative control, 11175471, 
Qiagen) or siRNA targeting human ACVRL1 (FlexiTube siRNA SI02758392, Qiagen). 
Transfections were carried out at a final concentration of 5nM in 12-well plates using 
OligofectamineTransfection Reagent (12252-011, Invitrogen) overnight and then medium 
was changed.
Protein extraction and western blot analysis. Cell lysates were prepared with RIPA buffer 
(50mM Tris-HCl, 250mM NaCl, 2% NonidentP40, 2.5mM EDTA-Na, 0.1% SDS, 0.5% 
DOC, pH 7.2) containing complete protease inhibitor cocktail II (Roche Applied Science). 
Protein concentrations were determined using the DC Protein Assay Kit II (BioRad). 
Samples were analyzed by Western blot using 10% polyacrylamide gels, followed by 
overnight wet-transfer of the proteins to activated nitrocellulose membranes Hybond-C Extra 
(Amersham, Biosciences). Membranes were blocked in TBS-T (0.01 M Tris-HCl, pH 7.4, 
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0.15M NaCl, 0.1% Tween-20) with 5% dried milk and incubated overnight with the indicated 
antibodies. Signal detection was performed using the ECL system and SuperSignal West 
Pico Chemiluminecent Substrate (Thermo Scientific). The antibodies used in the study are 
the following: anti-pSMAD1/5 (1:1000, Cell Signaling Technology, Danvers, MA, USA), 
SMAD1/5 antibody (1:1000, Santa Cruz, SC-6031), anti-GAPDH (1:1000, Sigma), HRP-
conjugated secondary antibodies IgG(1:5000, Cell Signaling).
Quantitative PCR analysis. RNA was isolated from HuAECs using the RNeasy Mini 
Kit (QIAGEN, 74104). In vitro reactions were performed from every RNA sample 
using Superscript III Reverse Transcriptase first-Strand Synthesis Kit for real-time 
(RT)-PCR (Invitrogen, 18080-044). RNA extracted was quantified using a Biomate 3 
Spectrophotometer. Quantitative PCR (MyiQ Single Color Real-Time Detection System, 
Bio-Rad) was performed in duplicate using the MyIQTM real-time PCR system (Biorad). 
Each 20ml contained 200ng of cDNA, 10ml iQTM SYBR® Green Supermix (Biorad, 
1708880), 250nM of forward and reverse primers and nuclease free water. Primers used 
were as followed: GJA5 (Forward primer 5’- AATCAGTGCCTGGAGAATGG-3’, 
reverse primer 5’CGAACCTGGATGAAACCTTC-3’), HEY2 (Forward primer 
5’-GATTCAGCCCTCCGAATG-3’, reverse primer 5’ TGGCAGAGAGGGACAAGAG-3’), 
ID1 (Forward primer 5’-TGTCTGTCTGAGCAGAGCGT- 3’, reverse primer 
5’-TAGTCGATGACGTGCTGGAG-3’) and the human reference genes GAPDH (QIAGEN, 
QT01192646) and ACTB (QIAGEN, QT00095431) for normalization. Quantitative PCR was 
performed with an initial denaturation step of 15min at 95oC followed by 40 cycles of 15s 
denaturation at 95oC, 30s annealing at 58oC, and 30s extension at 72oC. Four biological 
replicates were carried out for all quantitative PCR reactions.
Vasomotion and Red blood cell flow analysis. Adult mice were anesthetized by inhalation 
of isofluorane 2% (Baxter S.A.S, DDG9623). 100ml of Fluorescence Rhodamine B 
isothiocyanate-Dextran (Sigma-Aldrich, R9379- 250MG) was retro-orbitally injected. After 
3min, the selecting points of interest in the arterial vessels or in the capillaries were captured 
by fast fluorescence-based scanning using 25x objective (HCX IRAPO L 25x/0.95 W). We 
have recorded spontaneous vasodilation and vasoconstriction of the arterial vessels at 1Hz 
during 100s. The relation between vessel diameter and a vasomotion index is defined as the 
area under the curve for percent spontaneous changes in vessel diameter with a ±5% cutoff 
threshold. We have also measured short transients in the PMT signal collected during xt 
phase at 1.4MHz for 20 seconds in each capillary vessel as previously described 35. Red blood 
cells (RBCs) appeared as dark shadows on bright red background because of the Dextran 
contained in the blood plasma. Importantly, when the diameter of the vessel allowed passage 
of RBCs only in single file, as in the case of capillaries, the flux of RBCs is simply the 
number of RBCs that pass per second 35.
Electrostimulation. Electrostimulation of the retinal arteries was performed as described 
46,47 . Briefly, whole retina were mounted and maintained in an extracellular solution (37 
°C) (NaCl 140 mM; Glucose 25 mM; KCl 5.5 mM; CaCl2 1.8 mM; MdCl2 1 mM; Hepes 
10 mM; ph = 7.3)). On whole mounted retinas, vascular smooth muscle cells were patched 
with pipette filed with the same solution. Resistance of the pipette was measured before each 
experiment in order to define the input voltage (pulses 0.02 ms, 10 Hz for 5 s) to be applied 
so as to deliver a current intensity increasing from 1 to 4μA. Vascular smooth muscle cells 
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were stimulated by applying voltage pulses 20 seconds after the patch. A total of 300 images 
was recorded in 2.5min.
BrdU staining in P7 retina. To investigate endothelial cell proliferation, P7 pups were 
injected subcutaneously with 250μg of BrdU per gram body weight 3 hours before euthanasia. 
Retinas were subjected to antigen retrieval with 2N HCl and 1%Triton, washed with 0.1M 
Tris-HCl pH8 and stained with mouse anti-BrdU (1:500, Sigma-Aldrich, B8434). Secondary 
Alexa Fluor555 anti-mouse IgG1 (Life Technologies, 1:250) was used to detect primary anti-
BrdU antibody.
Whole E12.5 embryo staining. E12.5 mouse embryos were isolated and fixed in 4% 
paraformaldehyde for 3 hours. Washed with TNT solution (10%Tris pH7.4, 0.15M NaCl and 
0.05% Tween) and permeabilized in PBS with 0.3% Triton. Embryos were then incubated 
in blocking buffer TNBT (10%Tris pH7.4, 0.15M NaCl, 0.5% Perkin Elmer blocking and 
0.5% Triton X100) overnight at 4°C. Vasculature was stained with primary rat anti-mouse 
CD31 antibody (BD Pharmingen Clone: MEC 13.3, 1:100) for 2 days and secondary Alexa 
Fluor555 anti-rat (BD Biosciences, 1:250) overnight at 4°C.
Statistical Analysis. We performed statistical analyses with Prism 6 software (GraphPad) 
using one-way Anova analysis the mean of three or more independent groups and using 
the two-tailed, unpaired Student’s t test. Data were expressed as mean ±SEM. P< 0.05 was 
considered to be statistically significant.
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Supplementary Figures
Figure I: Gja5 and Acvrl1 mRNA expression levels in control, Gja5EGFP/+, Acvrl1+/- and 
Acvrl1+/-; Gja5EGFP/+ mice. (A-B) Graphs showing relative expression levels of Gja5 (A) and 
Acvrl1 (B) mRNA isolated from P7 retinas. Error bars represent s.e.m. *P< 0.05, **P< 0.01, ***P< 
0.001 result from unpaired t test. NS, not significant.
Figure II: Vascular network density 
analysis related to the distribution 
of hemodynamic forces in P7 mouse 
retina. (A) Scheme of the distribution 
of the hemodynamic forces as generated 
by computation methods. Vessels with 
preferential high blood flow are labeled in 
green and correlate with arteries and with 
areas where advanced state of pruning 
are typically found at P7. The outlined 
red boxes indicate the areas in which 
vascular parameters were quantified. 
Acvrl1+/-; Gja5EGFP/+ mutant mice 
show reduced capillary density in post-
arterial vessels of the vascular front (area 
1) compared to control, Gja5EGFP/+ or 
Acvrl1+/- mice. (B-C) Quantification of 
the capillary density in area 2 (B) and in 
area 3 (C) of control (n= 9), Gja5EGFP/+ 
(n= 8), Acvrl1+/- (n= 9) and Acvrl1+/-; 
Gja5EGFP/+ (n= 7). Error bars represent 
s.e.m. P results from unpaired t test. NS, 
not significant.
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Figure III: (A-B) Effect of reduced expression of Gja5 in Acvrl1-iHET mouse model. Graphs 
showing relative expression levels of Gja5 (A) and Acvrl1 (B) in the retina P7 of control, Gja5EGFP/+; 
Acvrl1-iHET and Acvrl1-iHET; Gja5EGFP/+ pups injected intraperitoneally twice at P2 and P4 with 
50μg of Tamoxifen. Effect of reduced expression of Gja5 in Acvrl1-iHET mouse model. (C) Top, 
Isolectin B4-stained endothelial cells in retinal vessels in control (n=12), Gja5EGFP/+ (n=11), Acvrl1-
iHET (n=12) and Acvrl1-iHET; Gja5EGFP/+ (n=14) mice at P7. Bottom: higher magnifications of 
the post-arterial capillary plexus shown in the top row. Outlined boxes indicate the areas in which 
vascular parameters were quantified. (D-E) Quantification of post arterial capillary density (D) and 
quantification of the number of vessel branch points (E) per field. All error bars represent s.e.m. *P< 
0.05, **P< 0.01, ***P< 0.001 and ****P< 0.0001, result from unpaired t test. NS, not significant a, 
arteries; v, veins. Scale bars, 200μm.
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Figure IV: Development of transient AV connections in Acvrl1-iHET; Gja5EGFP/+ neonatal 
retina. (A) Confocal images of flat-mounted retinas labeled with isolectin-B4 show the vascular plexus 
of control (n=12), Gja5EGFP/+ (n=9), Acvrl1-iHET (n=11) and Acvrl1-iHET; Gja5EGFP/+ (n=13) at 
P7. The white arrow indicates a direct connection between an artery and vein. (B) The development 
of an AVM shunt in Acvrl1-iHET; Gja5EGFP/+ P7 retinas is characterized by increased proliferation 
indicated by BrdU staining. Scale bars, 200μm
Figure V: Effect of 
reduced expression of 
Gja5 in Acvrl1+/- mutant 
mice during embryonic 
development. (A) Left, 
P E C A M - 1 - s t a i n e d 
endothelial cells in E12.5 
Gja5EGFP/+ (n=5) and 
Acvrl1+/-; Gja5EGFP/+ 
(n =5) embryos. Right: 
higher magnifications of 
the mesenchephalic artery 
from the images on the 
left. Scale bars 100μm. 
(B) Quantification of 
the arterial diameter and 
(C) quantification of the 
number of branch points 
of the EGFP (+) arteries. 
(D) Increased arterial 
diameter in E17.5 lung 
and intestine of Acvrl1+/-; 
Gja5EGFP/+ mice 
compared to Gja5EGFP/+ 
mice shown by imaging the 
EGFP (+) arterial network. 
Scale bars 200μm
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PSCs, both ESCs and iPSCs are already a useful and renewable source of all cell 
types of the body. PSCs enable the generation of autologous cells for the in vitro investigation 
of molecular mechanisms underlying physiologic and pathophysiologic states characteristic 
of a number of diseases. In particular, with the development of robust endothelial specific 
differentiation protocols (Chapter 3,(Orlova et al., 2013)) and new genetic manipulation 
approaches (Chapter 3), hPSCs can be used to recapitulate and analyze defined steps of 
early human development with respect to endothelial cell fate commitment. Furthermore, the 
isolation and expansion of pure populations of hPSC-derived ECs (Chapter 5) enables further 
phenotypic and functional characterization of these cells. 
Modeling embryonic development using hPSCs
In Chapter 3 and Chapter 5, we derived hESC-ECs and hiPSC-ECs using a 
spin-EB (embryoid body) or a monolayer-based two-dimensional (2D) differentiation 
approach, respectively. Both systems demonstrated controlled sequential gene expression 
characteristic of mesoderm formation and patterning, starting from the enrichment of key 
transcription factors during early embryonic mesoderm development (BRY and MESP1), 
via a hematovascular mesodermal precursor stage (ETV2), to ECs (CD31, ALK1, ENG), 
mimicking endothelial development in vivo (Chapter 3,(Orlova et al., 2013)). Therefore, both 
approaches provided excellent systems to characterize vascular progenitor stage-specific key 
signaling pathways. This research is driven not only by the practical need to find cures for 
the numerous human diseases caused by developmental defects, but also by the importance 
of identifying the critical regulators guiding commitment and diversification of endothelial 
progenitors, allowing further enhancement of the differentiation efficiency and the derivation 
of tissue-type specific ECs(Wilson et al., 2014).
In the developing mouse embryo, the VEGF signaling pathway has been implicated as 
the major regulator of vasculogenesis, leading to the aggregation and de-novo-formation 
of angioblasts into a primitive vascular plexus (Coultas et al., 2005; Dvorak et al., 1995; 
Klagsbrun and Soker, 1993; Poole et al., 2001). This signaling pathway family consists of 
five secreted VEGF ligands (VEGF-A, VEGF-B, VEGF-C, VEGF-D and PIGF), which 
can bind with differing specificities to three endothelial VEGF tyrosine kinase receptors 
(VEGFR-1, VEGFR-2 and VEGFR3) (Holmes and Zachary, 2005; Shibuya, 2013). Notably, 
our data showed that VEGF signaling is also required for the generation of human endothelial 
cells from hPSCs in vitro (Chapter 3,(Orlova et al., 2013)), as previously described by others 
(Patsch et al., 2015; Sahara et al., 2014; White et al., 2013). Analysis of VEGF ligands and their 
receptors, during mouse embryogenesis, demonstrated the interaction between VEGFR-2 and 
VEGF-A as essential for the development of mesoderm (Coultas et al., 2005; Rossant and 
Howard, 2002). In Chapter 3 we showed that treatment of differentiating hESCs with VEGF 
resulted in the enrichment of VEGFR2+ (KDR+) population with increased expression of 
ETV2 gene, a key regulator of hematoendothelial lineages, suggesting a relationship between 
VEGFR-2 and ETV2 similar to that described in the mouse system (Kataoka et al., 2011; 
Rasmussen et al., 2012). 
The need for a new genetic tool
As described in Chapter 3, ETV2 belongs to the transcriptional regulatory ETS 
protein family and is transiently expressed in the primitive streak, yolk sac blood islands, 
and large vessels such as dorsal aorta during early embryonic development (Lee et al., 
2008). Ectopic transient expression of etv2 can significantly increase the number of ECs 
in differentiating mESCs (Koyano-Nakagawa et al., 2012; Lee et al., 2008) and hESCs 
(Elcheva et al., 2014; Lindgren et al., 2015), suggesting the protagonist role of etv2 in 
transcriptional complexes mediating mesodermal plasticity of early endothelial progenitor 
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cells. Further studies will be needed to elucidate the differentiation potential of ETV2-
expressing populations in our spin-EB differentiation cultures. Mechanistically, a few Etv2 
interacting regulators, such as OVOL2 (Kim et al., 2014), Jmjd1a (Knebel et al., 2006) and 
Gata2 (Shi et al., 2014), and DNA binding sites, including VE-cadherin (Cdh5), Fli1, Erg, 
Tie2 and Lmo2 (Koyano-Nakagawa et al., 2012; Liu et al., 2012), have been identified using 
ChIP or mass spectrometry (MS) analysis. However, major drawbacks of the latter studies 
include the fact that experiments were largely confined to examining interacting protein 
partners or DNA binding site conditions of forced ETV2 overexpression, which made it 
difficult to discern between functional and artifactual ChIP or MS signals. Misleading results 
are in line with recent, carefully controlled ChIP reports in yeast demonstrating that highly 
expressed genes exhibit potentially artifact-based ChIP peaks (Park et al., 2013; Teytelman 
et al., 2013). In Chapter 2 and Chapter 3, mouse and human ESCs were used to describe 
a newly developed knock-in fusion strategy based on gene targeting by HR that could 
circumvent these limitations by providing non-invasive physiological expression of the gene 
of interest and allowing further transcriptomic characterization (Figure 1). However, a major 
bottleneck of this knock-in fusion strategy when applied in transiently expressed genes, such 
as ETV2, remains the accessibility to a sufficiently large ETV2-expressing population for 
high-throughput analysis. Thus, it is important to optimize culture conditions that increase 
efficiency of and highly enrich the ETV2-expressing cell fractions.
Gene targeting by homologous recombination has been an indispensable tool in generating 
hESC reporter lines following a knock-in deletion strategy, in which the first exon of the gene 
of interest is replaced by a sequence encoding for a fluorescent protein; this results in the 
deletion of one wildtype allele which for important genes could alter the biological outcome 
or conclusions of studies using the reporter line. It is important to remember however 
that this knock-in strategy may not recapitulate all features of normal gene regulation. In 
contrast, our gene targeting knock-in fusion strategy allowed the accurate integration of the 
modified targeting construct into the 3’ end and in frame with the coding sequence of the 
gene of interest. With this approach, the C-terminus of the targeted protein can be fused 
either with a fluorescent protein or with a composite affinity tag protein allowing multiple 
protein purification to be performed using TAP technology (Rigaut et al., 1999). Using the 
pluripotency transcription factor Nanog as an example, in Chapter 2 we confirmed that this 
knock-in fusion strategy allowed the generation of functional TF fusion proteins mirroring 
normal protein distribution in vivo and in vitro. As seen in a subsequent study, this approach 
further permitted continuous non-invasive quantification of TF fusion-protein expression 
dynamics and its functional significance on the correlation networks of other pluripotent 
TFs over many generations in culture, which made this strategy critical for many clonal 
applications and downstream assays of single-cell studies (Filipczyk et al., 2015) .
Future directions
As mentioned above, ETV2 has been one of the master regulators in the intersection 
of embryonic vessel and blood cell development. Using ETV2mcherry/w fusion-reporter hESCs 
in which the emergence of ETV2+ cells can be followed by the expression of a red fluorescent 
protein (mcherry), chemical compounds that induce, maintain ETV2-mcherry expression 
and determine their cell fate conversions could be tested and combined with extensive 
transcriptomic and epigenomic analysis (Figure1). The results can lead to the identification 
of new signaling pathways specifying endothelial and/or hematopoietic development and 
generate culture conditions in which pure populations of ETV2+ cells can be expanded and 
stored. The latter is of particular importance in cellular transplantation therapy, as this pool 
of cells could be an unlimited autologous source for de novo generation of human HSCs, red 
blood cells, platelets, and T cells in vitro. Similarly, for the vascular system, the identification 
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and manipulation of critical gene networks combined with microfluidics approaches can 
lead to the generation of tissue specific arterial/venous/lymphatic endothelial cells that 
may allow one to mimic vital EC functions that are central to in vitro disease modeling and 
toxicology studies including microvascular permeability, vasomotor tone, coagulation and 
anticoagulation, inflammation and angiogenesis. Finally, single-cell continuous time-lapse 
imaging could reveal the clonal origin of different subtypes of endothelial and hematopoietic 
cells from hemangioblast in vitro.
Figure1. Strategies for using the ETV2mcherry/+ hPSC fusion line. 1. Differentiation of ETV2mcherry/+ 
hPSC fusion line towards ETV2+ population. 2. Identification of cell factors required for ETV2+ cells 
to acquire self-renewing ability in order to expand and bank pure ETV2+ populations. 3. Identification 
of cell factors required for the sequential ESPCs and HSPCs commitment of ETV2+ cells. 4. Generation 
of arterial, venous, lymphatic endothelial cells and stable capillary networks using microfluidics 
technologies for in vitro tissue-specific modeling and drug toxicity studies. 5. Generation in vitro 
of HSPCs with primitive/definitive hematopoietic (macrophages, granulocytes, megakaryocytes, 
erythrocytes, dendritic cells, B and T cell lineage) and bone marrow reconstitution potential  in mouse 
models. 6. Identification of stage-specific molecular networks (using epigenetic, transcriptomic and 
proteomics approaches)  required for the specification and expansion of ESPCs and HSPCs derivatives 
from ETV2+ cells; ESPC (endothelial stem/progenitor cells), HSPC (hematopoietic stem/progenitor 
cells).
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Modeling HHT using hiPSCs
In addition to their relevance for studying normal development, hPSCs also have 
potential for investigating the pathogenesis of human diseases in vitro. As described in 
Chapter 1, HHT is caused by mutations in genes encoding proteins involved in binding 
TGF-β and those associated with its signaling pathway in endothelial cells. In particular, the 
majority of HHT patients harbor mutations in ENG or ACVRL1 genes, which are responsible 
for HHT1 and HHT2, respectively. In Chapter 4 and Chapter 5, we described the derivation 
of iPSC lines from healthy individuals and patients diagnosed with HHT. To date, four 
HHT1 and three HHT2 iPSC lines harboring nonsense, missense or deletion mutations have 
been generated in our laboratory (Freund, Orlova, unpublished) providing a potential model 
system that can be used to identify mechanisms of HHT, further explain findings between in 
vitro/in vivo models and the human disease and screening new drug compounds. 
Characterization of HHT1 iPSC-ECs
Most mutations in ACVRL1 and ENG generate a null allele, giving rise to unstable 
or non-functional truncated proteins in addition to the normal wildtype protein at reduced 
levels. This is in line with our observation that HHT1 iPSC-ECs exhibit constitutively reduced 
levels of ENG when compared to control iPSC-ECs (Chapter 5). However, cell density 
culture conditions clearly affect gene expression levels of TGFβ related genes (Chapter 5) 
so that care should indeed be taken to analyze control and mutant lines at the same density. 
Gene expression profiling of HHT1 iPSC-ECs and control iPSC-ECs revealed several 
differentially expressed genes that could have been the result of reduced levels of ENG. 
Among these, MTUS1 had not been described before in ECs. We showed that MTUS1 
upregulation was directly dependent on ENG levels by using siRNA to knock-down ENG 
in ECs, suggesting its direct association with ENG. However, extensive experimentation 
will be required to determine its function in ECs and HHT1. MTUS1 encodes a number of 
isoforms, termed AT2 receptor-interacting proteins (ATIPs), with distinct tissue distribution 
and subcellular localization (Rodrigues-Ferreira and Nahmias, 2010). ATIP1, which is the 
principle isoform expressed in our hiPSC-ECs (Chapter 5), has mainly been associated with 
AT2 receptor transport from the Golgi and intracellular signaling pathways (Rodrigues-
Ferreira and Nahmias, 2010). Interestingly, MTUS1 has also been found to be downregulated 
in a number of solid tumors, including pancreas (Seibold et al., 2003), ovary (Pils et al., 
2005), head-and-neck (Ding et al., 2012; Ye et al., 2007), colon (Zuern et al., 2010), bladder 
(Xiao et al., 2012) and breast tumors (Rodrigues-Ferreira et al., 2009). Furthermore, ATIP1 
has been shown to mimic the inhibitory effects of the AT2 receptor on bFGF and PDGF-
induced ERK2 phosphorylation and cell proliferation (Nouet, 2004). An important point is 
that, in contrast to the canonical TGFβ/Smad pathway, TGFβ is able to signal through a 
number of non-Smad pathways, including the Ras / Erk / MAPK pathway. Thus, the possible 
involvement of ATIP1-AT2 receptor in ENG-TGFβ or bFGF-mediated Erk activation in 
promoting or inhibiting cell proliferation in HHT1 iPSC-ECs remains to be elucidated. In 
addition, one study showed that ATIP1 can also function as a Golgi membrane-associated 
protein, where is involved in the intercellular transport of the AT2 receptor to the plasma 
membrane(Wruck et al., 2005). Finally, the remaining question emerging from this study 
is whether intracellular crosstalk exists between ATIP1 and ENG, that might account for 
activation or translocation of TGFβ/BMP signaling in ECs. To address this question, yeast 
two-hybrid and crosslinking approaches could be applied. 
HHT patients develop abnormal vascular structures, such as AVMs.  The formation of AVMs 
is still poorly understood but several mechanisms have been proposed based on both in vitro 
and in vivo studies. These include increased production of VEGF (Cirulli et al., 2003; Sadick 
et al., 2005a; 2005b), inappropriate responses of mutated endothelial cells to TGF-β (Lebrin 
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et al., 2004; Xu et al., 2004), or to BMP9/10 stimulation (Kim et al., 2012; Ricard et al., 
2010; Young et al., 2012), defective endothelial cell specification during the Tip cell selection 
(Larrivée et al., 2012) and disengagement of the endothelium from the surrounding mural 
cells due to reduced activation of local TGF-β (Carvalho, 2004). In all cases, the endothelium 
becomes more susceptible to growth factor stimulation, resulting in excessive endothelial 
cell proliferation and the formation of a denser and more highly branched vascular plexus 
(Larrivée et al., 2012; Lebrin et al., 2010; Mahmoud et al., 2010; Park et al., 2009; Ricard 
et al., 2012; Roman et al., 2002). The generation of control and HHT1 iPSC-ECs allowed 
us to study the physiological functions of disease-relevant ECs and the role of ENG in the 
responses of HHT1 iPSC-ECs to TGFβ or BMP9 stimulation (Chapter 5). 
TGF-β signaling in control and HHT1 iPSC-ECs
A key aspect in understanding how endothelial cells respond to TGFβ related 
ligands is to know their receptor localization. ALK1 is expressed exclusively in ECs and 
ENG largely in vascular cells, pericytes and cells of the bone marrow, whereas ALK2, 
ALK3, ALK5, BMPRII and TGFBRII are expressed in a numerous other cell types (Leon 
and Arthur, 2002; Sachiko et al., 1995; Seki et al., 2005) . Importantly, ALK1 and ALK5 
exhibit distinct expression in blood vessels (co-expressed in ECs; ALK5 only in vSMCs), 
suggesting different functions in blood vessel development (Seki et al., 2005).
In ECs, TGFβ can bind and signal through both TGFBR-II/ALK5/Smad2, 3 and TGFBR-II/
ACVRL1 (ALK1) /Smad1, 5 and 8 complexes (Chen and massague, 1999; Finnson et al., 
2008; Goumans et al., 2003; Lux et al., 1999; Oh et al., 2000). Specifically, TGFβ1 and 
TGFβ3 are able to phosphorylate both Smad1/5 and Smad2/3 in a broad range of primary 
ECs, including MEECs, BAECs, BCECs, yolk sac (YS) and BMECs (Goumans et al., 2002). 
This is not consistent with a number of studies using HUVECs, in which phosphorylation 
of SMAD1/5/8 was not induced by TGFβ1, suggesting that the effect of TGFβ is highly 
dependent on the cellular context  (David et al., 2007; Liu et al., 2014; Nolan-Stevaux et al., 
2012; Ota et al., 2002; Seki et al., 2005; Shao et al., 2009; Wang et al., 2013). 
Furthermore, these two receptor combinations in ECs have also been shown to give rise to 
different cellular responses. These include stimulation of cell proliferation and migration 
via TGFβ/ALK1 and inhibition of cell proliferation leading to vascular quiescence through 
the TGFβ/ALK5 complex (Goumans et al., 2002; 2003; Oh et al., 2000). It is important 
to note that these biphasic responses are observed only at high doses of TGFβs in primary 
ECs (Goumans et al., 2002). Interestingly, the TGFβ co-receptor ENG was further shown 
to mediate these biphasic signaling and cell functional responses in MEECs and HMEC-
1 (Blanco et al., 2005; Lebrin et al., 2004). This is in line with our observation that ENG 
is required for TGFβ-3/ALK1-mediated activation of SMAD1/5 in hiPSC-ECs at high cell 
densities (Chapter 5), but further research is necessary to elucidate the biphasic functional 
responses in these hiPSC-ECs. 
It was demonstrated previously that BMP9 can signal through BMPRII / ActRIIA / ALK1 
inducing SMAD1 /5 /8 phosphorylation in HMVEC-d’s, BAECs and HUVECs (David et al., 
2007; Scharpfenecker et al., 2007). In Chapter 5 we also showed this was the case in hiPSC-
ECs. Interestingly, the BMP9 response is increased by ENG expression, which is further 
supported by the fact that BMP9 is the only ligand able to bind directly to ENG and ALK1 
(Brown et al., 2005; David et al., 2007; Mitchell et al., 2010; Ricard et al., 2012; Scharpfenecker 
et al., 2007). In addition, BMP9 was also shown to inhibit proliferation and migration of ECs 
and to block VEGF-induced angiogenesis in vitro, as evidenced by the formation of vascular 
tube-like structures (David et al., 2007; Scharpfenecker et al., 2007). In contrast and in line 
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with our observations, high doses of BMP9 can give rise to the activation of both, SMAD1/5 
and SMAD2 and not SMAD3 in human pulmonary artery ECs (PAECs), HAECs, HMEC-1 
and hPSC-ECs (Upton et al., 2009) (Chapter 5). Finally, it is important to note that treatment 
of HUVECs, HUAECs and HBMVEC with serum leads to the phosphorylation of Smad1/5 
via ALK1 similar to BMP9 (Wöltje et al., 2015). Thus, there is no doubt that downstream 
phosphorylation of Smad proteins is highly cellular-context dependent, where different 
ligand concentrations, receptor localization, serum supplementation and as we showed, cell 
density, resulting in conflicting outcomes of TGFβ signaling in vitro.
 
In Chapter 5 we provided evidence that TGFβ/BMP9 concentration and EC density conditions 
contribute to this ‘‘cross-over’’ SMAD activation, considerations that should be borne in 
mind when studying downstream signaling. Even though TGFb signals through SMAD2 and 
BMP9 via SMAD1/5, high TGFb and BMP9 concentrations under high cell density conditions 
induced phosphorylation of both SMAD1/5 and SMAD2 (Chapter 5). Importantly, the major 
drawback of this study includes analysis that is largely confined to examining differences in 
the total SMAD2/3 or SMAD1/5/8 proteins under different cell density culture conditions. 
Another remaining question emerging from the latter is whether these cell density studies 
in vitro relate to behaviour of ECs in vivo. Cell density conditions in vitro may recapitulate 
the three main endothelium structural types, including the continuous non-fenestrated, 
continuous fenestrated and discontinuous fenestrated (sinusoidal) endothelium (Atkins et al., 
2011). These can be found predominantly in: continuous non-fenestrated: arteries, veins, 
skin, muscle, heart, lung capillaries of the brain; continuous fenestrated: capillaries of all 
exocrine and endocrine glands, digestive tract mucosa, kidney; discontinuous fenestrated: 
certain sinusoidal vascular bed in the liver and bone marrow (Atkins et al., 2011). 
The exact molecular mechanisms underlying these variable SMAD activation events in ECs 
remain largely elusive. Mathematical models of TGFβ signaling dynamics have shown that 
stimulation with a given concentration of TGFβ determines signaling duration and this is 
dependent on the cell density: signaling persists longer when cell density is decreased (Zi 
and Klipp, 2007). Additionally, Clarke et al. showed that the potency of the same TGFβ 
concentration depended on the number of cells that are exposed to TGFβ and proposed that 
the “TGFβ concentration” expressed as “TGFβ molecules per cell” is a better predictor of 
Smad2 activation since it takes into account the number of cells in each experiment (Clarke 
et al., 2009). Thus, a key parameter to consider for the “cross-over” SMAD activation events 
in ECs maybe “ligand molecules per cell” and since individual cells are likely to express 
different numbers of receptors at cell surface, the “ratio of ligand to cell surface receptor 
number” might be more appropriate. This latter is of particular importance in hPSC field, 
as the number of cell surface receptors in hPSC-ECs might differ between iPSC lines and 
differentiation experiments, leading to heterogeneous signaling responses. 
Current limitation to HHT iPSC modeling
The primary concern regarding the potential use of iPSC technology as a method 
to model a hereditary disease, such as HHT, is the risk that normal genetic variations or 
backgrounds among hiPSC cell lines derived from two different individuals may lead to non-
disease related differences in phenotype. It would be impossible to determine or completely 
eliminate the possibility that the observed phenotypes are the direct result of causal mutations 
or an effect of possible genetic variation between the different hPSC lines unless very many 
cell lines were examined as in a population type study. A good solution to this problem 
is the use of isogenic-control iPSC lines in which the mutated gene has been repaired by 
gene targeting. This was a major limitation of the studies in this thesis although certain 
aspects could be examined by siRNA knockdown for example, since the underlying disease 
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mechanism is known to be haploinsufficiency, which reduces the level of cell surface protein 
available for signaling.  Another limitation of the use of hPSC-ECs for HHT modeling is 
obtaining the  subtype affected by the disease. In Chapter 6 we showed in mice that the post-
arterial capillary network plays a critical role in the formation of direct AV connections in 
HHT2 mutants, which highlights the need of tissue-specific ECs. Thus, the development of 
robust hPSC-EC differentiation protocols to generate disease-tissue-specific microvascular 
ECs that match the in vivo counterpart as closely as possible could address this issue. 
Modeling HHT using mouse models
The “HHA model” for AVM formation
Data from the most recent HHT mouse models in which Acvrl1 or Eng gene 
deficiency is inducible rather than ubiquitous led to the hypothesis that three events are 
necessary for the development of AVMs. These are: (i) Acvrl1 or Eng heterozygosity, (ii) 
local/somatic mutations in the remaining normal allele leading to homozygous loss and 
(iii) pro-angiogenic or pro-inflammatory triggers (Tual-Chalot et al., 2015). However, the 
concept of a local somatic mutation in HHT patients has not been experimentally proven 
and needs to be re-assessed using the more advanced DNA sequencing technology currently 
available. In Chapter 6, we provided evidence that suggests altered blood flow contributed 
to the development of AVM in HHT2 mice, where the flow-dependent adaptive responses in 
the post-arterial capillary network could in the first instance be masked by HHT phenotypes 
during angiogenic events. This data led us to suggest a new three event hypothesis, which 
we refer to as the “HHA model”, for AVM formation in HHT patients: Acvrl1 or Eng 
Heterozygosity representing the variable baseline condition in HHT; Hemodynamic changes 
leading to the formation of enlarged venous-like capillaries with abnormal flow and transient 
AV connections; and pro-Angiogenic triggers cause further remodeling of the transient AV 
shunts into large AVMs. This may also explain why new AVMs or enlargement of existing 
AVMs have been reported during physiological hemodynamic changes, including pregnancy 
(de Gussem et al., 2014; Ference et al., 1994; Shovlin et al., 2008; 1995), exercise and drug-
induced systemic vasodilation (Anand and Florea, 2001; Mehta and Dubrey, 2009).
Cellular origin of AVMs
As described in Chapter 1, some HHT mouse model studies have focused on 
investigating the involvement of different cell types other than ECs being responsible for the 
formation of visceral and mucocutaneous AVMs in both HHT1 and HHT2 adult models. For 
that purpose, Acvrl1 and Eng were specifically deleted from smooth muscle cells, pericytes, 
macrophages, vSMCs and a subpopulation of ECs using Myh11-CreER, NG2-CreER, LysM-
Cre and SM22a-Cre lines, respectively (Chen et al., 2014a; 2014b; Garrido-Martin et al., 
2014; Milton et al., 2012).
Both, Chen et al and Garrido-Martin et al investigated whether tamoxifen induced deletion 
of Acvrl1 or Eng in adult pericytes (NG2-CreER) or smooth muscle cells (Myh11-CreER) is 
sufficient to induce AVMs in the area close to the wounded skin (Chen et al., 2014a; Garrido-
Martin et al., 2014). Interestingly, Acvrl1 deletion in these cell types did not affect blood 
vessels undergoing active angiogenesis even after VEGF stimulation (Chen et al., 2014a; 
Garrido-Martin et al., 2014). Similarly, deletion of Eng in macrophages using lysosome 
M-positive macrophage (LysM)-Cre adult mice did not result in the development of AVMs in 
the brain or near the wounded-ear even after external angiogenic stimulus (Choi et al., 2014). 
On the other hand, conditional deletion of Acvrl1 or Eng using SM22a-Cre mice give rise to 
the formation of AVM in the brain and spinal cord, leading to paralysis or lethality in the first 
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6 to 15 weeks of life (Choi et al., 2014; Milton et al., 2012). Interestingly, a mosaic of Cre-
recombined and non-recombined cells was detected in the spinal cord-AVMs, supporting the 
hypothesis that a mixture of affected and non-affected cells is contributing to the formation 
of AVMs in HHT patients. In addition, it is important to note that SM22a expression is not 
restricted to vSMCs but is also detected in cardiac muscle in embryos and in a wide-range 
of cell types in adult, confounding perhaps the experiments using SM22 as a cre-driver and 
suggesting that another cell type than vSMC might be responsible (Milton et al., 2012). Finally, 
as described in Chapter 1, the most dramatic AVM phenotype in neonatal or adult mice is 
only observed when Acvrl1 or Eng are primarily deleted using Scl-CreER, Cdh5-CreERT2, L1-
Cre or Pdgfb-CreER (Chen et al., 2014a; Garrido-Martin et al., 2014; Mahmoud et al., 2010; 
Park et al., 2009; Tual-Chalot et al., 2014). These observations lead to the conclusion that 
the major cellular source for the development of an AVM phenotype in several organs is the 
endothelium. In Chapter 6 we used the Cdh5-CreERT2 mice to reveal an AVM neonatal retinal 
phenotype that overlapped with that of Eng-iKOe and Acvrl1-iKOe neonates (Mahmoud et 
al., 2010; Tual-Chalot et al., 2014). Together, our data suggests that endothelium is also the 
key cell type in our “HHA model” for AVM formation in HHT2 mice (Chapter 6). In this 
respect, we have also found that increased production of ROS in the arterial endothelium 
plays a key role in the development of AVM, further providing a molecular mechanism in 
the HHA model.  Finally, it will not yet clear whether these increased ROS is mitochondrial, 
NADPH oxidase-dependent or eNOS uncoupling-derived as further work needs to be done. 
HHT Modifier genes 
The remarkable intra-familial variation in HHT human phenotype and the 
distinct disease severity in different mouse strains of HHT1 models, suggest the effect of 
environmental factors and/or genetic modifiers on HHT clinical manifestations.  More than a 
decade ago, Akhurst’s laboratory mapped the genetic modifier locus Tgfβm on chromosome 
1 as the major determinant of the dramatic variation in penetrance of Tgfβ1 null on early 
prenatal mortality in mice (Bonyadi et al., 1997; Tang et al., 2003). Follow up studies have 
recently validated Tgfβm2 and Tgfβm3b locus as a modifiers of phenotype in Tgfβ1 null 
mice in a plethora of different congenic mice stains, including 129, C57 and NIH (Benzinou 
et al., 2012; Kawasaki et al., 2014). Using gene-centric tag-SNP technology within and 
flanking the TGFBM2 human locus, Banzinou et al identified two unique SNPs (rs2936018 
and rs2936017) located within the non-receptor tyrosine phosphatase 14 (PTPNP14) gene 
showing significant genetic association of PAVM in Dutch and French HHT1 and HHT2 
populations. Following a similar approach, Kawasaki et al presented evidence that functional 
polymorphism of two SNPs (rs10495565 and rs12474540) within the ADAM17 gene, 
located at TGFBM2β locus, exhibit significant correlation with the clinical outcome of 
PAVM in HHT1 patients. In Chapter 6 we identified GJA5 gene as new component in ALK1 
signaling interplay that acts in combination with Acvrl1 in the development of the HHT 
phenotype. Genetic polymorphisms have been detected in both promoter regions of GJA5 
and suspected to be associated with risk of cardiovascular diseases including hypertension 
(Molica et al., 2014). These findings emphasize the importance of knowing whether functional 
polymorphisms within the GJA5 gene or other genes implicated in the regulation of vascular 
tone can determinant different clinical risks and outcomes of HHT phenotype.
 
Finally, since pulmonary and cerebral AVMs are more common in HHT1 patients, whereas 
hepatic AVMs are more prevalent in HHT2 patients, a key step leading to novel insights into 
the molecular mechanisms underlying HHT lesions in different tissues and possible early 
clinical prognosis would be the identification of tissue-specific HHT modifier genes. 
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Future directions 
With the advent of in vitro and in vivo HHT modeling tools, a new era to understand 
and explain the pathophysiology seen in HHT has begun. HHT exhibits significant phenotypic 
variability, in which the common, classic symptomatic feature remains the development of 
telangiectases and AVMs. 
As we continue to improve the derivation of HHT-specific hiPSCs harboring the same 
disease-causing mutation and begin to produce isogenic controls that have been genetically 
repaired for comparison, we hope to be able to recapitulate AV shunts in vitro and investigate 
to what extent these malformations are developed and maintained, by additional factors 
than ACVRL1 or ENG heterozygosity, including altered blood flow, inflammation and mural 
cell coverage. Such an ideal platform may further allow one to identify AVM markers that 
could be potential drug targets for HHT therapies. In the meantime, the establishment of 
robust direct differentiation protocols for large-scale tissue-specific ECs will provide the 
opportunity to unravel why AV shunts are more common in lung and brain in HHT1 than 
hepatic AVMs in HHT2 patients.
Our findings in this thesis indicate that altered blood flow is necessary event for AVM 
development and that GJA5 can be used as potential genetic modifier for HHT2. It will 
be important to determine whether human polymorphic variants of GJA5 influence clinical 
variability and progression of HHT. Finally, yet undiscovered genetic modifiers may also be 
associated with the development of vascular malformations seen in HHT, leading therefore 
to the development of more robust animal models of HHT. 
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Summary
Over the last two decades, significant advances have been made in better understanding 
the molecular and cellular mechanisms of vascular cell development and disease. PSCs are 
proving to be a useful and renewable source to study the molecular mechanisms underlying 
physiologic endothelial cell development and pathophysiologic states of a disease in vitro, 
such as HHT. In the same line, mouse models carrying mutations in HHT-related genes are 
also essential to increase our understanding of the disease mechanisms. 
Chapter 2 investigated the generation of knockin mESC line in order to study the biallelic 
distribution of Nanog expression at the protein level. Nanog is a key transcription factor 
expressed in pluripotent cells and is required for self-renewal in vitro. We found that this 
knock-in fusion strategy allows the generation of functional Nanog fusion proteins mirroring 
normal protein distribution in vivo and in vitro. This approach will be of value in creating new 
genetic vascular disease models and reporter lines for vascular lineage specification.
Chapter 3 investigated the generation of human ECs from hESCs using a spin-EB 
differentiation approach. Although significant advances have been made in inducing 
endothelial differentiation from hPSCs, new methods would be useful to identify the critical 
regulators guiding commitment and diversification of endothelial progenitors and allow the 
derivation of tissue type specific ECs. Latest studies have described ETV2 as one of the 
master regulators in the development of ECs. In this chapter, we showed that ECs originate 
from a VEGF-treated mesodermal population and that ETV2 expression is enriched on day 
4 of differentiation in endothelial progenitors in both PDGFRα+APJ+KDR+ and PDGFRα-
APJ+KDR+ fractions. Furthermore, we provided a new knock-in fusion strategy that allows 
non-invasive quantification of ETV2-expressing cells.
Chapter 4 described the first derivation of three human iPS cell lines in the Netherlands: 
two from healthy individuals and one from a patient with HHT. All of these human iPSC 
lines were derived from fibroblasts grown from skin samples and were able to give rise 
to multiple cardiovascular cell types including beating cardiomyocytes, when seeded on 
visceral endoderm-like (END-2) cells.  
Chapter 5 investigated the use of hiPSC-EC as a model for studying HHT1 in vitro. HHT 
is an autosomal dominant vascular disorder caused by mutations in one of two receptors 
of the TGFβ family, ENG or ACVRL1, which are mainly expressed by ECs and lead to 
HHT1 or HHT2, respectively. We found that cell density culture conditions are coupled to 
SMAD phosphorylation in hiPSC-ECs and that ENG haploinsufficency can affect TGFβ 
signaling. We further identified MTUS1, as a new TGFβ signaling candidate gene that is 
highly upregulated when ENG levels are reduced. 
Chapter 6 investigated the role of Gja5 that encodes for the gap junction protein Cx40 in the 
development of AVMs in the HHT2 mouse model. We identified GJA5 as a downstream target 
gene of BMP9/ALK1 signaling pathway and also found reduced Cx40 levels in a small group 
of HHT2 patients. In the Acvrl1+/- mice, Gja5 haploinsufficiency led to the rarefaction of the 
capillary bed and the vasodilation of the arteries, in which ROS production was elevated. We 
showed that altered hemodynamic forces in Acvrl1+/-;Gja5EGFP/+ mice could develop transient 
arteriovenous shunts in the capillaries, where large malformations can be developed upon 
exposed to environmental insults, such as wounding. 
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Samenvatting 
Over de afgelopen twee decaden, significante vooruitgang is geboekt in het beter 
begrijpen van moleculaire en cellulaire mechanismen van vasculaire cel ontwikkeling en 
ziekte. PSC’s hebben zich bewezen bruikbaar te zijn en een nieuw terrein om moleculaire 
mechanismen te bestuderen, betreffende fysiologische endotheelcel ontwikkeling en 
pathofysiologische staat van ziekte in vitro, zoals HHT. Muismodellen met HHT-gerelateerde 
genmutaties zijn essentieel om ons begrip van ziektemechanismen te vergroten.
Hoofdstuk 2 bestudeert het generen van knock-in mESC cellijnen om de bi-allelische distributie 
van Nanog expressie op eiwit niveau te bestuderen. Nanog is een sleuteltranscriptiefactor 
welke tot expressie komt in pluripotente cellen, en is vereist voor zelf-vernieuwing in vitro. 
We bevonden dat deze knock-in fusie strategie de generatie van functionele Nanog fusie-
eiwitten mogelijk maakt, kijkend naar normale eiwit distributie in vivo en in vitro. Dit zal 
in de toekomst waardevol zijn voor het maken van genetisch modellen van cardiovasculaire 
ziektes en reporter lijnen voor oa vasculair celspecificatie op basis van hiPSC.
Hoofdstuk 3 bestudeert de generatie van humane EC’s van hESC’s, gebruik makend van 
spin-EB differentiatie benadering. Hoewel significante vooruitgang moet worden geboekt 
in induceren van endotheel differentiatie vanuit hPSC’s, nieuwe methoden zullen bruikbaar 
zijn om kritische regulatoren die de begeleiden inzet en diversificatie van endotheel 
voorlopercellen te identificeren en maken van weefselspecifieke EC’s mogelijk. De meest 
recente studies beschrijven dat ETV2 is een van de master regulatoren in EC ontwikkeling. 
In dit hoofdstuk laten we zien dat EC’s stammen van VEGF-behandelde mesodermale 
populaties, en dat ETV2 expressie wordt verrijkt op dat 4 van de differentiatie in endotheelcel 
voorlopercellen in zowel PDGFRα+APJ+KDR+ als PDGFRα-APJ+KDR+ fracties. Daarnaast 
hebben we een nieuwe knock-in fusiestrategie ontwikkeld die ons toestaat om non-invasief 
ETV2-expressing cellen te kwantificeren.
Hoofdstuk 4 beschrijft de eerste humane iPS cellijnen gemaakt in Nederland: twee van 
gezonde proefpersonen en een  van een HHT patiënt. Deze humane iPSC cellijnen waren 
gemaakt van fibroblasten van huidbiopten en konden differentiëren tot verschillende celtypen, 
inclusief kloppende cardiomyocyten indien samengekweekt met viscerale entoderm-achtige 
END-2 cellen.
Hoofdstuk 5 bestudeert het gebruik van hiPSC-EC als een model om HHT1 in vitro te 
onderzoeken. HHT is een autosomaal-dominante vasculaire aandoening die ontstaat door 
mutaties in een of twee receptoren in de TGFbeta familie, ENG of ACVRL1, welke vooral 
tot expressie komen in EC’s, en tot respectievelijk HHT1 of HHT2 leiden. We ontdekten 
dat celdensiteit in kweek gekoppeld worden aan SMAD fosforylatie in hiPSC-ECs en dat 
ENG haploinsufficiëntie het TGFβ signaling kan beïnvloeden. Daarnaast hebben we MTUS1 
geïdentificeerd als een nieuw TGFβ signaling kandidaat gen welke significant worden zodra 
ENG levels gereduceerd zijn.
Hoofdstuk 6 bestudeert de rol van Gja5, welke de gap junction eiwit Cx40 encodeert in de 
ontwikkeling van AVM in het HHT2 muismodel. We identificeerden GJA5 als een downstream 
target gen van BMP9/ALK1 signaling pathway en vonden gereduceerde Cx40 hoeveelheden 
in een kleine groep HHT2 patiënten. In Acvrl1+/-  muizen, Gja5 haploinsufficiëntie leidt 
tot veranderingen in het capillair bed en vasodilatatie van arteriën waarin ROS productie 
verhoogd was. We toonden aan dat veranderde hemodynamische krachten in Acvrl1+/-
;Gja5EGFP/+ muizen tijdelijke arterioveneuze shunts in de capillairvaten konden doen 
ontstaan, terwijl grote malformaties konden worden geïnduceerd bij omgevingsinvloeden 
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zoals verwondingen.
ΣΥΝΟΨΗ
Τις τελευταίες δύο δεκαετίες, αισθητές προόδους έχουν σημμειωθεί για την 
βέλτιστη κατανόηση των μοριακών και κυτταρικών μηχανισμών της κυτταρικής ανάπτυξης 
των αγγείων σε φυσιολογικές και ασθενείς συνθήκες. Τα πολυδύναμα βλαστοκύτταρα ή 
PCs είναι μία χρήσμιμη ανανεώσιμη πηγή για τη μελέτη των μοριακών μηχανισμών της 
ανάπτυξης των ενδοθηλιακών κυττάρων σε φυσιολογικές και παθοφυσιολογικές καταστάσεις 
ασθενειών in vitro, όπως η Κληρονομική Αιμοραγική Τηλεαγγειεκτασία (KAT). Ακολούθως 
ποντίκια που φέρουν μεταλλάξεις σε γονίδια που σχετίζονται με την ΚΑΤ ασθένεια μπορούν 
να χρησιμοποιηθούν για τη αναγνώριση των μηχανισμών της ασθένειας.
Στο 20 κεφάλαιο μελετήθηκε η παραγωγή μίας διαγονιδιακής κυτταρικής σειράς εμβρυονικών 
βλαστοκυττάρων ή mESCs (εκφράζουν μετάλλαξη τύπου knock-in) με σκοπό τη μελέτη της 
διαλλειλικής διανομής της έκφρασης του Nanog σε πρωτεϊνικό επίπεδο. Η πρωτεϊνη Nanog 
είναι ένας βασικός μεταγραφικός παράγοντας που εκφράζεται στα πολυδύναμα κύτταρα και 
είναι απαραίτητη για την αυτο-ανανέωσή τους, in vitro. Η χρήση της knock-in τεχνολογίας 
μας επέτρεψε να πιστοποιήσουμε πως οι πρωτεϊνες Nanog ήταν λειτουργικές αντανακλώντας 
την φυσιολογική διανομή της πρωτεϊνης in vivo και in vitro. Η συγκεκριμένη προσέγγιση 
μπορεί να σταθεί χρήσιμη στο μέλλον για την παραγωγή νέων αγγειακών μοντέλων για τη 
μελετη της ασθένειας και κυτταρικών σειρών αναφοράς για προδιαγεγραμμένη αγγειακή 
γενεαλογία κυττάρων. 
Στο 30 κεφάλαιο μελετήθηκε η παραγωγή ανθρώπινων ενδοθηλιακών κυττάρων ή ECs 
από ανθρώπινα εμβρυονικά βλαστοκύτταρα ή hESCs χρησιμοποιώντας την τεχνική 
διαφοροποίησης τύπου spin-EB.  Έχουν σημειωθεί σημαντικές προόδους για την παραγωγή 
ενδοθηλιακής διαφοροποίησης από ανθρώπινα πολυδύναμα βλαστοκύτταρα ή hPSCs στο 
παρελθόν, ωστόσο νέες τεχνικές θα μπορούσαν να φανούν χρήσιμες στο μέλλον για την 
αναγνώριση των σημαντικών ρυθμιστών που καθορίζουν τη δέσμευση  και διαποικίληση των 
προγόνων του ενδοθηλίου και επιτρέπουν την παραγωγή του συγκεκριμένου ιστού των ECs 
κυττάρων. Πρόσφατες μελέτες έχουν αναγνωρίσει το μόριο ETV2 σαν ένα πολύ-ρυθμιστή 
της ανάπτυξης των ECs κυττάρων. Σε αυτό το κεφάλαιο, αναγνωρίσαμε πως τα ECs κύτταρα 
προέρχονται από ένα πληθυσμό μεσεγχυματικών κυττάρων τύπυ VEGF- και ότι η έκφραση 
του μορίου ETV2 αυξάνεται σημαντικά κατά την 4η ημέρα διαφοροποίησης στα πρόδρομα 
των ενδοθηλιακών κυττάρων, πιο συγκεκριμένα στα 2 κλάσματα, PDGFRA+APJ+KDR+ και 
PDGFRA-APJ+KDR+. Επιπλέον αναγνωρίσαμε μία νέα στρατηγική τύπου knock-in που 
επιτρέπει τη μη επεμβατική ποσοτικοποίηση των κυττάρων θετικών ως προς την έκφραση 
του μορίου ETV2.
Στο 40 κεφάλαιο μελετήθηκε η πρώτη παραγωγή των «ηθικών» πολυδύναμων κυττάρων 
ή IPSCs από 3 ανθρώπινα δείγματα στην Ολλανδία: 2 υγιείς δείγματα και 1 που φέρει την 
ΚΑΤ ασθένεια. Τα παραπάνω IPSCs από όλα τα δείγματα, προέρχονται από ινοβλάστες 
που έχουν καλλιεργηθεί από δείγματα δέρματος και ήταν ικανά για την παραγωγή 
διαφόρων καρδιοαγγειακών κυτταρικών τύπων, συμπεριλαμβανομένου των ρυθμικών 
καρδιομυοκυττάρων, τοποθετούμενα στο σπλαχνικό ενδόδερμα όπως τα κύτταρα τύπου 
END-2 (END: Ενδοθήλιο).
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Στο 50 κεφάλαιο έγινε χρήση των ανθρώπινων πολυδύναμων βλαστοκυττάρων-
Ενδοθηλιακών κυττάρων ή hiPSC-EC αντίστοιχα σαν μοντέλο για τη μελέτη της ασθένειας 
ΚΑΤ1, in vitro. Η ασθένεια ΚΑΤ είναι μία επικρατής αυτοσωμική αγγειακή πάθηση που 
προέρχεται από μεταλλάξεις σε ένα από τους δύο υποδοχείς της οικογένειας πρωτεϊνών 
TGFβ, ENG ή ACVRL1, όπου εκφράζονται κυρίως από τα EC κύττταρα και προκαλούν 
τις ασθένεις ΚΑΤ1 ή ΚΑΤ2, αντίστοιχα. Αναγνωρίσαμε πως η κυτταρική πυκνότητα σε 
συνθήκες κυτταροκαλλιέργειας συνδέεται με τη φωσφορυλίωση της πρωτεϊνης SMAD στα 
κύτταρα hiPSC-EC και πως η απλοανεπάρκεια του παράγοντα ENG μπορέι να επηρεάσει 
τη σηματοδότηση TGFβ. Στη συνέχεια, αναγνωρίσαμε επιπλέον το μόριο MTUS1, σαν ένα 
νέο υποψήφιο γονίδιο που εμπλέκεται στη σηματοδότηση TGFβ και εκφράζεται σε υψηλά 
επίπεδα όταν τα επίπεδα έκφρασης του παράγοντα ENG μειώνονται.
Στο 60 κεφάλαιο αναλύθηκε ο ρόλος του μορίου Gja5 που ελέγχει την κωδικοποίηση της 
πρωτεϊνης των χασμοσυνδέσμων Cx40 κατά την ανάπτυξη της αρτηριοφλεβικής δυσπλασίας 
ή AVMs στο μοντέλου ποντικού για την ασθένεια ΚΑΤ2. Πιστοποιήσαμε πως το μόριο 
GJA5 είναι ένα καθοδικό γονίδιο-στόχος του σηματοδοτικού μονοπατιού BMP9/ALK1 
και επίσης επηρεάζει αρνητικά τα επίπεδα του μορίου Cx40 σε ένα μικρό δείγμα ασθενών 
ΚΑΤ2. Στα ετερόζυγα ποντίκια Acvrl1+/-, η απλοανεπάρκεια του μορίου Gja5 οδήγησε 
στην αραίωση των αγγειακών πλεγμάτων και της αγγιοδιαστολής των αρτηριών, όπου η 
παραγωγή των δραστικών μορφών οξυγόνου ή ROS αυξήθηκε. Δείξαμε πως η τροποποίηση 
στις αιμοδυναμικές δυνάμεις στα ποντίκια με γονότυπο Acvrl1+/- ;Gja5EGFP/+ είναι ικανή να 
αναπτύξει παροδικές αρτηριοφλεβώδεις αναστομώσεις στα τριχοειδή αγγεία, όπου μπορούν 
να δημιουργηθούν μεγάλες δυσμορφίες ύστερα από έκθεση σε περιβαλλοντικές συνθήκες, 
όπως τραυματισμοί.
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A
ACT    
ActR-IB  (ALK4)
ActR-IIA   
ActR-IIB   
ACVR1  (ALK2)
ACVRL1 (ALK1) 
AGM 
Akt     
AMHR-II   
Ang1  
APLNR /APJ
aSMA   
AVM    
B
Bio   
BMP    
BMPR-IA (ALK3)
BMPR-IB (ALK6)
BMPR-II
BrdU
BPEL
BSA    
C
Cdc42
Cdh5–CreER
cDNA    
CD31 (PECAM-1)
CD105   
ChIP-Seq  
CM 
Co-Smad
Cre-recombinase   
C57BL/6 (black 6)
D
DAPI   
DMEM
DMSO   
DNA   
E
E   
EB 
ECM   
ECs  
Efnb2
eGFP 
EMT  
ENG (CD105) 
eNOS (NOS-3)
EphB4   
Erk  
ESCs 
ESPC
F
F    
FIAU 
FISH 
Flk-1 (Kdr, Vegfr2) 
FP 
Activin
Activin A receptor type IB
Activin A receptor type IIA
Activin A receptor type IIB 
Activin A receptor type 1
Activin A receptor type 1L
Aorta-gonal-mesonephros 
Protein kinase B signaling pathway
Anti-Mullerian hormone receptor type II 
Angiopoietin 1
Apelin receptor
a-smooth muscle actin
Arterio-venous malformation
Bone morphogenetic protein 
Bone morphogenetic protein receptor type 1A
Bone morphogenetic protein receptor type 1B
Bone morphogenetic protein receptor type 2
Bromodeoxyuridine
Bovine serum albumin polyvinylalchohol essential lipids
Bovine serum albumin
Cell division cycle 42
Tamoxifen-inducible Cadherin 5 Cre recombinase 
complementary DNA
Platelet/endothelial cell adhesion molecule 1
Endoglin
Chromatin immunoprecipitation with sequencing
Cardiomyocytes
Common mediator Smad
Tyrosine recombinase enzyme
C57 inbred mouse strain
4’,6-diamidine-2-phenylindole-dihydrochloride
Dulbecco’s Modified Eagle Medium
Dimethyl sulfoxide
Deoxyribonucleic acid
Embryonic day
Emrbyoid bodies
Extracellular matrix
Endothelial cells
Ephrin B2
Enhanced green fluorescent protein
Epithelial-mesenchymal transition
Endoglin
Endothelial nitric oxide synthase-3
EPH receptor B4
Extracellular-signal-regulated kinase
Embryonic stem cells
Endothelial stem/progenitor cells
Forward primer
1-(2-deoxy-2-fluoro-,-D-arabinofuranosyl)-5- iodouracil
Florescence in situ hybridization
Fetal liver kinase-1, kinase insert domain receptor
Fluorescent protein
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G
GAPDH   
GDF
GI
GS-box   
GSK3
GTPases
H
h      
HA
HAoEC
HE
HEY2
HHT
HPC
HR
HSCs
HSPC
HSV-TK
HUVEC   
I
ID1   
INH  
iPSCs  
I-Smad  
2i    
J
Jag1   
JNK 
K
KDR/VEGFR2   
Ki67
L
Lefty     
LIF 
L1-Cre
M
MAPK 
MEF 
MH1 
MH2
MIS
MKK
mRNA
mTOR
MVD
N
NADPH
NeoR
NF-kB   
NO
Nodal
NOTCH4
O
Ola /129
   
Glyceraldehyde 3-phosphate dehydrogenase, G3PDH
Growth and differentiation factor
Gastrointestinal
Glycine-serine rich domain
Glycogen synthase kinase 3
Guanosine triphosphates hydrolase enzymes 
Human
Homology arms
Human aortic endothelial cells
Hemogenic endothelium
HES-related repressor protein 2
Hereditary hemorrhagic telangiectasia
Hematopoietic cell
Homologous recombination
Hematopoietic stem cells
Hematopoietic stem/progenitor cells
Herpes simplex virus thymidine kinase
Human umbilical venous endothelial cells
Inhibitor of differentiation 1
Inhibin
Induced pluripotent stem cells
Inhibitory Smad protein
MEK inhibitor and GSK3 inhibitor
Jagged 1
c-Jun N-terminal kinase, signaling pathway
Kinase insert domain receptor
Marker of proliferation ki67
Left-right determination factor
Leukemia inhibitory factor
L1 driven Cre-recombinase
Mitogen activated protein kinase, signaling pathway
Mouse embryonic fibroblasts
Mad-homology 1 domain
Mad-homology 2 domain
Mullerian inhibiting substance
Mitogen-activated protein kinase kinase
messenger RNA
Mammalian target of rapamycin
Microvessel density
Nicotinamide adenine dinucleotide phosphate
Neomycin resistance gene
Nuclear factor kappa B
Nitric oxide
Nodal growth differentiation factor
Neurogenic locus notch homolog protein 4
 
Ola/129 mouse strain
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P
PAH  
PBS   
PBST   
PCR 
PD   
PDGF  
PDGF-B
PDGFR-a
PDGFR-b
Pdgfrb-iCreER
PECAM-1
PGK 
PI3K  
PreScission 
PSCs 
P+  
Q
Q-PCR   
R
Rac1
Ras 
R   
RhoA
RT-qPCR   
RNA
ROSA26-CreER
ROS
R-Smad  
RT-PCR    
RVH
S
SB
SCF
Scl-CreER
SDS
SEM
Sh   
Smad   
SMC  
Smurf    
SM22a (TAGLN)
SSXS   
T
TAK1   
TAP 
TbR-I (ALK5, TgfbR1)  
TbR-II, TGFbR-II
TEV
TF 
TG
TgfbR3, TbRIII    
TGFβ  
TRAF6   
TSP-1 
Tyr   
T2A
Pulmonary arterial hypertension
Phosphate buffered saline
PBS-Tween
Polymerase chain reaction
PD0325901, inhibitor of the MEK/ERK pathway
Platelet-derived growth factor
Platelet-derived growth factor B polypeptide
Platelet-derived growth factor receptor, alpha
Platelet-derived growth factor receptor, beta
Tamoxifen-inducible Pdgfrb Cre recombinase 
Platelet-Endothelial Cell Adhesion Molecule-1
Phosphoglycerate kinase promoter
Phosphoinosistide 3-kinase, signaling pathway
PreScission Protease
Pluripotent stem cells
Phosphorylated
Quantitative polymerase chain reaction
Ras-related C3 botulinum toxin substrate 1 
Ras sarcoma, small GTPases, signaling pathway 
reverse primer
Small GTPases, signaling pathway
Real-time quantitative PCR 
Ribonucleic acid
ROSA26 locus driven Cre-recombinase
Reactive oxygen species
Receptor-Smad protein
Reverse transcriptase polymerase chain reaction
Right ventricular hypertrophy
SB431542, inhibitor of ALK5
Stem cell factor
T-cell acute lymphocytic leukemia 1 (TAL) driven Cre
Sodium dodecyl sulfate
Standard error of the mean 
Short hairpin construct
Sma mothers against decapentaplegic
Smooth muscle cells
Smad ubiquitin regulatory factor
Transgelin 2
Serine-serine-X-Serine motif
TGFb associated kinase 1
Tandem affinity purification
TGFb type I receptor
Tgfb type II serine/threonine kinase receptor
TEV protease
Transcription factor
Targeted allele
Tgfb receptor type III, betaglycan
Transforming growth factor-b
Tumor necrosis factor TNF receptor associated factor 6
Thrombospondin-1
Tyrosine
2A peptide cleavage
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V
VCAM1
VE-cadherin (CD144)   
VEGF
VEGFR
vSMC
v/v    
vWF
V5
W
WT
w/v   
Vascular cell adhesion molecule 1
Vascular endothelial-cadherin, 
Vascular endothelial growth factor
Vascular endothelial growth factor receptor
Vascular smooth muscle cell
volume/volume
von Willebrand factor
V5 tag peptide  
wild type
weight/volume
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